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ABSTRACT OF DISSERTATION

A BIOCHEMICAL CHARACTERIZATION OF THE FUSION PROTEINS
FROM ENVELOPED RNA VIRUSES

Enveloped viruses must bind target cells and then fuse the viral membrane
with a cell membrane to enter a host cell. These viruses use one or more surface
glycoproteins to carry out these critical functions. The surface glycoprotein that
carries out the fusion function, termed a fusion protein, is divided into three classes
based on structural similarities. Some of the most studied human viral pathogens,
such as human immunodeficiency virus (HIV), Ebola virus, influenza, measles, and
the recently emerged severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), possess class I fusion proteins. Following synthesis, class I fusion proteins
associate as non-covalently linked homo-trimers, and remain as trimers
throughout the fusion process. Key proteolytic processing events and subsequent
receipt of a triggering signal, drive the fusion protein to undergo large, irreversible
conformational changes to facilitate the merging of the viral and host cell
membranes. Using this same fusion process, several class I fusion proteins can
also promote cell-cell fusion.
Previous work has demonstrated that protein-protein interactions within the
transmembrane region of some fusion proteins may play a role in the overall
trimeric association. Utilizing fusion protein from viruses in the family
Paramyxoviridae

and

Pneumoviridae,

we

targeted

interactions

in

the

transmembrane (TM) regions, disrupting overall protein stability and fusion
function, thus demonstrating a novel target for antiviral therapeutic development.
To further delineate the role of residues within the Hendra virus fusion protein TM
domain, we performed alanine scanning mutagenesis of the N-terminal end of that
region, demonstrating that residues M491/L492 appear to play a role in the protein
fusion process. In early 2020, we shifted to investigating the fusion protein of

SARS-CoV-2 (spike) and examined spike protein stability, proteolytic processing,
and factors involved in cell-cell fusion. Through this work we assessed cleavage
patterns, identified residues that modulate the fusion process, and showed that
protein processing impacts the trimer stability. Finally, we examined the fusion
protein of respiratory syncytial virus (RSV). In this study we characterized protein
trafficking, cleavage, and post translational modification differences between the
fusion proteins from the two RSV subtypes, A and B. Using mutagenesis, we
investigated the role of the two cleavage sites that are present and conserved
between these subtypes to better understand the cleavage and subsequent fusion
processes of the RSV fusion protein. Since these fusion proteins are located on
the viral surface and are crucial for viral entry, they are key therapeutic targets.
Therefore, understanding the mechanisms and interactions that drive protein
function and novel ways to target this protein are critical.
KEYWORDS: fusion protein, membrane fusion, pneumoviruses, paramyxoviruses,
SARS-CoV-2
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CHAPTER 1. VIRAL
MEMBRANE
TRANSMEMBRANE DOMAINS

FUSION

PROTEINS

AND

THE

Portions of this chapter were adapted and reprinted with permission from
Viruses: Barrett CT, Dutch RE. 2020. Viral Membrane Fusion and the
Transmembrane Domain. Viruses. 12(7):693.
Enveloped viruses include many important pathogens, such as human
immunodeficiency virus type 1 (HIV-1), Ebola virus (EBOV), influenza (IAV),
measles (MeV), rabies virus, and severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2). Enveloped viruses can possess a double-stranded DNA genome
or a single-stranded RNA genome. Members of the families Coronaviridae,
Paramyxoviridae, and the recently assigned Pneumoviridae fall into the latter
category. Viruses in the family Coronaviridae have a positive-sense RNA genome,
while members of Paramyxoviridae and Pneumoviridae have a negative-sense
RNA genome. Each of these viral families contain unique respiratory viral
pathogens that pose significant threats to human health.
Paramyxoviruses
Significant human pathogens in the Paramyxovirdae family include measles
virus (MeV), mumps virus (MuV), and the human parainfluenza viruses (PIV).
These viruses cause infections in the respiratory tract, transmit via airborne
particles, and can be highly contagious [1]. In addition to causing human infections,
paramyxoviruses can infect a number of animal hosts [1, 2]. More recently, several
zoonotic paramyxoviruses have emerged, notably Hendra virus (HeV) in 1994 [3]
and Nipah Virus (NiV) in 1998 [4, 5].
Paramyxovirus particles are generally pleomorphic, but vary between
spherical or filamentous shapes, and range from 150 to 500 nm in diameter [1].
The non-segmented negative sense RNA genomes of paramyxoviruses are 15-19
kilobases in length and encode for six to ten proteins, with a viral envelope derived
from the host cell [1, 6-9]. Proteins encoded for include a large RNA-dependent
RNA polymerase (L), a nucleoprotein (N), a phosphoprotein (P), a matrix protein
(M), a small hydrophobic protein (SH), a fusion protein (F), and an attachment
1

protein (G/HN/H) (Fig. 1.1) [2, 9]. Viral entry is initiated by attachment to and fusion
with a target cell, mediated by the surface glycoproteins G/HN/H and F proteins,
respectively. Once the virus membrane fuses with a target cell membrane, the
ribonucleoprotein complex (RNP) enters the cell cytoplasm to begin transcription.
The RNP consists of the RNA genome coated with the N protein and associated
with L, and P. P and N serve as accessory proteins to L, as it uses the negativesense RNA genome as a template to synthesize mRNA that is then translated by
the machinery of the host cell to make viral proteins. The negative-sense genome
is also used as a template to make positive-sense genome. Once the positivesense genome is made, it can then be used to make additional negative-sense
genome copies that form new RNP complexes and traffic to the cell membrane for
assembly with the viral proteins M, G/HN/H, and F.

The necessary viral

components are then assembled and new virions bud from the cellular plasma
membrane [6, 7, 10, 11].
Due to the high degree of genetic similarity, comparable pathogenesis, and
a wide host range, the zoonotic paramyxoviruses, HeV and NiV were classified
into their own genus, Henipavirus [12-14]. HeV was first isolated in 1994, in a
suburb of Brisbane, Australia during an outbreak that caused the deaths of 13
horses and one trainer [3, 15].

In horses, HeV infection causes respiratory

symptoms and high fevers. HeV infection in humans typically causes respiratory
symptoms that can advance to severe pneumonia or bronchiolitis, and in some
cases the infection may progress to a neurologic infection, resulting in encephalitis
[14-18]. Since its initial emergence, small HeV outbreaks have occurred
throughout Australia, exhibiting an 89% fatality rate among infected horses and a
57% fatality rate in humans [17, 18]. All human cases have been the result of
close contact with an infected horse and the transmission of HeV has been
suggested to be from bat to horse and horse to human. The natural reservoir host
for HeV was identified as Australian flying fox fruit bats in the genus Pteropus [12,
19, 20]. Just a few years after the initial HeV outbreak in 1999, NiV emerged in
Malaysia causing an outbreak of respiratory and neurologic disease on pig farms
[4, 21]. During this initial outbreak, 265 humans were infected and 105 of them
2

died [22]. Subsequent outbreaks of NiV have occurred in Malaysia, Singapore,
Bangladesh, and India with the most recent occurring in Kerala, India in 2018 and
2019 [21, 23]. Similar to the zoonotic transmission route demonstrated for HeV,
NiV has been postulated to transmit from bat to pig, and pig to human, with
Pteropus flying foxes as the likely reservoir [12, 19]. In some cases, NiV
transmission may occur directly from bats to humans, and direct human-to-human
transmission has also been documented [21, 24].

No vaccines or antiviral

treatments for either HeV nor NiV have been approved for human use [19, 21, 25].
This fact, along with their zoonotic transmission, and high fatality rates led to their
classification as biosafety level 4 agents.
Pneumoviruses
Pneumoviridae, originally a subfamily of the Paramyxoviridae family, was
reclassified in 2016 to its own viral family [26]. Similar to paramyxoviruses,
pneumoviruses have enveloped virions and negative-sense single stranded RNA
genomes. Their genome is 13 to 15 kilobases in length and encodes nine to eleven
proteins, depending on the virus. While several proteins encoded are similar to
those described for paramyxoviruses (Fig 1.1), the presence of the M2 gene is
unique to this viral family [9]. The M2 gene encodes for the proteins M2-1, a
processivity factor, and M2-2, involved in the switch from viral transcription to
replication. M2 proteins also help form the RNP complex that coats the genome.
Pneumoviruses are further divided into two genera, orthopneumovirus and
metapneumovirus,

with

slight

genomic

differences

between

the

two.

Orthopneumoviruses have a different gene organization from metapneumoviruses
and possess two additional genes, NS1 and NS2, upstream of the N gene [9]. The
proteins encoded for by these genes help interfere with host immune response
and prevent apoptosis of infected cells.
The pneumoviruses respiratory syncytial virus (RSV) and human
metapneumovirus (HMPV) cause significant human disease, presenting as
respiratory infections that can advance to severe pneumonia and bronchiolitis in
3

some cases [9, 27, 28]. RSV and HMPV pose particular threats to young children,
immunocompromised, and the elderly.

RSV is the leading cause of

hospitalizations for the children under the age of two [29-32]. Both viruses can
transmit through respiratory droplets and appear seasonally, with onset occurring
in the winter months [27, 33]. Despite the yearly occurrence, there is currently only
one FDA approved antiviral treatment for RSV, a prophylactic monoclonal antibody
[29]. There are no vaccines or antiviral therapeutics for HMPV.
Coronaviruses
Viruses in the family Coronaviridae are also enveloped RNA viruses,
however their genome is composed of 26 to 32 kilobases of single stranded
positive-sense RNA, significantly larger than the genomes of paramyxo- and
pneumoviruses [2]. This genome encodes for replicase polyprotein (pp1ab), spike
protein (S), envelope protein (E), membrane protein (M), and nucleocapsid protein
(N) [34]. Additionally, the replicase protein is cleaved to form 16 non-structural
proteins, including the replication proteins such as an RNA-dependent RNA
polymerase, RNA helicase, and an exoribonuclease [34].
Coronaviruses (CoVs) can cause disease in mammals and birds, with
several CoVs known to cause common colds in humans [34, 35]. In 2003, severe
acute respiratory syndrome coronavirus (SARS-CoV) emerged in Asia [36].
Research has demonstrated that this outbreak likely originated from a spillover
event from bats to humans, or bats to palm civets, and then from palm civets to
humans [36, 37]. SARS-CoV caused severe respiratory symptoms, spreading
mainly through respiratory droplets, and ultimately infected just over 8,000 people
worldwide, with a mortality rate of 9% [38]. Since 2004, there have been no
documented cases of SARS-CoV. In 2012, middle eastern respiratory syndrome
coronavirus (MERS-CoV) emerged, again resulting from a spillover event from a
bat reservoir [36-38]. MERS-CoV infection often causes severe respiratory
symptoms, similar to SARS-CoV, however additional gastrointestinal disease is
common as well [38]. MERS-CoV continues to pose a significant human threat
4

with small outbreaks occurring almost yearly in the Middle East and Asia, resulting
in the death of 35% of infected patients [39, 40]. Despite this, there are currently
no approved vaccines or antiviral treatments for either MERS or SARS-CoV.
Another novel CoV emerged in late 2019, named severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) [40]. In March of 2020, SARS-CoV-2
reached a pandemic level, having spread throughout the world. Infection causes
severe respiratory illness, gastrointestinal issues, and in some cases neurologic
complications. As of January 2021, SARS-CoV-2 has infected over 100 million
people, resulting in death for just over 2 million of those cases. About a year after
the SARS-CoV-2 pandemic started, in December 2020, the FDA granted
emergency use approval for two vaccines to this virus [41, 42]. Both vaccines were
composed of mRNA for the fusion protein (S) of SARS-CoV-2, although several
other vaccination strategies are under investigation [43, 44]. Of the other vaccines
currently in phase III clinical trials, two are using inactivated virus, four are using
adenovirus vectors with the S protein, and one is using a recombinant
nanoparticle, again expressing S protein, demonstrating that S is highly soughtafter therapeutic target [43, 44].
Dissertation Overview
For viral entry, enveloped RNA viruses must bind to target cells and then
fuse the viral membrane with a membrane of the host. These viruses use one or
more surface glycoproteins to carry out these critical functions. The surface
glycoprotein that carries out the fusion function, termed a fusion protein, is divided
into three classes based on structural similarities. Some of the most studied
human viral pathogens, such as human immunodeficiency virus (HIV), Ebola virus,
influenza, measles, and the recently emerged SARS-CoV-2, possess class I fusion
proteins. Following synthesis, class I fusion proteins associate as non-covalently
linked homo-trimers, and remain as trimers throughout the fusion process. Key
proteolytic processing events and subsequent receipt of a triggering signal drive
the fusion protein to undergo large, irreversible conformational changes to facilitate
the merging of the viral and host cell membranes. Using this same fusion process,
5

several class I fusion proteins can also promote cell-cell fusion. Throughout my
graduate research I have investigated the viral fusion proteins of Hendra virus
(HeV), respiratory syncytial virus (RSV), and the recently emerged, SARS-CoV-2.
For HeV to facilitate viral entry, it uses an attachment protein (G) to bind a
target cell, and a fusion protein (F) to merge the viral and host cell membranes.
Previously, we have shown that the TM domain of the F protein, separate from the
rest of the protein, is present in a monomer-trimer equilibrium. This TM-TM
association contributes to the stability of the prefusion form of the protein,
supporting a role for TM-TM interactions in the control of F protein conformational
changes. In Chapter 3, we hypothesize that the TM region of HeV F can be
targeted to destabilize the pre-fusion conformation of the protein. To do this,
constructs expressing the HeV F TM with limited flanking sequences were
synthesized. Co-expression of these constructs with HeV F resulted in dramatic
reductions in the stability of F protein expression and fusion activity in a sequence
specific manner. To further examine this, a TM peptide homologous to the PIV5 F
TM domain was synthesized. Addition of the peptide prior to infection inhibited
infection with PIV5 but did not significantly affect infection with human
metapneumovirus, a related virus. To complete the assessment the role of the TM
region in protein function, we performed alanine scanning mutagenesis of the Nterminal TM region of HeV F in Chapter 4. Through the N-terminal mutagenesis,
we discovered that changes to residues M491/L492 significantly reduce F fusion
without drastically altering protein expression. Additionally, we show that residues
S490, S493, and Y498 play important roles in protein processing, a critical step for
fusion, consistent with previous work [160, 173]. Our studies in these two chapters
demonstrates that targeted disruption of TM-TM interactions significantly impact
viral fusion protein stability and function, presenting these interactions as a novel
target for antiviral development
As SARS-CoV-2 emerged and caused the global pandemic in early 2020,
we shifted to investigating the fusion protein of SARS-CoV-2 S. S is the sole viral
protein responsible for both viral binding to a host cell and the membrane fusion
6

event needed for cell entry. In addition to facilitating fusion needed for viral entry,
S can also drive cell-cell fusion, a pathogenic effect observed in the lungs of SARSCoV-2 infected patients [234-237]. While several studies have investigated S
requirements involved in viral particle entry [179, 181, 182, 238, 239] , examination
of S stability and factors involved in S cell-cell fusion remain limited. In Chapter 5,
we aim to understand factors that mediate S cell-cell fusion, including proteases
involved, and cleavage events required. We demonstrate that S must be
processed at the S1/S2 border in order to mediate cell-cell fusion, and that
mutations at potential cleavage sites within the S2 subunit alter S processing at
the S1/S2 border, thus preventing cell-cell fusion. We also identify residues within
the internal fusion peptide and the cytoplasmic tail that modulate S cell-cell fusion.
Additionally, we examine S stability and protein cleavage kinetics in a variety of
mammalian cell lines, including a bat cell line related to the likely reservoir species
for SARS-CoV-2, and provide evidence that proteolytic processing alters the
stability of the S trimer. This work therefore offers insight into S stability, proteolytic
processing, and factors that mediate S cell-cell fusion, all of which help give a more
comprehensive understanding of this highly sought-after therapeutic target.
RSV, a member of the Pneumoviridae family, is ubiquitous and an important
respiratory pathogen, particularly dangerous for children under two, elderly, and
the immunocompromised. Despite the global importance of RSV, there is currently
only one FDA approved treatment for it, a prophylactic monoclonal antibody.
Similar to HeV and SARS-CoV-2, RSV possesses a class I fusion protein (F) that
is critical for facilitating the membrane merging needed for viral entry, making F a
key therapeutic target. While there is an incredible amount of work being done to
target F for vaccine and antiviral treatment development, studies that analyze the
proteolytic processing requirements and factors that impact F function remain
limited. Additionally, a majority of the current work being completed on RSV F
focuses on a F protein from strain A2, a RSV strain that has been cultured in a
laboratory setting for many decades. Analysis of RSV F from the B subtype of this
virus, or from clinically relevant strains of either subtype, has not been previously
done. In Chapter 6, we hypothesize that RSV F from different subtypes has
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different requirements for membrane fusion, including timing and proteolytic
cleavage events. Our work, therefore, focused on characterizing differences in the
RSV F proteins from both lab-adapted and clinical F proteins from both A and B
subtypes. Through a series of mutations, we investigated the proteolytic
processing, stability, protein trafficking kinetics, and fusion function of RSV F
proteins from the difference subtypes.

Collectively, the work presented here

investigates the fusion proteins from several important human enveloped RNA
viruses, providing insight into proteolytic processing, protein stability, and factors
that influence cell-cell fusion. Importantly, this work provides insight into these
highly sought-after therapeutic targets.
Viral Membrane Fusion and the Transmembrane Domain
A critical early step for all enveloped viruses in the entry and infection process
is the fusion of the viral membrane with a target cell membrane [45-48]. This
process is mediated by at least one viral surface membrane glycoprotein, often
referred to as the fusion protein. Since this is a critical step for viral entry, and these
fusion proteins sit on the virion surface, they are a key therapeutic target. Viral
fusion proteins generally fall into one of three classes, based on structural
similarities. However, despite these structural differences, the overall mechanism
of how fusion proteins facilitate membrane merging is relatively conserved.
Membrane fusion promoted by viral fusion proteins can occur either at the surface
of the cell or within an endosome [49], and the location of this event is often
determined by factors within the fusion protein or viral attachment protein ligand.
For most viral fusion proteins, two key steps are needed to allow for the large
conformational changes which bring the viral membrane and cell membrane
together [50]. The first is a priming step, a proteolytic cleavage by a cellular
protease that exposes the highly hydrophobic fusion peptide (FP) or fusion loop
(Fig. 1.4A). This cleavage can occur in the trans-Golgi network as the viral protein
traffics to the cell surface, in recycling endosomes after initial transport to the cell
surface, upon receptor binding or viral particle endocytosis into a target cell, or as
the virus is released from a cell (Fig. 1.2). Additionally, this cleavage can occur to
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either the fusion protein itself (Class I fusion proteins) or an accessory viral protein
(Class II). The second step is a triggering event. Triggering of the protein can be
completed in a number of ways, including the fusion protein binding to a ligand,
the viral attachment protein binding to a ligand and subsequent interaction of the
attachment protein with the fusion protein, or exposure of the fusion protein to the
low pH environment of an intracellular compartment (Fig. 1.4B).
Once a fusion protein has been activated and receives a triggering signal, the
large, essentially irreversible conformational changes begin. The protein first
extends away from the viral membrane to insert the FP or loop into the target
membrane (Fig. 1.4C). The merging of the viral envelope with the target cell
membrane involves a high kinetic barrier, despite ultimately being a
thermodynamically favorable reaction [46, 47, 51-53]. Because of this kinetic
barrier, the energy contained in the fusion protein must help drive this process.
While the depiction in Figure 1.4 is a Class I fusion protein, all the classes of viral
fusion proteins share a similar end to the fusion pathway. This similarity arises
during the pre-hairpin intermediate, where all fusion proteins studied to date share
a homo-trimeric association [54]. The subsequent steps of fusion are hypothesized
to involve a refolding of the protein back on itself to bring the fusion peptide and
transmembrane regions into close proximity, and thus the two opposing
membranes together (Fig. 1.4D–F). During the membrane merger, there is likely
first a hemi-fusion state between the viral and target cell membrane (Fig. 1.4E),
which then continues to a complete integration of the membranes resulting in the
formation of a fusion pore which allows the genetic material of the virus to enter
the cell (Fig. 1.4F). Structures for the pre-fusion and post-fusion forms of multiple
viral fusion proteins have been published [55-69], and the intermediate steps of
this process, while previously unknown, are now being analyzed in a number of
single particle studies, some of which will be discussed later [70-74]. Due to this
intricately orchestrated process, studying all regions of these viral fusion proteins
is critical for understanding the overall mechanism and forces that drive these
processes.
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The transmembrane domain (TMD) of viral fusion proteins remains one of the
more poorly understood components of the membrane fusion process. Over time,
the views of fusion protein TMDs have evolved as the field has shifted from
considering them as simple membrane anchors to active players in membrane
fusion [75]. In the 1990s, several seminal studies on influenza hemagglutinin (HA)
and parainfluenza virus fusion proteins demonstrated that replacing this region of
the protein with a glycosylphosphatidylinositol (GPI) membrane anchor resulted in
loss of fusion but not outer leaflet mixing [76-79], suggesting the need for a
proteinaceous membrane-spanning region for the hemi-to-full fusion transition.
Subsequent studies analyzed sequence-specific requirements by creating
chimeric fusion proteins in which the native TMD was replaced and found that
some fusion proteins have sequence requirements while others do not [80-85].
Additional results suggested that there is a TMD length requirement for viral fusion
proteins, as the TMD of these proteins needs to be long enough to span both
leaflets of the viral envelope to facilitate the fusion process [80]. These studies
suggest that TMDs of these viral fusion proteins play several functional roles in
viral entry, including a role in the hemi-fusion to full-fusion transition, in promotion
of outer leaflet mixing, and in fusion pore enlargement. Recently, significant
advances have been made in understanding TMD interactions and the role of the
TMD in fusion protein stability, structure, and function. In this review, we will
discuss findings from the last decade that broaden our knowledge of the viral
fusion protein TMD and the important role it plays in the overall membrane fusion
process.
Class I Fusion Proteins
Some of the most studied viral families, including orthomyxoviruses (IAV),
paramyxoviruses (HeV), pneumoviruses (RSV), retroviruses (HIV), coronaviruses
(SARS-CoV-2), filoviruses, and arenaviruses, possess class I fusion proteins.
Class I fusion proteins exhibit a homo-trimeric association in both the pre-fusion
and post-fusion states, and most of the secondary structure of these proteins is αhelical in both states. While these fusion proteins have been extensively studied
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for decades, there have been numerous advances on their mechanisms of action
in the past ten years including work aimed at structurally and functionally
characterizing the TMDs
Influenza
The fusion protein of IAV, also known as hemagglutinin (HA), is one of the
best studied viral fusion proteins. HA is a homo-trimeric protein that requires
proteolytic processing to cut the protein into two subunits, HA1, important for
binding to target cell receptors, and HA2, which facilitates membrane fusion.
Previous work on the TMD of HA has implicated this region as playing a functional
role, as there is a specific amino acid length requirement for this region and it was
shown to be critical in late stage aspects of membrane fusion, such as fusion pore
formation and enlargement [76, 77, 80, 86, 87]. Recent studies have continued to
elucidate the important role of the HA TMD in the function of the full-length protein.
In this section, we will discuss the contemporary findings that provide insight into
the structure of the HA TMD, its role in the dynamic intermediates, the post-fusion
conformation, and in HA interactions with the membrane environment during the
fusion process.
While structures of the ectodomain of HA have been available for several
decades [56, 57, 88-95], the first structure of the full-length HA protein, including
the TMD, was published in 2018 [96]. When compared to previously published
structures of the HA ectodomain alone, the ectodomain of the full-length HA
structure is very similar, indicating that inclusion of the TMD does not profoundly
affect the ectodomain conformation. Interestingly, the TMD was found at angles
between 0° and 52°, with respect to the ectodomain region (Fig. 1.5A), revealing
the presence of a flexible linker region between the ectodomain and the TMD. This
flexible linker region consists of a conserved glycine followed by a small fiveresidue α-helix and a four-residue extended chain (residues 175–184). When the
structure was solved in complex with a FISW84 Fab, this angle was restricted to
20° or less. Analysis of the structure showed that the base of the ectodomain lies
in a horizontal orientation relative to the membrane. Conserved glycine residues
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at the C-terminus of the ectodomain and the end of the helix in the flexible linker
allow for side chain turning to facilitate flexibility in this region. A conserved
isoleucine begins the bundled α-helices of the TMD, which extend for 16 residues
to a conserved leucine, then glycine residue. Within this α-helical bundle, a tyrosine
residue provides a linkage point between the helices. Although the TMD extends
seven residues past the conserved glycine, the helices become less ordered in
this region. It is likely that the three conserved glycine residues are critical to allow
the large degree of tilt of the TMD with respect to the ectodomain observed in the
solved structures. Furthermore, in these different tilted forms, the helices in the
TMD maintain their secondary structure but rotate with respect to the other helices
in the trimeric bundle. In all the tilted forms, there are consistent contacts with the
central tyrosine, indicating this may be crucial for maintaining inter-helix contacts.
This independent movement of the individual TMDs of HA is consistent with
previous molecular dynamics simulations of the TMD in isolation which found that,
when inserted into a DMPC lipid bilayer, there was no direct contact observed
between multiple TMDs [97]. Additionally, a single HA TMD peptide exhibited a tilt
angle of about 60° in the membrane in molecular dynamics simulations. When
three TMD peptides were present, the tilt angle increased by 10o, and the peptides
arranged in a triangular manner, similar to the arrangement in the full-length
structure [96]. When mutations were introduced into the TMD peptide, the helicity
of the peptides was altered, but no overall effect was seen on the tilt angle of the
peptide in the membrane. These studies indicate that the tilt of the TMD of HA with
respect to the membrane may play a role in membrane fusion, as different angles
may be needed to compensate for the large conformational change experienced
by the ectodomain of the protein. Additionally, the finding that the TMD peptides
alone arranged into trimers suggests that the TMD may play a role in the overall
trimerization of the protein.
In the cascade of HA viral membrane fusion, there are likely a series of
intermediate protein arrangements between the metastable pre-fusion HA
conformation and the post-fusion form, but these have been difficult to capture.
Recent studies have succeeded in identifying protein intermediates in the fusion
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process [98], and two have used the full-length protein [71, 99], providing important
new information. The first used cryo-microscopy and cryo-tomography to visualize
viral particles fusing with liposomes upon low pH treatment [99]. Images captured
showed that prior to full viral-liposome fusion, the viral particle has several contacts
with the liposome membrane. These contacts were seen as thin, continuous lines
between the viral particle and the liposome, with the length of these lines
consistent with an extended conformation of the HA protein, with the TMD still
embedded in the viral particle and the FP in the liposome membrane. Around these
zones, the liposome membrane exhibited a dimpling effect out towards the viral
particle, potentially as a result of multiple FP insertions into the target membrane.
Additionally, bent versions of the extended structure were observed, consistent
with the protein folding back on itself as it moved towards the post-fusion structure.
Radiating outward from the central dimpled region were dense bars of HA protein.
These bars appeared even before full fusion pore formation, which may be the
result of either already folded back HA proteins or HA proteins that triggered but
did not insert in the target membrane. This work confirms the presence of a full
extended intermediate of HA along the fusion cascade and demonstrates several
other intermediate forms.
Another study analyzed conformational changes of the protein that occur prior
to the full extension intermediate of HA. To analyze the HA protein in a single
molecule study, a Forester resonance energy transfer (FRET) HA protomer, which
includes the full-length HA from the strain H5N1, with its TMD, was created [71].
The addition of two fluorophores to the HA2 subunit allowed for reporting of a prefusion conformation (high FRET) or a post-fusion conformation (low FRET).
Analysis of this tagged HA protein within the context of a single viral particle found
that even at neutral pH (pH = 7.0), the protein spent time in three distinct
conformations, a high FRET, an intermediate FRET, and a low FRET state. As the
pH was decreased from neutral pH, the HA protein demonstrated an increase in
occupancy of the low FRET state in a stepwise manner. The amount of protein
found in the intermediate state stayed consistent regardless of the pH.
Interestingly, samples that were exposed to low pH for short periods of time were
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able to revert back to high FRET states upon return to neutral pH. However, those
that were exposed to low pH for extended times (30 minutes or more), were unable
to return to high FRET states. This indicates that the protein may sample low pH
conformations prior to irreversibly converting to the post-fusion conformation.
FRET experiments were also completed in the presence of stalk-targeting
antibodies, the HA receptor sialic acid, and a target membrane. Co-expression
with stalk-targeting antibodies prevented transition of the protein to the low FRET
state while increasing the occupancy of the protein in both the high and
intermediate FRET states. The presence of sialic acid increased the overall
kinetics of the conversion between high and intermediate to low FRET states, while
the presence of a target membrane increased the amount of protein that was found
in the irreversible low FRET state. This suggests that there is a breathing
movement of the full-length HA protein prior to the extended intermediate in the
fusion cascade. This dynamic movement may help temporally control the fusion
process by allowing HA to sample its environment, thus ensuring conditions are
correct for a full fusion event to occur. Movement of the TMD with respect to the
ectodomain, conferred by the flexible linker region [96], may be important for these
dynamic intermediates to occur.
In the post-fusion form of the HA protein, the FP and the TMD are in close
proximity. Previous work has demonstrated that these regions can form a complex
within the membrane environment [100], though the role of this complex is
unknown. To address this, a recent study examined the effect of the HA FP and
TMD both alone and together on membranes using electron spin resonance [73].
Both the FP and TMD alone have an ordering effect on several different types of
membranes, with a synergistic effect observed when both the TMD and FP are
present in the same membrane. When FP is alone, pH affects the membrane
ordering, but the FP-TMD membrane ordering is not affected by changes in pH.
While it has been previously shown that the TMD alone induces distinct microdomains in the membrane [101], the FP-TMD complex is also able to induce these,
to a greater extent than the TMD alone [73]. To further examine the FP-TMD
relationship, mutations known to affect membrane fusion were made to FP
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residues. When an FP with a G1S mutation, known to block fusion at the hemifusion step [102], is present, some lipid ordering still occurs, but no synergistic
effect was observed when the wildtype TMD peptide was added. In contrast,
addition of the fusion-blocking mutation G1V to the FP resulted in complete loss of
lipid ordering, suggesting this glycine residue in the FP is critical for the FP-TMD
complex formation. A mutation at Y14, also previously shown to block fusion, was
still able to induce membrane ordering when the TMD was present, suggesting
that this mutation does not block the FP-TMD interaction. In the TMD, mutations
K183E and L187A have been demonstrated to abolish the membrane ordering
effect of the TMD itself [101]. Analysis of these mutations using electron spin
resonance to measure membrane ordering in the presence of the FP suggested
that L187 played a key role in the FP-TMD interaction, while the mutant K183E did
not. This suggests that the FP-TMD interaction is strongly influenced by the Nterminal portion of the FP and the hydrophobic segment of the TMD. Furthermore,
the insertion depth into the membrane of the N-terminus of FP was found to
increase in the presence of the TMD, again supporting an interaction between the
two.
Contrary to the work described above, a study from 2018 on the FP-TMD did
not provide evidence of complex formation [103]. Using hydrogen–deuterium
exchange mass spectrometry (HDX-MS), Ranaweera et al. studied the full-length
HA2 subunit or the HA2 ectodomain with either the FP or the TMD present.
Extensive exchange was observed when the FP region was present in both the
full-length and the truncated protein, while the TMD demonstrated very little,
supporting a model in which the FP lies along the membrane face a portion of the
time, allowing for exchange, while the TMD traverses the membrane. The results
did suggest, however, that the orientation of the FP and TMD with respect to each
other and the HA ectodomain may play a role in creating positive membrane
curvature to help with fusion pore expansion. The contrasting results from these
two studies warrant further research into the relationship between the HA FP and
TMD.
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Since the TMD does not exist in isolation but in the context of the membrane
environment, several studies have examined the relationship between HA and the
lipids of the membrane [104-107]. HA contains two raft targeting signals, one on
the outer leaflet of the TMD and one at the interface of the TMD and cytoplasmic
tail [108-112]. Mutation of the signal in the outer leaflet of the TMD caused slower
transport through the Golgi, whereas mutation of the second signal did not delay
transport [104], and both mutants displayed reduced association with rafts at the
plasma membrane. To further delineate the relationship between membrane lipids
and HA, a study analyzed the effect of mutating a conserved cholesterol binding
motif, YKLW, found at the interface of the TMD and the flexible linker in HA proteins
from the phylogenetic group 2 [105]. This work demonstrated cholesterol directly
binds to HA through this region. Mutation of this motif to alanines resulted in a
reduction in viral replication, HA and cholesterol incorporation into viral particles,
and HA fusion activity. This mutation appears to specifically affect the extent and
kinetics of lipid mixing during the hemi-fusion state, suggesting that an HA TMDcholesterol interaction is critical for this aspect of membrane fusion. However, work
completed in 2015 suggests these interactions may not be critical for all subtypes
of HA. Using high-resolution secondary ion mass spectrometry on stable cell lines
expressing HA (H2 subtype, phylogenetic group 1), the colocalization of HA with
common membrane lipids was assessed [106]. HA demonstrated little
colocalization with either cholesterol or sphingolipids, suggesting HA, at least from
this subtype, does not associate with membrane raft domains. These contrasting
data may be due to the difference in HA subtypes used, but further exploration of
the interactions of HA with the surrounding membrane is warranted.
Recent work has illuminated the influenza HA TMD structure and has
characterized a flexible linker region that lies between the ectodomain and the
TMD [71, 96, 97, 99]. Additionally, studies have shown that some subtypes of HA
bind cholesterol in the TMD, suggesting that, together with the FP, the TMD plays
a role in the membrane manipulation needed to facilitate the merging of the viral
and target membrane [73, 103-106]. While this section reflects the immense
amount of work completed on HA TMD over the past several years, it is clear from
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the number of conflicting studies that more work needs to be completed. Though
there is some conservation of the TMD of different HA subtypes [113], the TMD of
each subtype may have its own unique properties that need to be investigated.
Human Immunodeficiency Virus (HIV)
The fusion protein of HIV is known as the Envelope protein (Env). Similar to
the influenza HA protein, HIV Env (gp160) consists of two subunits, a gp120
receptor-binding domain and a gp41 membrane-spanning domain that mediates
viral fusion. There is a high degree of conservation in the TMD of gp41 from
different HIV strains, and that conservation was first used to implicate the TMD as
more than just a membrane anchor [114]. Similar to influenza HA, there has been
extensive work over the past decade on the gp41 TMD. In this section, we review
studies which illuminate the structure of the TMD, the dynamic nature of FP-TMD
interactions, the role of the TMD region as a modulator of immune function, and
the role of the TMD in overall protein trafficking.
The number of structural studies of the TMD or TM proximal regions of Env
gp41 exemplify the considerable amount of work recently completed in this area.
In the past decade alone, there have been studies examining the TMD in isolation
[115-117], the TMD with the membrane proximal external region (MPER) [118120], the gp41 ectodomain with the FP proximal region and the MPER [121], as
well as a full-length structure of gp41 (including the TMD) [122]. All-atoms
molecular simulation models and nuclear magnetic resonance (NMR) have been
used to probe the structure of the HIV Env TMD in isolation [115-117]. These
studies suggested that the TMD forms a closely assembled trimer [115, 116]. The
conserved residue R696 serves as a midpoint between two distinct domains in the
TMD, an N-terminal coil-coiled domain, and a C-terminal hydrophilic core domain.
The N-terminal coil-coiled contains a GXXXG oligomerization motif, but the data
showed that only the first G in the motif lies at the interface of the trimer, while the
other lies away from it [115]. This suggests that for trimer formation using a GXXXG
motif, only the first G is essential. Further analysis demonstrated that the N17

terminal half of the TMD appeared to be less structurally stable than the C-terminal
half [116]. These studies did not report on the orientation of the TMD with respect
to membrane, though an all-atoms molecular dynamics simulation determined that
a single protomer of the TMD formed a stable tilted α-helical region [117].
To situate the TMD in relation to the ectodomain of gp41, a series of structural
studies were completed with peptides containing both the TMD and the MPER of
gp41 [118-120], but interestingly the findings vary. The earliest study found that
the MPER and N-terminal portion of the TMD create an aligned α-helix, while the
C-terminal region of the TMD is also α-helical, but is not in frame with the rest of
the protein [120]. Subsequent work demonstrated that the MPER exists in two
distinct α-helices which are connected to the TMD through a kink at residue K683
[118]. In agreement with this, another study demonstrated a turn at residue 683,
but their data suggested that both the MPER and TMD consisted of a single αhelical region each [119]. These discrepancies may be due to the use of bicelles
in the first two studies [118, 120] and phospholipid bilayers in the latter [119],
differences in the peptide purification method, and the use of a tag on the peptide
[120], or the differences may reflect different states of these regions along the
fusion cascade. Regardless, further work is needed to delineate the structure of
these regions in context to each other, and studies using the full-length protein
may help better understand the relationship of these regions.
Work that includes the entire full-length protein, or just portions of the
ectodomain, does not yet resolve these questions [121-124]. When the entire
protein was present, the TMD and MPER were unable to be resolved, suggesting
either different conditions are needed for structural analysis or there is an increase
in flexibility in this region when the entire ectodomain is present [122]. When all
protein domains, other than the FP and the TMD, are structurally determined in the
post-fusion form gp41, the ends of the FP proximal region and the MPER splay
outward from each other [121], suggesting the FP and TMD may not be in close
proximity to each other in the post-fusion structure. The structure of an MPER
trimer in isolation also supports this by demonstrating a splaying out of the helices
of the trimer as they approach the membrane [123]. Both of these studies also
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found some MPER insertion into the detergent micelle, suggesting that the MPER
has some degree of interaction with the membrane.
During the viral-membrane fusion process, the ectodomain of gp41 undergoes
a large conformational change, moving from a pre-fusion state and refolding to a
post-fusion conformation. This change brings the TMD and FP in close proximity,
similar to HA, but there is some debate as to whether these hydrophobic regions
physically interact. One study demonstrated that gp41 FP- and TMD-derived
peptides directly associated with each other and together were able to induce lipid
mixing in membranes [125]. Work with a synthetized protein that included the FP,
a small region of the ectodomain at the C-terminus of FP, MPER, and TMD with a
short flexible region connecting the FP proximal region and the MPER, revealed
that the FP has mostly β-sheet structure and is partially inserted into the
membrane, while the TMD region is α-helical and traverses the membrane [126].
In contrast to the previous work, this study showed no evidence for FP-TMD
interactions. These data, however, do suggest that protein conformations
associated with a hemi-fusion intermediate step exist between the pre-fusion and
post-fusion conformations of the protein.
While the dynamic nature of the gp41 ectodomain is apparent by the
differences in pre-fusion and post-fusion structures, the dynamic nature of the TMD
is just beginning to be uncovered. Work that replaced the TMD of gp41 with a TMD
of another viral fusion protein or another membrane-spanning protein found that
fusion inhibition occurred, likely due to alterations in the ectodomain conformation
of the protein, suggesting differences in interactions within the TMD play a critical
role in the overall protein conformation [127]. Further illuminating the dynamics of
the TMD, several studies have investigated conformational changes that occur in
the TMD during the fusion process, with many of these focusing, at least in part,
on a mid-TMD arginine residue (R696). R696 is highly conserved among different
HIV subtypes and has been implicated as critical for membrane fusion [128].
Molecular dynamic simulations suggest the position of R696 with respect to the
membrane leaflets likely plays a role in facilitating the fusion event. R696 can
snorkel to interact with the inner leaflet of the membrane, allowing for water
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penetration into the membrane and membrane thinning needed for membrane
fusion [129]. Additional simulations investigated the relationship between
cholesterol and R696 [130]. It was determined that R696 allows for water
penetration in a variety of membranes, but cholesterol-containing membranes help
localize the overall membrane thinning associated with this water penetration to
the mid-span arginine residue, likely by regulating the tilt angle of the TMD relative
to the membrane. There is evidence that R696 also acts in concert with the Cterminal hydrophilic core of the TMD to allow for water penetration into the
membrane [131]. This concerted action is consistent with R696 snorkeling to the
inner membrane leaflet (towards the C-terminus), allowing for membrane
perturbations consistent with those needed to facilitate viral entry. There are two
additional conserved basic residues (K683 and R707) in the TMD of gp41 [129].
These residues likely interact with the head groups of the outer and inner
membrane

lipids,

respectively.

Observations

from

membrane

dynamics

simulations conclude that these head groups anchor the TMD to the edges of the
membrane so that when R696 snorkels, the pull on both of these residues also
contributes to the membrane thinning.
HIV-1 infection of cells disrupts normal immune responses, allowing the
virus to avoid detection. Both Toll-like receptor (TLR) activity and T cell receptor
(TCR)/cluster of differentiation 3 (CD3) complex formation are down-regulated in
HIV infection, and gp41 can disrupt TCR and CD3 complex formation to inhibit
immune activity [132, 133]. However, this disruption was only recently shown to be
due to direct binding of the gp41 TMD with the TMD of both TCRs and CD3. These
interactions occur within the membrane environment and specifically use the
GXXXG motif found in the TMD of these proteins [134, 135]. Down-regulation of
TLRs was also found to involve interaction with the TMD of gp41 through the
GXXXG motif, suggesting that this motif could play a role in other interactions that
disrupt the immune response during an infection [136]. The isolated peptides from
the gp41 FP region also interact with the TMD of TCRs through a similar motif,
AXXXG, which suppresses TCR immune activity [133, 137-139]. When the
AXXXG motif was present in FP-mimicking peptides, lipid mixing could be induced,
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but when this motif was mutated, lipid mixing did not occur, suggesting this motif
may be important in the transition from hemi-fusion to fusion pore formation during
membrane fusion.
Induction of broadly neutralizing antibodies (bNAbs) is a critical part of
current HIV vaccine strategies. bNAbs to the HIV Env protein have several different
targets, one of which is the MPER region bordering the TMD. However, stabilized
soluble trimer mimics of Env, termed SOSIPs, lacking a majority of the MPER and
all of the TMD are commonly used in HIV vaccine development. Recent research
has demonstrated that antibody binding differences may be dependent on which
regions of the Env protein are present [140, 141]. A direct comparison of a SOSIP
trimer to a full-length Env trimer showed that SOSIP trimers had less complex and
less processed glycans compared to the full-length protein. Glycans are part of
several binding epitopes for bNAbs, and the differences in complexity in SOSIP
trimers resulted in lower binding affinity of these antibodies compared to the fulllength Env. This comparison also revealed that the full-length protein had more
conformational flexibility than SOSIPs and therefore exposed epitopes that also
bound the non-neutralizing antibodies tested. Inclusion of the TMD with an MPER
peptide has been shown to increase the binding affinity of bNAbs to these
peptides, although there is conflicting data on whether a trimeric TMD further
increases this affinity. One set of binding assays completed in nanodiscs suggests
that the addition of a trimeric-TMD recapitulates the bNAb binding of native-like
Env protein [140], while another suggests inclusion of a single MPER-TMD peptide
in each nanodisc increased the percentage of antibody bound to that peptide [142].
It has been shown by both NMR modeling [120] and crystallography with molecular
dynamics simulations [143] that bNAbs targeting the MPER region of gp41 bind
residues within the TMD as part of their epitope, explaining why the presence of
the TMD increases binding affinity. Additionally, analysis of one specific MPER
bNAb demonstrated that this antibody also interacted with membrane lipids [143].
This suggests that the conflicting results on the effect of TMD oligomerization on
MPER-TMD bNAb binding may be due to the presence or absence of certain lipids.
Taken together, these studies suggest that efficient testing and analysis of bNAbs
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targeting Env MPER should include the TMD and potentially a representative
membrane environment. Beyond just enhancing the testing efficacy of MPERtargeting bNAbs, utilizing versions of the full-length protein may be a way to further
improve current vaccine candidates.
During an HIV infection, Env is synthesized in the endoplasmic reticulum
and traffics through the Golgi and secretory pathway to reach the plasma
membrane [144]. The TMD of the Env (gp41) protein has been implicated in this
protein trafficking. As previously described, the TMD contains both a GXXXG
oligomerization motif and a mid-span arginine that are highly conserved. When the
distance between the last G in the GXXXG motif and the mid-span arginine is
increased by the addition of an alanine residue, a defect in membrane fusion is
seen [145]. This was shown to be due to a defect in protein transport through the
endoplasmic reticulum (ER) and Golgi. This transport delay may be due to
disrupted contacts of the individual trimer TMs with each other or through
disruption of protein-membrane interactions. Further analysis of this region
demonstrated that R696 does not confer a strict ER localization on the gp41
protein, despite the presence of charged residues within a TMD being a wellrecognized ER localization motif [146]. Therefore, other elements in the HIV Env
TMD, including its length, override the potential retention signal.
It is clear that the HIV gp41 TMD plays an essential part in the structural
stability, function, and trafficking of the gp41 protein. This recent work has
demonstrated that the gp41 TMD is critical for processes such as virus-to-cell
fusion, immune modulation, antibody recognition, fusion protein trafficking, and
several aspects of the membrane fusion cascade. These studies also continue to
uncover vaccine and antiviral targets for this important human pathogen by
understanding key molecular and cellular interactions.
Paramyxoviruses and Pneumoviruses
Paramyxoviruses have Class I fusion (F) proteins that require both a
proteolytic cleavage event and receptor binding to facilitate fusion. However, unlike
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the previously discussed IAV HA and HIV Env proteins, the receptor binding
function of this process is executed by a separate viral surface glycoprotein, the
attachment protein (HN, N, or G). There are a number of different methods for
proteolytic priming of the paramyxovirus and pneumovirus F proteins. The majority,
including measles F, PIV5 F, and mumps F, undergo a single cleavage by furin in
the trans-Golgi network [46, 50, 147]. A small number, including HMPV F and
Sendai, are cleaved by exogenous proteases [148, 149]. The proteolytic
processing of HeV F occurs in recycling endosomes. HeV F is initially synthesized
and trafficked to the cell surface. From there it is endocytosed, shuttled through
recycling endosomes, where it is cleaved by cathepsin L, and then returned to the
cell surface for particle assembly (Fig. 1.2b) [150, 151]. HeV F protein cleavage
exposes a hydrophobic fusion peptide, and leaves the protein as a disulfide linked
heterodimer (F1 and F2), (Fig. 1.3a). RSV F, on the other hand, is cleaved in the
trans-golgi network, likely by the cellular protease furin, during the initial protein
trafficking to the cell surface (Fig. 1.2a)[152, 153]. Interestingly, RSV F contains
two furin cleavage sites, 27 amino acids apart. The second cleavage site exposes
the hydrophobic fusion peptide, however the role and timing of cleavage of the first
cleavage sites remains unknown (Fig. 1.3b) [154-156].
Work in the last decade has demonstrated a role for the TMD in the overall
structure of the fusion protein. In addition, it has also been shown to be important
for pre-fusion stability, membrane fusion, post-fusion FP-TMD interactions, fusion
protein trafficking, and viral particle assembly.
Crystal structures have been solved for the ectodomain portions of several
paramyxovirus fusion proteins [55, 61, 62, 67-69], but structural insights into the
TMDs of these proteins remain limited [157, 158]. Solid-state NMR analysis of
isolated TMD peptides of parainfluenza virus 5 (PIV5), separate from the rest of
the protein, found that portions of the TMD display some membrane-dependent
conformational plasticity. Both ends of the TMD adopt a β-strand conformation in
phosphatidyl ethanolamine (PE) rich (negative curvature) membranes but form a
continuous α-helix with the central portion of the peptide in phosphatidyl choline
(PC)/cholesterol rich membranes [157, 158]. These flexible regions of the TMD are
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rich in β-branched residues. This indicates both termini of the TMD could play a
role in the membrane perturbation needed to mediate membrane fusion. The
central portion of the TMD, however, was shown to form a core α-helical region
that associates as a trimer with neighboring TMDs regardless of the membrane
composition. This 12-residue, leucine-rich stretch may serve as the central
trimerization domain needed for overall protein oligomerization.
Despite limited structural data, biochemical and biophysical studies have also
probed the trimeric nature of paramyxovirus TMDs. Initial work that substituted the
residues in the predicted TMD of PIV5 F with cysteine residues to induce disulfide
bonds within the membrane demonstrated that the TMD of F existed as α-helices
and formed a helical bundle with the other TMDs of the protein trimer [159]. Further
analysis of the TMD helical bundle was completed using sedimentation equilibrium
analytical ultracentrifugation (SE-AUC). Using this technique, the fusion protein
TMD of Hendra, human metapneumovirus (HMPV) (now in the Pneumoviridae
family [26, 158]), and PIV5 were demonstrated to exist in a monomer–trimer or
monomer–trimer–hexamer equilibrium when studied in isolation [160].
To examine the effect of this TMD association on overall protein folding and
function, two common oligomerization motifs, a AXXXG motif [160] and a LeucineIsoleucine Zipper (L-I Zipper) [161], were mutated in the Hendra F protein.
Mutations of the glycine in the AXXXG motif led to a decrease in cell surface
expression and a decrease in fusion activity at levels consistent with the reduced
protein expression. Single alanine mutations of each residue in the L-I Zipper had
varying effects on protein expression and fusion activity, suggesting that each has
a unique role. However, when all four residues in the L-I Zipper were mutated to
alanine, a decrease in the expression of the protein was shown, and the fusion
activity of the protein was abolished. Further analysis with SE-AUC showed a
1000-fold decrease in the association constant in the monomer–trimer equilibrium,
indicating TMD-TMD associations were destabilized when the L-I Zipper was
altered [161]. A heat-induced triggering assay demonstrated that mutations which
altered TMD-TMD association also led to a decrease in stability of the pre-fusion
form of the Hendra F protein, suggesting TMD-TMD associations are important for
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holding the F protein in the prefusion conformation prior to triggering. Replacement
of the TMD of Newcastle disease virus (NDV) with either related or non-related
viral protein TMDs demonstrated alterations in conformation-specific antibody
binding [162], suggesting that, similar to Hendra, specific TMD-TMD associations
are needed for the stability of the proper pre-fusion conformation of the fusion
protein. Interestingly, mutation of the L-I zipper motif in the TMD of PIV5 to alanine
had no effect on the total expression or pre-fusion stability of the protein and only
a minor effect on surface expression, but fusion activity was abolished [159, 163].
Taken together, these data suggest that the contribution of leucine zippers in
fusion protein TMDs to the overall protein stability and function may be virus
specific.
Following triggering, the F protein of paramyxoviruses undergoes large
conformational changes that include insertion of the FP into the target membrane,
followed by the protein refolding back on itself to facilitate formation of the six-helix
bundle. While the details of the TMD throughout this process are still being
investigated, there is clear evidence for an active role of the TMD and TMD-TMD
interactions along the fusion cascade [158, 159, 162-165]. Illustrating the role of
the TMD in the fusion process, replacement of the NDV F protein TMD with the
TMD of a related viral fusion protein abolished fusion, including hemi-fusion
intermediates, despite the chimeric fusion protein being expressed and cleaved at
the cell surface [162]. This lack of fusion may be due to an inability of these proteins
to form complexes with the NDV HN protein which is critical for membrane fusion,
though other mechanisms are also possible.
To further probe specific residues of the TMD that are critical for fusion, several
studies performed mutagenesis on paramyxovirus F protein TMDs and analyzed
differences in fusion activity [159-161, 163-165]. Alanine scanning mutagenesis
found that β-branched or just branched amino acid residues at the C-terminus of
the TMD appear to play an important role in fusion in both PIV5 [159] and Hendra
[165]. Analysis of these branched residues in PIV5 demonstrated that mutating
them likely blocks fusion during the hemi-fusion or fusion pore formation stages,
indicating they may play a role in lipid mixing. This hypothesis is further supported
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by the structural analyses that revealed conformational flexibility found in the βbranched-rich TMD termini of PIV5 and showed this flexibility promotes changes
within the membrane needed for fusion to occur [157, 158]. Recent work also
suggests that TMD-TMD associations in paramyxovirus F proteins are important
for controlling the fusion cascade. Mutating the L-I Zipper motif in the F protein
TMD completely suppressed fusion activity in both PIV5 and Hendra, despite there
being cleaved protein at the cell surface in both cases [161, 163]. Interestingly,
introduction of disulfide bonds to prevent TMD-TMD dissociation also disrupts
fusion in Hendra [164], as does introduction of disulfide bonds directly N-terminal
to the TMD in PIV5 F [166]. These studies suggest that TMD-TMD association and
dissociation must be intricately controlled for membrane fusion to occur.
The final steps of fusion involve a zippering together of the N- and C-terminal
heptad repeat regions [46, 47, 167, 168], and this refolding brings the FP and the
TMD in close proximity to one another. Solid-state NMR analysis of the FP and
TMD of PIV5 F in a lipid membrane suggests these do not form a tightly associated
bundle. The data, however, did indicate weak interactions occur between the FP
and TMD, since when they are found in the same membrane, the conformation of
both was largely α-helical regardless of the membrane composition [169]. In
contrast, using SE-AUC, the FP was found to have a strong interaction with TMD
peptides in detergent micelles [170]. Analysis of the FP or TMD alone found that
regions of both adopted β-strand conformations in a lipid-dependent manner [158,
171]. Furthermore, when the FP and TMD were in the same membrane, a
synergistic effect induced significant negative curvature in the membrane. When
either the FP or TMD was alone, induction of negative curvature occurred only in
membranes that tend towards negative curvature domains (PE membranes).
These conflicting results suggest the need for additional analysis of the FP–TMD
relationship in paramyxovirus F proteins.
Recent studies have also implicated residues within the TMD as crucial for F
protein trafficking and therefore efficient viral particle assembly [172-174]. Hendra
and Nipah F proteins have a unique trafficking pattern. After synthesis in the ER,
the F proteins traffic through the secretory pathway to the plasma membrane as
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an uncleaved trimer. The F protein is then endocytosed and cleaved in recycling
endosomes by the protease cathepsin L before returning back to the surface in its
activated pre-fusion form [150, 151, 175]. Two polar residues within the TMD, S490
and Y498, were shown to be critical for endocytosis and recycling of the F protein,
specifically the hydroxyl group of S490 and aromatic ring of Y498. Mutating Y498
decreased trimer association, as judged by association constants from SE-AUC,
indicating this residue participates in TMD-TMD associations [173]. Thus, changes
in the TMD association may contribute to alterations in intracellular trafficking
decisions. Further analysis showed that the proper endocytosis and recycling of
the F protein, mediated by residues S490 and Y498, were critical for proper viruslike particle (VLP) formation [172]. This suggests that residues in the TMD
participate in viral assembly by facilitating specific intracellular trafficking in Hendra
and Nipah viruses, but the extent and mechanism remain unclear, as there are
conflicting results on the nature of F trafficking and incorporation in Nipah VLPs
[176, 177]. Residues in the F protein ectodomain likely also assist in proper F
protein incorporation into viral particles, since a chimera of the Rabies virus particle
ectodomain and NDV TMD and CTD demonstrated inefficient incorporation into
NDV viral particles [174].
Over the past decade, the understanding of the roles of the TMD of
paramyxovirus fusion proteins has significantly expanded, demonstrating the
critical nature of this region. These studies have shown that the TMDs of
paramyxovirus fusion proteins have an active role in both spatial and temporal
regulation of the F protein, mediating viral entry, and may be important for efficient
viral particle assembly.

Other Class I Viral Fusion Proteins
The above sections review recent findings on the three most intensively
studied families of Class I fusion proteins, but additional important studies on the
fusion proteins from the Filoviridae and Coronaviridae families, as well as on Env
proteins from retroviruses other than HIV have illuminated the roles of TMDs. The
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fusion proteins of EBOV and coronaviruses (CoV), such as SARS-CoV, MERSCoV and SARS-CoV-2, are known as GP (for glycoprotein) and S (for Spike),
respectively. Both proteins have dual functions in receptor binding and membrane
fusion, similar to the HIV Env protein, and both have to undergo proteolytic
processing to be primed for membrane fusion. The S protein of SARS-CoV-2,
investigated in this dissertation, contains two subunits, S1 and S2.

S1 is

responsible for the receptor binding function and S2 is responsible for carrying out
membrane fusion.

Analysis of the CoV-2 S protein revealed three potential

cleavage sites [178]: A canonical furin site at the border of S1/S2, shown to be
cleaved during protein trafficking to the cell surface (Fig 1.2a and 1.3c) [179, 180],
a site 10 amino acids downstream of the border, shown to be cleaved in SARSCoV S by cathepsin (Fig. 1.3c), and one 100 amino acids downstream of the border
termed the S2’ (Fig. 1.3c), thought to be cleaved by TMPRSS2 during receptor
binding or viral particle endocytosis (Fig. 1.2c and d) [181-183].
The TMDs of both EBOV GP and the SARS-CoV S proteins have been
shown to exhibit monomer–trimer–hexamer oligomerization equilibrium when
analyzed in isolation by SE-AUC [184]. Analysis of the EBOV GP MPER and TMDs
using NMR revealed that both regions appear to be continuous helices
independent of the pH, with a turn in between the two adjacent regions [185],
similar to the MPER-TMD HIV structure discussed previously [118-120]. The
MPER of the GP protein appears to lie on the membrane face, with tryptophan and
threonine residues mediating contact with the membrane interface. This
orientation may represent only one of several potential conformations of the MPER
in relation to the TM, as an in situ structure of the full-length EBOV GP protein
within the membrane demonstrated that the MPER helices and TMD helices are
in line with each other in some conformations of the protein [186]. Biochemical
analysis of the GP protein from Marburg virus (MARV), a virus closely related to
EBOV, showed MARV GP existed as a monomer in lipid-mimicking environments,
further indicating that protein conformations and oligomerization may be
dependent on host environmental factors such as lipid composition or pH [187].
While structural analysis has not been completed on the TMDs of CoV S proteins,
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modeling predictions place a tryptophan-rich region immediately proximal to the
TMD [188]. This tryptophan-rich region and its location with respect to the highly
hydrophobic coil of the S protein TMD is critical for S-mediated membrane fusion.
This study also suggests there is flexibility in the region adjacent to the membrane
region [189], with flexibility in the region between the MPER and the TMD critical
for large-scale conformational changes of the overall protein. Flexibility between
the TMD and the upstream region is characteristic of many Class I fusion proteins,
as it has been demonstrated for several different families (Flexible linker IAV,
MPER-TMD HIV), though data from paramyxovirus F proteins do not support
flexibility for that system [190].
The TMD region of the EBOV GP protein also plays a role in counteracting
the host protein tetherin, which can inhibit viral particle release from infected cells
[191], in contrast to the mechanism used by HIV-1, which counter-acts tetherin
using an accessory viral protein (Vpu) [192]. The first characterization of the role
of the EBOV GP protein TMD in counteracting tetherin showed that substituting
the TMD of EBOV GP with the Lassa virus GP TMD prohibited EBOV VLPs from
inhibiting tetherin activity [193, 194]. Further analysis discovered that a GXXXA
motif within the EBOV GP protein TMD was responsible for counteracting tetherin
activity [195]. This motif was also found to be critical for EBOV filamentous particle
release from cells. Mutating this GXXXA motif in EBOV GP decreased viral particle
release in a cholesterol-dependent manner [196]. Together, these data suggest a
model in which GP trimers, aided by GXXXA motifs within the TMD region, form a
lattice along the surface of infected cells in cholesterol rich regions of the
membrane. This lattice serves as a particle budding site, eventually closing around
actin filaments that are driving this region outward. Particle release then relies in
part on this same GXXXA motif interacting with tetherin present within the
membrane to counter-act its particle tethering ability.
Using cryo-electron tomography and cryo-electron microscopy (cryo-EM),
the structure of full-length Foamy Virus Env was determined [197]. Foamy Virus
Env is composed of the gp18 leader peptide, the gp80 surface subunit, which
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contains the receptor binding site, and the gp48 transmembrane subunit. TMD
helices were observed in both the gp48 subunit and the gp18 leader peptide. This
structure showed three central coiled helices that were in contact with one another,
likely one from each gp48 of the protein trimer. Outside of this coiled-coil, TMD
helices from gp18 each appeared to interact with a single helix from the gp48
subunit. Since the TMDs of gp48 likely need to dissociate to mediate membrane
fusion, this structure suggests a model in which the gp18 TMD helices block the
dissociation of the gp48 until the fusion cascade promotes movement of the entire
TMD complex. Computational analysis of the TMD subunits of several Foamy virus
strains revealed a conserved lysine–proline motif that suggests a break may exist
in the gp48 TMD helix [198], but this was not observed in the structural analysis.
However, this motif could serve as a flex point during the conformational changes
of the fusion process. Predictions also place a tryptophan-rich region of the protein
in the MPER, similar to the MPER in other Class I fusion proteins [118, 188].
The fusion proteins (GPs) from arenaviruses have an additional membrane
spanning component to consider, the stable signal peptide (SSP). Unlike HIV Env
and IAV HA, GPs of arenaviruses form three distinct subunits, G1, responsible for
receptor binding, G2, responsible for membrane fusion, and a 58-amino acid SSP
[199]. These SSPs have been shown to play a role in the pH-dependent membrane
fusion process [200]. Analysis of SSPs has demonstrated they have two
membrane-spanning domains, and residues within the membrane participate in
interactions with the TMD of the G2 subunit [201-203]. These interactions likely
serve to prime the G2 subunit for the membrane fusion event.
The past ten years have yielded numerous insights into the TMD of Class I
fusion proteins: the first TMD structures have been solved, the active role of this
region in several steps of the fusion cascade has been better characterized, and
this region has been implicated in protein trafficking and immune function. While
these contributions have been groundbreaking, contradictory studies indicate that
important work remains to understand this important TMD.
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Class II Fusion Proteins
In 2001, a new class of viral fusion proteins was created because of the
large difference in structure of these fusion proteins from Class I fusion proteins
[204]. Class II viral fusion proteins include members from the togavirus, flavivirus,
and bunyavirus families. While a large amount of α-helical secondary structure is
found in Class I fusion proteins, Class II fusion proteins contain three distinct
ectodomain regions consisting almost entirely of a β-sheet secondary structure
with helical TMDs. These viral fusion proteins associate as homodimers upon
synthesis but also form heterodimers with a companion protein. This creates a
four-protein complex consisting of two fusion proteins and two companion proteins.
Interestingly, for Class II viral fusion proteins, it is the companion protein, not the
fusion protein, that requires a proteolytic cleavage event. The companion protein
cleavage event primes the fusion protein for the low pH-triggered fusion reaction
that occurs in all Class II fusion proteins. To facilitate fusion after exposure to the
low pH environment of the endosome, the fusion protein homodimers dissociate
into monomers, exposing the previously buried fusion loop, allowing for insertion
of this hydrophobic loop into a target membrane. After insertion of the loop into the
target membrane, there is a re-association of the monomers into trimers. They
remain in a trimeric association throughout the rest of the fusion reaction,
completing a series of steps similar to the refolding of the trimer hairpin structure
described previously for Class I [205]. In contrast to the extensive work that has
been completed on the TMDs of Class I viral fusion proteins over the last decade,
only a small number of studies have been performed on the TMDs of Class II viral
fusion proteins. These data do, however, provide important structural insight into
the TMDs of several Class II fusion proteins [206-209] and demonstrate a
functional role for this region in membrane fusion [210, 211].
Using cryo-EM, studies have solved the structures of complete viral
particles from Dengue virus, Zika virus (both Flaviviruses), and Venezuelan equine
encephalitis virus (VEEV) (Alphavirus), which include the in situ full-length fusion
proteins, E and E1, respectively [207-209]. The structure of E proteins for Dengue
(Fig. 1.5B) and Zika show two anti-parallel TMD α-helices, as well as three peri31

membrane α-helices that lie perpendicular to the TMD helices on the exterior
surface of the viral membrane, with each helix connected to the next by a loop
[207, 208]. Analysis of the Dengue E protein structure showed that the loops of the
TMD helices are buried within the head-group region of the inner leaflet of the viral
membrane. The two TMD helices form a coiled-coil, with hydrophobic residues
facing outward, and multiple serine/threonine hydrophilic residues facing inward
on the coiled-coil [207]. These highly hydrophilic interactions appear to have a role
similar to the leucine zipper oligomerization motifs found in some Class I fusion
proteins [161]. The VEEV E1 protein TMD is composed of two α-helices, with a
highly conserved glycine–glycine (GG) kink between them [209]. Since these
studies encompassed the full viral particle, they also provide data for TMDs of their
respective companion proteins, M for Dengue and Zika and E2 for VEEV. The M
protein, similar to E, has two TMD helices that lie anti-parallel to one-another.
Despite being situated in close to proximity to the TMD helices of E, the data did
not demonstrate any protein-protein contacts between M and E within the
membrane space. It was revealed, however, that the presence of both the M and
E TMDs provided some lateral order to the membrane, and the membrane was
bent to accommodate the short length of the TMD helices, indicating that protein–
lipid interactions were likely occurring. The TMD of VEEV E2 was visualized as a
long, straight α-helix. When VEEV E1 and E2 were analyzed together, the GG kink
in the TMD of E1 appeared to allow TMD flexibility so that the lower portion of the
E1 TMD could associate with the E2 TMD helix.
Computational modeling has also provided structural insights into the TMDs
of the surface glycoproteins from a pestivirus known as bovine viral diarrhea virus
(BVDV) [206]. The two surface glycoproteins of BVDV, E1 and E2, are required for
viral entry, with charged residues in the TMD critical for this process [211]. E2 has
two TMD α-helices (tmH1 and tmH2), with extensive hydrophobic interactions
between them and an arginine residue (R1047) in the loop between the helices
which interacts with the phospholipid head groups on the inner leaflet of the
membrane. Additionally, hydrogen bonding between the helices at serines S1035
and S1060 may further stabilize the TMD-TMD interactions occurring between
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tmH1 and tmH2. The TMD of the second surface protein, E1, has two perimembrane α-helices (pmH1 and pmH2), as well as a single transmembrane αhelix (tmH). As shown by modeling of the E1-E2 hetero-tetramer complex based
on ectodomain structural constraints and previously published biochemical
constraints, the TMD helix of E1 is in close proximity to the tmH1 of E2, with
hydrophobic contacts and a single hydrogen bond (T688 from E1 and Y1056 E2)
occurring between the two. This suggests that TMD-TMD associations between
E1 and E2 may be important for overall complex formation. Similar to membrane
disruptions caused by the TMDs of the Dengue E and M proteins [207], residue
R1047 of E2 and charged residues in E1 appear to interact with the phospholipid
head groups of the membrane, potentially causing thinning of the membrane which
could further assist the viral fusion process. These data together present a model
for Class II fusion proteins in which TMD-TMD interactions occur between the
fusion protein TMD and the companion protein TMD, with residues in both of these
regions interacting with membrane phospholipid headgroups. These interactions
may play a role in fusion protein stability and the membrane distortion needed for
proper viral entry.
The role of TMD-TMD interactions in the Class II fusion process is also
suggested by biochemical studies of the flavivirus E protein, which showed the
functional relevance of the second TMD helix [210]. To probe the role of this region
in tick-borne encephalitis virus (TBEV), mutants were created with the second
TMD helix deleted, or one or both TMD helices substituted with the corresponding
helix of the closely related flavivirus, Japanese encephalitis virus (JEV). None of
the mutants, even a full deletion of the TMD2, affected early steps in fusion.
However, each of these mutants was found to destabilize the post-fusion E trimer
which did not allow for the formation of a fusion pore. Interestingly, the chimeras
which substituted the full length of both TMDs with a related virus were still able to
facilitate the full fusion process, albeit less efficiently than the wild type protein.
This suggests a concerted role for interactions between the TMDs in late steps of
the fusion pathway, potentially through intra-helix interactions or interactions with
the fusion loop in the post-fusion conformation of the protein [210].
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While less information is available on Class II fusion proteins compared to
recent studies on Class I fusion proteins, critical structural insights into the unique
TMDs of these fusion proteins have recently been made. Furthermore, this work
has begun to illuminate the extensive TMD-TMD interactions that occur in Class II
fusion proteins, potentially similar to those in Class I fusion proteins that may be
required for fusion complex formation and complex stability in the fusion process.
These recent studies also demonstrate the joint effort of the fusion protein TMD
and the TMD of the companion protein in mediating viral entry.
Class III Fusion Proteins
In 2006, ectodomain structures of fusion proteins from both vesicular
stomatitis virus (VSV) [63] and herpes simplex virus type 1 (HSV-1) [58] were
solved. The VSV G and HSV-1 gB proteins have remarkably similar structures
despite a lack of sequence homology. These fusion protein structures are distinct
from both Class I and Class II, prompting the creation of a new class of fusion
proteins, Class III [212]. This class now encompasses fusion proteins of viruses in
the rhabdovirus, herpesvirus, and baculovirus families [213].
Since 2006, ectodomain structures of the post-fusion forms of HSV-1 gB
[58], Epstein–Barr Virus gB [214], and baculovirus gp64 [215] have been solved,
and both pre- [64] and post-fusion structures [63] have been solved for VSV G. In
the post-fusion form, these fusion proteins are trimeric in nature, similar to both
Class I and II proteins. Each fusion protein ectodomain consists of five distinct
domains. Starting with domain I that contains fusion loops that lie on the end of
extended β-sheet structures, to domain V which forms an α-helical structure that
serves as an interacting interface between the proteins in the trimer, and serves to
connect the ectodomain with the TMD and cytoplasmic tail portion of these fusion
proteins [213]. Unlike the fusion processes in Class I and II, the conformational
changes experienced by Class III fusion proteins appear to be reversible in nature.
Initial work completed on Class III fusion proteins provided limited insight into the
TMD. However, several studies over the past decade have provided structural
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details and evidence for a role of the TMD in membrane fusion and viral particle
assembly.
Recent work demonstrated the crystal structure of a full-length fusion
protein from Class III, HSV gB, in its post-fusion form. This structure includes the
MPER, TMD, and cytoplasmic tail domain (CTD), all of which were absent in
previous structures [216]. The MPER-TMD-CTD regions form a pedestal-like
structure through the membrane, with the ectodomain resting on top. The MPER
regions of a gB trimer form dynamic helices that lie along the surface of the
membrane. At the C-terminus of these helices is a linker with conserved proline
and glycine residues that likely contribute to flexibility in this region. C-terminal to
this linker lies the TMD, which forms a straight helix that extends through the
membrane, with each TMD of the trimer contributing to one side of an inverted
teepee structure. The N-terminus of these regions is splayed apart, and each TMD
crosses the others at a ~46° angle. The C-terminal portions of the three TMDs do
not have cross-promoter linkages, but are in close proximity, in a structure
stabilized by knob-and-hole packing and the presence of conserved, small glycine
and alanine residues which allow for close fit of the helices. Residues at the Ctermini of TMD likely participate in hydrophilic interactions with the CTD. The CTD
of each gB monomer in the trimer forms two α-helices (h1a and h2) and one 310
helix (h1b). Immediately following the TMD, h1a and h1b form a zig-zag with
proline residues at the interfaces between each helix. Then, an unresolved linker
connects to the h2 helix that extends back up toward the membrane. Each CTD
region has several contacts with other CTDs of the gB trimer, further stabilizing
this base (Fig. 1.5C).
Characterization of the location of mutations within the TMD or CTD
previously shown to either enhance or reduce cell–cell fusion allowed for additional
insight into gB fusion regulation. Most hyperfusogenic mutants were found to be at
residues or regions that would disrupt the trimeric interfaces or the membrane
binding of the CTD. Mutants that reduced fusion mainly shorten hydrophobic side
chains that participate in interactions at the CTD trimer axis, thus reducing CTD
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trimer stability and likely causing protein misfolding. Taken together, this suggests
that this structure of the CTD also exists in the prefusion conformation of the gB
protein, forming a triangular base that may serve as a clamp to hold the TMDs in
place until appropriately stimulated, leading to conformational changes required to
mediate fusion. This would suggest a model for Class III membrane fusion in which
a release of the gB CTD clamp is needed for viral entry to occur, seemingly serving
a similar latch role to that of the M protein for flavivirus E [207]. The release of this
clamp may be facilitated in part by TMD-TMD interactions between the gH protein
and the gB, as work that replaced the gH TMD in pseudorabies virus rendered the
virus non-fusogenic [217].
Even before the creation of the new class of fusion proteins, several studies
demonstrated the functional role of the TMD of VSV G in membrane fusion [218,
219], highlighting specifically that glycine residues in the TMD of VSV G were
critical for fusion activity [220]. In the past decade, additional studies have further
characterized the contribution of the TMD in rhabdovirus fusion protein function.
Substituting the TMD and CTD of rabies virus (RV) fusion protein (G) with similar
regions from NDV fusion protein to attempt to aid with incorporation in NDV viral
particles as a vaccine vector strategy, showed lower incorporation of this chimera
protein in NDV viral particles, despite the chimeric protein having overall cellular
protein levels similar to the wild type RV G protein [174, 221]. Surface expression
of the chimeric protein was not analyzed. Additionally, when mice were vaccinated
with NDV particles containing the chimeric RV G protein, virus-induced neutralizing
antibodies to rabies virus were lower than those induced by vaccination with NDV
particles with the WT RV G protein. This may suggest that successful incorporation
into particles relies in part on the TMD or CTD of RV G protein, indicating that
signals in the TMD or CTD of RV may play a role in overall particle assembly.
These regions may also have a role in the host immune response to viral infection,
similar to the production of bNAbs specific to the MPER-TMD produced during HIV
infection [120, 142].
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Analysis of the VSV G TMD in isolation demonstrated a role of this region
as a catalyst for membrane fusion [221]. In early stages of membrane fusion (the
transition to hemi-fusion), addition of the VSV G TMD increased positive curvature
stress and membrane disorder by facilitating acyl-chain movement into the space
between the two bilayers. In later stages of fusion, the VSV G TMD created further
positive curvature stress at the edges of these induced regions, allowing for the
transition between hemi-fusion and fusion pore formation. This suggests that the
TMD of VSV G proteins could serve in part to help overcome the large energy
barrier to a membrane fusion event by creating physical changes to the membrane.
Targeting the TMD
As work continues to show the importance of TMDs in viral fusion protein
function, it is not surprising that there has also been tremendous growth in the
understanding of the role of TMD in the function of other proteins. TMD-TMD
interactions are important in the creation of amyloid-β, an important factor in
Alzheimer’s disease [222]; the dimerization of both neuropilin-1 [223] and tyrosine
kinase receptor ErbB2 [224]; the inhibitory function of the IgG Fc receptor, FcγIIB
[225]; and induction of the signaling cascade by frizzled receptors [226]. The
growing understanding of a role for TMD-TMD interactions has led to the
development of a unique area of therapeutic research studying small molecules
that disrupt TMD-TMD interactions [227]. Disrupting the dimerization of neuropilin1 has been shown to suppress glioma tumor growth in vivo [228]. Plexin-A1 TMDmimicking peptides disrupt complex formation between neuropilin-1 and PlexinA1, a complex that forms in gliomas with poor prognoses, and the Plexin-A1 TMD
peptides slow both tumor growth and metastasis in cell culture models [229].
Overexpression of p75NTR has been associated with advanced stages of
melanoma progression, but a small molecule was able to inhibit tumor growth in a
mouse model by targeting the TMD of p75NTR to disrupt oligomerization and
downstream signaling of this receptor [230]. Additionally, small molecules targeting
the TMD of Epstein–Barr virus latent membrane protein 1 prevent trimerization of
the protein, blocking oncogenic activation [231].
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TMDs of viral fusion proteins have also been investigated as a novel antiviral therapeutic strategy. Targeting TMD-TMD interactions as a potential anti-viral
therapeutic has been successfully demonstrated for both Class I and Class II
fusion proteins in initial studies. HIV-1 virions that were treated with peptides
derived from the FP or TMD of HIV Env exhibited a dose-dependent decrease in
infectivity. The Env TMD peptides were able to directly associate with WT fulllength Env protein, suggesting that the decrease in virus infectivity is due to the
peptide disrupting the native TMD-TMD association [125]. Similarly, work in this
thesis showed that co-expression of small proteins mimicking the TMD of the
Hendra F protein led to de-stabilization of the full-length F protein, consistent with
the presence of additional TMDs reducing the trimeric interactions needed for prefusion stability (Chapter 3)[232]. The TMD proteins also disrupted cell–cell fusion
when co-expressed with WT full-length Hendra fusion protein (Chapter 3, Fig. 3.3).
The ability of TMD peptides to interfere with fusion protein function was also
demonstrated in viral infection, as TMD peptides homologous to the TMD of the
PIV5 F protein decreased PIV5 infection when incubated with the virus prior to
cellular infection (Chapter 3, Fig. 3.5). This inhibition was sequence specific, as
pre-incubation with PIV5 F TMD peptides did not decrease the infection of a related
virus (HMPV) [232]. A similar antiviral strategy was demonstrated using peptides
derived from the MPER of Flavivirus E protein. Inclusion of hydrophobic residues
corresponding to the TMD of the E protein to the C-terminus of MPER-derived
peptides increased the viral inhibitory function of these peptides [233]. These
inhibitory effects occurred in a sequence-specific manner, similar to the study
completed in paramyxoviruses [232].
Apart from specifically targeting the TMD of fusion proteins as a method to
inhibit viral entry, inclusion of the TMD appears to be useful for other viral inhibition
strategies. The binding strength of neutralizing antibodies to the MPER region of
HIV-1 Env increased when the TMD of the protein was included. Furthermore,
when a trimeric TMD was included with the MPER peptide of HIV Env, binding was
similar to that of binding the native protein [140, 141]. These studies suggest that
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targeting the TMD or including portions of the TMD in anti-viral therapeutic
development may be important.
Conclusions and Questions
The past decade has provided significant insight into the TMDs of viral
fusion proteins from all three classes, further building our understanding of the
intricate nature of these regions. Structures have been elucidated for TMDs of
each class of fusion proteins, and a function for the TMD in viral fusion has been
shown for each class, whether it be in early, intermediate or late stages of the
fusion cascade. Significant work has also demonstrated the role of the TMD of
fusion proteins outside of the membrane fusion process, implicating it in antibody
recognition, host immune responses to viral infection, overall viral particle
assembly, and protein trafficking. Despite the large amount of work, critical
questions remain unanswered concerning the TMD of viral fusion proteins. How
does the conformation of the fusion protein TMD change throughout the membrane
fusion cascade? What membrane components influence the TMD for each virus?
Are there other interactions between viral or host proteins with the TMD of the
fusion protein? Do interactions with the fusion protein TMD exist that influence the
overall viral lifecycle? Hopefully, future studies over the next decades will provide
answers to these questions.
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Figure 1-1 Paramyxovirus and pneumovirus particle schematic.
Virions of paramyxo- and pneumoviruses contain a single stranded, negativesense RNA genome that is coated with the nucleoprotein.

The genome is

encapsulated within a lipid membrane derived from a host cell. This membrane is
studded with the fusion and attachment proteins, as well as a small hydrophobic
protein.
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Figure 1-2 Viral fusion protein proteolytic cleavage
All class I viral fusion proteins must be cleaved in order to facilitate viral membrane
fusion. a.) This cleavage can occur in the trans-golgi network as the protein is
trafficking to the cell surface following synthesis (a), protein endocytosis and
recycling back to the cell surface prior to particle assembly (b), after viral
attachment to a target cell by a cell surface protease (c), or within a endosome
following viral particle endocytosis into a target cell (d).
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Figure 1-3 Cleavage of viral fusion proteins.
a) HeV F is synthesized in an uncleaved form (F0) and trafficked to the cell surface.
Following this, the protein is endocytosed and cleaved by cathepsin L in recycling
endosomes to expose a highly hydrophobic fusion peptide (FP), leaving the protein
as a disulfide linked heterodimer (F1 and F2). The F1 portion of the protein contains
two heptad repeat regions (HRA and HRB), a transmembrane domain (TM), and
a cytoplasmic tail (CT). b) RSV F is also synthesized in an uncleaved form (F0),
however the protein is cleaved by furin or a membrane of the furin family during
protein egress to the cell surface. RSV F has two potential cleavage sites, one
that exposes a hydrophobic FP, and one is 27 amino acids upstream whose
function is unknown. If both sites are processed a small peptide (P27) is released
42

from the resulting disulfide linked heterodimer. Similar protein domains to HeV F
are found in RSV F. c) SARS-CoV-2 S is a large 1275 amino acid protein,
composed of an S1 and S2 subunit. S1 contains a signal peptide (SP), an Nterminal domain (NTD), and a receptor binding domain (RBD). The S2 subunit
contains a FP, an internal fusion peptide (IFP), two heptad repeat regions (HR1
and HR2), a transmembrane domain (TM), and a cytoplasmic tail (CT). S is
processed at the S1/S2 border during protein trafficking to the cell surface by furin
or a member of the furin family. There are two other potential cleavage sites within
the S2 subunit, one 10 amino acids downstream of the S1/S2 border, a conserved
site used by SARS-CoV S, and one is 100 amino acids downstream of the border,
termed the S2’ site. Cleavage at S2’ reveals an internal fusion peptide (IFP),
though the timing of cleavage at these two secondary sites remains unknown.
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Figure 1-4 A model of viral membrane fusion function.
This figure depicts a model of fusion mediated by a Class I viral fusion protein;
however, related processes occur in the case of Class II and III viral fusion proteins
as well. (A) The fusion protein situates itself in the viral membrane (yellow). The
first step of viral fusion is a priming event; in the case of Class I proteins, the protein
itself undergoes the proteolytic processing to prime it for fusion. For Class II fusion
proteins, it is a companion protein that gets proteolytically processed; (B) Once
primed, the viral fusion protein remains in a metastable, pre-fusion conformation
until it receives a triggering signal; (C) Upon receipt of the triggering signal, the
protein extends out, forming a pre-hairpin structure, allowing for the fusion peptide
or fusion loop (dark blue) to enter the target membrane (red); (D) This extended
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structure then begins to fold back on itself, bringing the N-terminal and C-terminal
heptad repeats closer (dark green and light green, respectively), and in turn pulling
the viral membrane and target membrane together; (E) As the N-terminal and C
terminal heptad repeats zipper together to form a six-helix bundle, the target and
viral membrane reach a hemi-fusion state, in which the outer leaflets have started
to mix (orange); (F) Finally, the fusion peptide and transmembrane domain (light
blue) come into close proximity to complete the merging of the two membranes
and opening of the fusion pore. This final structure of a trimer of hairpins is a
common conformation among all viral fusion proteins [54].
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Figure 1-5 Full-length structures of viral fusion proteins.
While the ectodomain structures of numerous viral fusion proteins have been
solved, only a few solved structures of full-length viral fusion proteins, including the
transmembrane domain (TMD) have been solved. (A) Full-length influenza
hemagglutinin (HA) was solved in 2018 [96]. Two structures were published, 6HJQ
(far left) and 6HQR (far right). The first is HA in its pre-fusion conformation, and
the ectodomain is in line with the TMD helices (middle left, zoomed in). In the
second structure, the ectodomain is tilted 52° with respect to the TMD helices
(middle right, zoomed in); this likely represents a scenario that is an intermediate
state of fusion. In each zoomed-in area, a linker region is indicated (slate), and this
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region remains flexible to help compensate for this tilt. (B) In 2013, the structure of
full-length Dengue virus E protein was solved [207]. This structure showed the
hetero-tetramer complex of two E proteins (light and dark purple) and 2 M proteins
(gray) with their respective TMD helices (3J2P). Flavivirus E proteins have two
TMDs that have extensive hydrophobic interactions between them. The structure
also includes three peri-membrane helices that lie on the outer surface of the viral
membrane, approximately perpendicular to the TMD helices. (C) Full-length
Herpes simplex virus 1 gB protein was published in 2018 [216]. This structure
(5V2S) shows the three TMD helices situated in a triangular teepee structure; the
MPER (dark grey) is a helix that lies almost perpendicular to the orientation of the
TMD helices. The solved structure also includes a large portion of the cytoplasmic
tail (CTD, light gray). Each CTD has two helices, the first of which is a small helix
that links to a larger helix which then angles back towards the inner leaflet of the
viral membrane. Because of the orientation, these CTDs may act as a clamp that
assists in holding the gB TMDs in specific conformation, and the angle of the CTD
may work in concert with the TMD helices to dictate the overall conformation of the
protein. Figure made with PyMOL (Schrödinger®, Neo York, NY, USA).
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CHAPTER 2. MATERIALS AND METHODS
Hendra Fusion Protein Projects
Cell lines
Vero cells (ATCC) and BSR-T7/5 cells (generously provided by Karl-Klaus
Conzelman, Pettenkofer Institute) were maintained in Dulbecco’s modified Eagle’s
media (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS).
BSR T7/5 cells were selected for the expression of the T7 polymerase by the
addition of G418 sulfate (Gibco/Invitrogen) every third passage to the DMEM.
Plasmids, Viruses, and Antibodies
Plasmids containing Hendra F or G were generously provided by Dr. Lin-Fa
Wang (Australian Animal Health Laboratory). The Hendra F TM constructs were
designed to include the predicted HeV F signal peptide, varying lengths of the HRB
domain, the full-length TM domain, the C-tail and an HA tag. The Hendra F TM
constructs were synthesized by GenScript and provided in the pUC57 vector. Each
construct was sub-cloned into the eukaryotic expression vector pCAGGS, as
described previously for Hendra F [165]. Anti-peptide antibodies to residues 527539 of the Hendra F cytoplasmic tail were used to pull down F and the TM proteins.
Additionally, mAb 5G7, provided by Dr. Christopher Broder (USUHS), was used
for immunoprecipitation to detect Hendra F. Co-immunoprecipitation studies were
performed

with

a

mouse

anti-HA

antibody

(12CA5,

Roche).

For

immunofluorescence, a rabbit anti-HA antibody (Abcam ab9110) was used at a
1:300 dilution to detect the TM proteins. Secondary antibodies used for
immunofluorescence were goat anti-mouse-FITC and goat anti-mouse-TRITC
(Jackson Immuno Research). The recombinant HMPV (rgHMPV) was kindly
provided by Peter L. Collins and Ursula J. Buchholz (NIAID, Bethesda, MA). The
recombinant PIV5 (rgPIV5) was kindly provided by Robert Lamb (Howard Hughes
Medical Institute).
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Surface Biotinylation
Vero cells (confluency 80-90%) in 60-mm dishes were transiently
transfected using Lipofectamine and Plus reagent (4µg of DNA) according to
manufacturer’s protocol (Invitrogen). For co-expression experiments, the ratio of
DNA transfected was 2:1 HeV F:TM, unless otherwise noted. Eighteen to twentyfour hours post-transfection, cells were washed with PBS and starved for 45 min
in DMEM deficient in cysteine and methionine. Cells were labeled for 3 h with
DMEM deficient in cysteine and methionine, containing Tran35S-label (100µCi/mL;
MP Biomedicals), biotinylated with 1 mg/ml EZ-Link Sulfo-NHS Biotin (Pierce)
diluted in pH 8.0 PBS, at 4oC for 35 min, followed by 15 min at room temperature.
Cells were then lysed in RIPA lysis buffer; supernatants were cleared by
centrifugation at 135,000xg for 15 minutes at 4oC. 4µl of an anti-peptide Hendra
F antibody was added to the supernatants, and incubated at 4oC for 3 hr with
rocking, and was then incubated for 30µl of protein A-Sepharose beads (GE
Healthcare). Immunoprecipitated proteins were then washed two times with each
of the following in order: RIPA buffer containing 0.3M NaCl, RIPA buffer containing
0.15M NaCl, and SDS wash II buffer. Samples were then boiled away from beads
in 10% SDS. Ten percent of the protein was removed as the TOTAL sample, and
the remainder (SURFACE) was diluted in biotinylation dilution buffer and incubated
with immobilized streptavidin beads (Pierce) at 4oC for 1 hr. Samples were again
washed as described above.

Samples were analyzed by 15% SDS-PAGE,

exposed to a phosphor-screen, and visualized using the Typhoon imaging system
(GE Healthcare), as previously described (11). Band densitometry using
ImageQuant 5.2 was performed for each experiment to quantitate the amount of F
expressed which was reported as % expression, the sum of F0 and F1, normalized
to the F+mock control.
Time Course Immunoprecipitation
Hendra virus F protein was co-expressed with the TM constructs in
subconfluent Vero cells using Lipofectamine and Plus (Invitrogen) as previously
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described. The next day cells were washed with PBS and starved for 45 min at
37°C in cysteine-methionine-deficient DMEM. Cells were then labeled for 30min
with Trans[35S] metabolic label (100µCi/mL; MP Biomedicals). At different time
points, cells were washed three times with PBS and lysed with RIPA lysis buffer.
Immunoprecipitation with the anti-peptide Hendra F antibody and protein ASepharose beads and analysis was performed as described for surface
biotinylation.

Higher molecular weight immunoprecipitation and native gel electrophoresis
Hendra virus F protein was co-expressed with the TM constructs in
subconfluent Vero cells using Lipofectamine and Plus (Invitrogen) as previously
described. The next day cells were washed with PBS and starved for 45 min at
37°C in cysteine-methionine-deficient DMEM. Cells were then labeled for 30 min
with Trans[35S] metabolic label (100µCi/mL; MP Biomedicals). Cells were then
washed three times with PBS and allowed to incubate at 37°C for indicated chase
times. Cells were washed three times with PBS and lysed with RIPA lysis buffer.
Lysates were incubated with anti-peptide antibodies to residues 527-539 of the
Hendra F cytoplasmic tail for 3 hours, and subsequently protein A-Sepharose
beads for 30 minutes, as described for surface biotinylation. After washing steps
were completed, 30 µl of 2X loading buffer without DTT was added to each of the
samples. Samples were then boiled away from beads at 60oC, 80oC, or 100oC as
indicated, for 10 minutes and analyzed on a 3.5% acrylamide gel under nonreducing conditions, the gel was imaged on the same system described for surface
biotinylation.
Syncytium assay
Subconfluent Vero cells in 6-well plates were transiently transfected with
Hendra F, Hendra G, TM protein at a ratio of 1:3:1 using Lipofectamine and Plus
Reagent (Invitrogen) per manufacturer’s protocol. Syncytia formation was
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observed 24 to 48h post transfection. Images were taken using a Nikon digital
camera mounted atop a Nikon TS100 microscope with 10X objective.

Luciferase Reporter Gene Assay
Vero cells (70-90% confluent) in 12-well plates were transiently transfected
with 0.15ug of pCAGGS-Hendra F or one of the HeV F mutants, 0.45ug of
pCAGGS-Hendra G, and 0.4ug of a T7 promoted Luciferase plasmid.
Transfections were performed using Lipofectamine and Plus reagent (Invitrogen)
according to the manufacturer’s protocol. At 24 h post transfection, BSR T7/5cells
were lifted with trypsin, resuspended in DMEM supplemented with 10% FBS were
overlain on to Vero cells that were washed once with PBS. These were incubated
for 4 h at 37C. Then, cells were lysed with reporter lysis buffer (Promega) and
analyzed for Luciferase activity using the luciferase assay system (Promega) per
manufacturer’s instructions. A SpectraMax iD3 plate reader (Molecular Devices;
Sunnyvale, CA) was used to read the luminescence. Results were normalized to
cells expressing WT Hendra F and G, after subtracting the background (HeV G
only).
Peptide inhibition assay
Recombinant GFP expressing HMPV or PIV5 were pretreated for 30 min at
room temperature with TM peptide corresponding to the TM domain sequence of
the PIV5 F protein. The peptide was synthesized by LifeTein with the following
sequence:

485VLSIIAICLGCLGLILIILLSVVVWKLL512

(accession #P04849). The

peptide was solubilized in sterile DMSO. Virus was diluted in OPTI-MEM for an
infection with a MOI=1 pfu/cell. Vero cells (70-90% confluency) were washed twice
with PBS and incubated with 500 µL of peptide treated virus for 4 hr at 37°C. After
the incubation, the infection media was removed, cells were washed 2X with PBS,
and cells were left overnight with DMEM+FBS. The following day, cells were
imaged for GFP-positive cells with a Nikon Axiovert-100 microscope. For flow
cytometry analysis, the cells were lifted with 100 uL of trypsin-EDTA and fixed with
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an equal volume of PBS + 2% paraformaldehyde + 50 mM EDTA. For each
sample, 50,000 cells were counted for flow analysis. Analysis was performed on
the LSR II flow cytometer by the UK Flow Cytometry Core.
Immunofluorescence
Cells grown in 6-well plates containing coverslips were co-transfected with
HeV F and the TM constructs. After 24hr, cells were washed in PBS and fixed in
4% paraformaldehyde for 15 minutes at room temperature. Cells were then
permeabilized in 1% Triton X-100 for 15 minutes at 4°C followed by blocking in 1%
normal goat serum. Cells were incubated with the corresponding primary antibody
overnight at 4°C. The following day, cells were washed with 0.05% tween-PBS,
secondary antibodies were added, and cells were incubated at 4°C for one hour.
Coverslips were then mounted on glass slides using Vectashield mounting media
(Vectorlabs, Burlingame, CA). Pictures were taken using a Nikon 1A confocal
microscope and analyzed with the NIS-Elements software. All images were
processed in Adobe Photoshop, with equivalent adjustments made to all panels.
SARS-CoV-2 Spike Project
Cell lines and culture
Vero (ATCC), BSR T7/5 cells (provided by Karl-Klaus Conzelmann,
Pettenkofer Institut), mouse embryonic fibroblasts (MEFs) from cathepsin L
knockout mice (Cath L- MEFs) (a gift from Terence Dermody, University of
Pittsburgh), and P. alecto bat cells harvested from fetus (pt. fetus) and lung (pt.
lung) (a gift from Linfa Wang, Duke-NUS) [240] were all maintained in Dulbecco’s
modified Eagle’s medium (DMEM, GE Healthcare), with 10% fetal bovine serum
(FBS) and 1% penicillin/streptomycin. Every third passage, 0.5mg/ml of G-418
(Invitrogen) was added to the culture media of BSR T7/5 cells to select for the
expression of the T7 polymerase. A549 and human colon carcinoma LoVo cells
(both purchased from ATCC) were cultured in F12 Kaighns Modification media
(GE Healthcare) with 10% FBS and 1% penicillin/streptomycin.
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Plasmids, Antibodies, and Mutagenesis
pCAGGS-SARS-CoV-2

spike

was

obtained from BEI

Resources.

pcDNA3.1(+)-hACE2 and pcDNA3.1(+)-TMPRSS2 were provided by Gaya
Amarasinghe (Washington University). Human Neuropilin-1 was expressed with
an exogenous PTPα signal sequence from the pLEXm vector (from Craig Vander
Kooi, University of Kentucky). SARS-CoV-2 S was subcloned into pUC57 and all
S mutants were created in pUC57 using the QuikChange site-directed
mutagenesis kit (Strategene) with primers purchased from Eurofins. Constructs
were then subcloned back into the pCAGGS expression vector. Other plasmids
utilized include pSG5-Cathepsin L (from Terence Dermody, University of
Pittsburgh), pCAGGS-furin (Promega), and T7 promoted-luciferase (Promega).
Antibodies anti-SARS spike glycoprotein (ab252690) and anti-hACE2 (ab15348)
were purchased from Abcam, and anti-TMPRSS2 (H-4) was purchased from Santa
Cruz Biotechnology, Inc.
Gel electrophoresis and western blotting
Proteins

were

separated

on

a

10%

polyacrylamide gel electrophoresis (SDS-PAGE).

sodium

dodecyl

sulphate-

For western blot analysis,

proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Fisher
Scientific) at 60V for 100 minutes. After blocking with 5% milk in tris-buffered saline
+ Tween-20 (tTBS) for 1 hour, membranes were incubated with respective
antibodies (anti-SARS S 1:5000 dilution, anti-TMPRSS2 1:1000 dilution, antihACE2 1:1000 dilution) at 4°C overnight. Membranes were then washed with tTBS
and incubated with (Li-Cor) secondary antibodies at 1:10000 dilution in 5% milk
solution for 1 hour. Membranes were washed again with tTBS and diH2O, before
being imaged on the Odyssey Image Analyzer (Li-Cor).
Syncytium Assay
Cells (Vero or A549s) in 6 well plates were transiently transfected with 2μg
of either wild-type or mutant SARS-CoV-2 S protein plasmid with Lipofectamine
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3000 (Invitrogen) at a ratio of 1:2:2 DNA: P3000: Lipofectamine 3000. For
experiments with the addition of proteases, the total DNA transfected was kept
constant at 2μg, in those cases we used 1μg of S and 1μg of the indicated
protease. Syncytia formation was imaged at 24 and 48 hours post transfection on
a Nikon Ti2 at 20X magnification.
Luciferase Reporter Gene Assay
Effector cells (Vero or A549s) were plated in 12-well plates at 70-90%
confluency and transfected with 1μg of total DNA (0.4μg of a T7 promoted
luciferase plasmid, 0.6μg of wild-type (wt) or mutant S protein or S protein with
additional proteases). At the same time BSR cells (constitutively expressing a T7
promoter) seeded in 6-well plates were transfected with 2μg either empty pCAGGS
or pcDNA3.1(+)-hACE2. Eighteen to twenty-four hours post transfection BSR cells
were lifted using trypsin, centrifuged for five minutes at 1500 rpm, resuspended in
normal DMEM+10% FBS, and overlaid onto the S expressing cells at a ratio of 1:1.
Overlaid samples were then incubated at 37°C for 9 hours (or as described in the
text). Samples were lysed in 100μL of Reporter Gene Lysis buffer (Promega) and
frozen overnight. Plates were then scraped on ice, lysates were vortexed for 10
seconds, centrifuged at 13,000 rpm for 1 minute at 4°C, and 20μL of the
supernatant was added to an opaque 96 well plate.

Luciferase activity was

measured on a SpectraMax iD3 (Molecular Devices) using a Luciferase Assay
System (Promega).

Background values were subtracted (empty pCAGGS in

BSRs and effector cells) and luciferase activity was expressed as a percentage of
wt S (effector cells) and hACE2 (BSR cells).
Surface Biotinylation
Two μg of wt or mutant S protein was transfected into Vero or A549 cells
using the Lipofectamine 3000 system (Invitrogen; ratios described above).
Eighteen to twenty-four hours post transfection, cells were starved in Cys-/Metmedia (Gibco) for 45 minutes, and metabolically labelled for six hours using 50μCi
of S35 (PerkinElmer) incorporated into Cys and Met (S35 Cys/Met). After the label,
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cells were washed once with PBS (pH 8) and incubated with 1 mg/ml of EZ-link
Sulfo-NHS-biotin (Thermo Fisher) in PBS (pH 8) at 4°C for 35 minutes, and then
at room temperature for 15 minutes. Next the cells were lysed in 500μl of RIPA
buffer (100 mM Tris-HCl [pH 7.4], 0.1% SDS, 1% Triton X-100, 1% deoxycholic
acid) containing 150 mM NaCl, protease inhibitors (1 U aprotinin, 1mM PMSF,
[both from Sigma-Aldrich]), 5 mM iodoacetamide, and cOmplete EDTA-free
Protease Inhibitor Cocktail Tablets (all from Sigma-Aldrich). Cell lysates were
centrifuged at 55,000 rpm for 10 minutes, and the supernatant was incubated with
anti-SARS S polyclonal antibody at 4°C for three hours. Following incubation,
Protein A conjugated to Sepharose beads (Cytiva) were added to the samples,
and incubated at 4°C for an additional 30 minutes. Post-incubation samples were
washed two times with each RIPA Buffer+0.3M NaCl, RIPA Buffer+0.15M NaCl,
and SDS-Wash II buffer (50mM Tris-HCl [pH 7.4], 150mM NaCl, and 2.5mM
EDTA). After buffer aspiration and addition of 10% SDS, samples were boiled for
10 minutes. The supernatant was removed to a separate tube. 15μl of supernatant
was removed and added to an equal portion of 2X SDS loading buffer and labeled
“TOTAL”. Biotinylation buffer (20 mM Tris [pH 8], 150mM NaCl, 5mM EDTA, 1%
Triton X-100, and 0.2% BSA) and Streptavidin conjugated beads were added to
the remaining supernatant, and this was incubated at 4°C for one hour. Samples
were again washed as described above and 2X SDS loading buffer was added
following the washes. Samples were boiled for 15 minutes and run on a 10% SDSPAGE gel. Gels were dried and exposed on a phosphoscreen for two to four days,
then visualized using a Typhoon Imaging System (GE Healthcare). Bands were
quantified using band densitometry using the ImageQuant software (GE
Healthcare).
Time Course Immunoprecipitation
Two μg of wt or mutant S was transfected into Vero or A549 cells using the
Lipofectamine 3000 system (Invitrogen; ratios described above). Eighteen to
twenty-four hours post transfection, cells were starved in Cys-/Met- media (Gibco)
for 45 minutes, and metabolically label for one hour using 50μCi of S35 Cys/Met.
55

After the one-hour label, cells were washed once with PBS and normal DMEM +
10% FBS was added for indicated times. Cells were then lysed in 500μl of RIPA
lysis buffer. Anti-SARS S polyclonal antibodies were used to immunoprecipitate
the CoV-2 S protein as previously described and the protein was analyzed on a
10% SDS-PAGE gel. Gels were dried and exposed on a phosphoscreen for 2-4
days and visualized using a Typhoon Imaging System (GE Healthcare). Bands
were quantified using band densitometry using the ImageQuant software (GE
Healthcare).
Non-reducing Gel Electrophoresis
Two μg of wild-type or mutant S was transfected into Vero or A549 cells
using the Lipofectamine 3000 system (Invitrogen; ratios described above).
Eighteen to twenty-four hours post transfection, cells were starved in Cys-/Metmedia (Gibco) for 45 minutes, and metabolically labeled for six hours using 50μCi
of S35 Cys/Met.

Lysed cells were immunoprecipitated as described above,

however after the washing steps, 30μl of 2X SDS loading buffer without
dithiothreitol (DTT) was added to each sample. Samples were treated at 50°C or
100°C, as indicated, for 20 minutes and analyzed on a 3.5% acrylamide gel under
non-reducing conditions. The gel was dried, exposed, and imaged as described
for surface biotinylation.
Immunofluorescence experiments
Sub-confluent cells on coverslips in 6 well plates were transfected with 2μg
of DNA using the Lipofectamine 3000 transfection system (Invitrogen). Eighteen
to twenty-four hours post transfection cells were fixed with 4% PFA for 15 minutes
at room temperature. Cells were permeabilized in a solution of 1% Triton X-100 in
PBS+0.02% Sodium Azide (PBSN) for 15 minutes at 4°C. After permeabilization,
coverslips were moved to a humidity chamber and blocked with 1% normal goat
serum (NGS) in PBSN for 1 hour at 4°C. Cells were labeled with anti-SARS S
antibody (1:2000 dilution) in blocking buffer overnight at 4°C or for three to five
hours at room temperature. Samples were washed with PBSN+0.01% Tween-20
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seven times and incubated for 1 hour at 4°C with goat anti-rabbit FITC (1:2000
dilution). Samples were again washed with PBSN+0.01% Tween seven times and
mounted onto slides using Vectashield mounting media (Vector Laboratories).
Slides were imaged on an Axiovert 200M (Zeiss) at 63x magnification using
Metamorph to collect Z-stacks and processed using Nikon NIS Elements.
Statistical analysis
Statistical analysis was performed using Prism 7 for Windows (GraphPad).
A p value of <0.05 was considered statistically significant. Multiple comparison
tests were generated using one-way or two-way analysis of variance (ANOVA)
with Dunnett’s multiple comparison test. *: p<0.05, **: p<0.01, ***: p<0.0005, ****:
p<0.0001
RSV Fusion Protein Project

Cell lines
Vero cells, LLC-MK2 cells, and BSR-T7/5 cells were maintained in
Dulbecco’s modified Eagle’s media (DMEM; Invitrogen) supplemented with 10%
fetal bovine serum (FBS; Sigma). BSR T7/5 cells were selected for the expression
of the T7 polymerase by the addition of G418 sulfate (Gibco/Invitrogen) every third
passage to the DMEM. HEp-2 cells (a gift from AstraZeneca) were maintained in
Opti-MEM (Invitrogen) supplemented with 2% FBS. All cells were grown at 37°C
and 5% CO2.
Plasmids, Viruses, and Antibodies
pVAX plasmids containing RSV F A2 and B9320 were generously provided
by Dr. Hong Jin (AstraZeneca). A MP340 plasmid contained RSV F from the D53
strain was provided by Dr. Mark Peeples (Nationwide Children’s Hospital,
Columbus, OH) [241]. Mutagenesis was completed in the pVAX vectors using the
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QuikChange sit directed mutagenesis kit with primers purchased from Eurofins.
Palivizumab (a gift from AstraZeneca), a mAb to RSV F, was used to pull down
RSV F (2 μl at a concentration of 1μg/μl). Recombinant green fluorescent protein
expressing human respiratory syncytial virus A2 (rgRSV) long, RSV A Clinical, and
RSV

F B

clinical strains

were

used

at

MOIs

indicated

(gifts from

Medimmune/AstraZeneca).
Syncytia, Surface Biotinylation, and Immunofluorescence
These assays were completed in the cell lines indicated as described for
the SARS-CoV-2 and HeV Fusion projects.
Time Course Immunoprecipitation
RSV F protein into cells indicated using the Lipofectamine 3000 (Invitrogen)
system, as previously described. The next day cells were washed with PBS and
starved for 30 minutes at 37°C in cysteine-methionine-deficient DMEM. Cells were
then labeled for 15 min with Trans[35S] metabolic label (50μCi/mL; MP
Biomedicals). At indicated time points, cells were washed three times with PBS
and lysed with RIPA lysis buffer. Immunoprecipitation with the anti-RSV F
antibody, Palivizumab (2 μl at a concentration of 1μg/μl, then protein A-Sepharose
beads and analysis was performed as described for surface biotinylation.
Luciferase Reporter Gene Assay
Veros overlaid on BSR/T7
BSR/T7 cells in 12-well plates were transiently transfected with 1μg pVAXRSV F. Vero cells in 6-well plates were transiently transfected with 0.8μg of a T7
promoted Luciferase plasmid and 1.2μg of empty vector. Transfections were
performed using Lipofectamine and Plus reagent (Invitrogen) according to the
manufacturer’s protocol. At 18-24 h post transfection, Vero cells were lifted with
100μl of trypsin/well, resuspended in DMEM supplemented with 10% FBS were
overlain on to BSR/T7 that were washed once with PBS. These were incubated
58

for 9-24 h (as indicated) at 37C. Then, cells were lysed with reporter lysis buffer
(Promega) and analyzed for Luciferase activity using the luciferase assay system
(Promega) per manufacturer’s instructions. A SpectraMax iD3 plate reader
(Molecular Devices; Sunnyvale, CA) was used to read the luminescence. Results
were normalized to cells expressing WT RSV F A2, after subtracting the
background (EV only).

BSR/T7 overlaid on Veros
Vero cells in 12-well plates were transiently transfected with 0.4μg of a T7
promoted Luciferase plasmid and 0.6μg of pVAX-RSV F. Transfections were
performed using Lipofectamine and Plus reagent (Invitrogen) according to the
manufacturer’s protocol. At 18-24 h post transfection, BSR T7/5cells were lifted
with trypsin, resuspended in DMEM supplemented with 10% FBS were overlain on
to Vero cells that were washed once with PBS. These were incubated for 9-24 h
at 37C. Then, cells were lysed with reporter lysis buffer (Promega) and analyzed
for Luciferase activity using the luciferase assay system (Promega) per
manufacturer’s instructions. A SpectraMax iD3 plate reader (Molecular Devices;
Sunnyvale, CA) was used to read the luminescence. Results were normalized to
cells expressing WT RSV F A2, after subtracting the background (EV only).
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Introduction
The importance of TM domains in protein oligomerization has been shown
for several cellular proteins. For example, the amyloid precursor protein (APP) TM
must dimerize for the generation of amyloid-β, which is linked to Alzheimer’s
disease [222]. The TM domain of neuropilin-1 (NRP1), a co-receptor for vascular
endothelial growth factor receptor 2, contains a GxxxG motif that is required for
dimerization and ultimately downstream signaling [223]. It has been shown that
targeting the NRP1 TM domain with synthetic peptides could inhibit glioma tumor
growth in vivo [228]. Together, these studies exemplify the potential of targeting
the transmembrane domain to disrupt protein function and/or trafficking, which
could lead to potential therapeutic targets. Moreover, the importance of TM-TM
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interactions in protein function is apparent from these studies. In the case of viral
systems, replacement of the viral fusion protein TM domain with other fusion
protein TM domains or lipid anchors has been shown to alter fusion protein function
in examples including influenza, Newcastle disease virus, vesicular stomatitis
virus, parainfluenza virus 5, and measles virus [79, 162, 242-245]. Additionally,
mutation of motifs within the TM domain known to promote protein oligomerization,
such as GxxxG motifs, affects fusion protein function. For example, mutation of the
GxxxG motif of the Hendra virus fusion (F) protein TM domain resulted in a
reduction of active fusion protein at the cell surface, possibly as a result of reduced
protein stability or changes in protein trafficking [160, 165]. Mutation of the GxxxG
motif of HIV gp41 also affected intracellular trafficking of the HIV Env protein [145,
246].
The life cycle of an enveloped virus requires fusion of the viral envelope
with a target cell membrane. There are several points in the early stages of the
paramyxovirus fusion process that can be targeted for disruption: the receptor
binding step mediated by the attachment protein, the interaction between the
attachment protein and fusion protein that facilitates triggering of F, and the overall
refolding of the fusion protein necessary for membrane fusion [247]. Class I fusion
proteins, including those of the Paramyxoviridae family, are folded as trimers [46]
and it has been shown that the TM domain is important for proper protein folding
and function [125, 145, 161, 162, 243, 245, 248]. To drive membrane fusion, the
fusion protein must undergo dramatic conformational rearrangements from the
meta-stable pre-fusion conformation to the post-fusion conformation. The
triggering process of the fusion protein is an essentially irreversible process, so
spatiotemporal control of the triggering and refolding events is crucial. While there
is little sequence homology among class I fusion proteins, the steps critical for
membrane fusion appear to be conserved [46].
Previously, we have shown that the HeV F protein TM domain associates
in a monomer-trimer equilibrium in isolation and contributes to overall F protein
stability. More specifically, we have shown that HeV F TM-TM association is
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sequence specific, with a L/I zipper motif significantly contributing to the interaction
[161, 165]. The HeV F protein is synthesized as a trimer with a domain structure
composed of two heptad repeat domains (HRA and HRB), a highly hydrophobic
fusion peptide (FP), a TM domain, and a cytoplasmic tail (CT) (Fig 3.1A) [7, 22].
Since the TM domain self-associates and has been shown to be important for F
protein trafficking and function [173], we hypothesized that introduction of
exogenous TM proteins homologous to the native F protein would competitively
disrupt the TM-TM interactions in the native F protein, resulting in premature
triggering or protein misfolding. To test this, exogenous constructs containing
the Hendra F TM and limited flanking sequences were co-expressed with the fulllength F protein. We demonstrate that the homologous TM protein constructs
interacted with F and reduced the expression and fusion activity of the full-length
protein. Furthermore, we show that the effects seen upon co-expression of the TM
proteins are sequence specific. Since HeV is a BSL-4 pathogen, parainfluenza
virus 5 (PIV5), another paramyxovirus, was used to test whether F protein function
could be disrupted in viral particles. A synthetic TM peptide homologous to the
PIV5 F TM domain successfully inhibited viral infection in cells and the effect was
specific, as treatment of human metapneumovirus (HMPV) with the PIV5 F TM
peptide did not significantly affect infectivity. Together, these results emphasize
the importance of the TM domain in fusion protein function and present fusion
protein TM-TM interactions as a potential antiviral target.
Results
HeV F TM proteins interact with the full length HeV F
To test whether addition of homologous TM domains affect F protein folding,
trafficking or protein function, exogenous constructs containing the TM were
designed based on the HeV F protein sequence. Three constructs were
synthesized to contain a signal peptide, a variable-length linker, the full-length TM
domain and C-tail, and an HA-tag (Fig 3.1A). A signal peptide was included to
target the TM constructs to the endoplasmic reticulum during translation. The linker
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represented varying lengths of the HRB domain upstream of the TM domain added
to assist with protein solubility, as it was unclear how stable the only the TM domain
would be by itself. These different constructs will be designated as short linker
(SL), long linker (LL), or HRB TM (HRB) (Fig 3.1A), throughout the remainder of
the study. The C-tail was included to maintain proper protein trafficking [151, 249],
as well as for antibody detection and the HA-tag was added for antibody detection
purposes. During HeV F synthesis, the inactive form of the protein (F0) is trafficked
through the ER to the plasma membrane, endocytosed, cleaved to its active form
(F1) by cathepsin L, and trafficked back to the plasma membrane where it can
ultimately promote membrane fusion. To determine if the signal peptide directed
the TM proteins to the secretory pathway, immunofluorescence was performed to
determine the co-expression of HeV F with each of the TM constructs. Wild type
HeV F (green) and each of the TM proteins (red) co-localized in similar regions
throughout the cell (Fig 3.1B). A strong signal appeared near the nucleus at the
expected location of the ER, which was to be expected with the addition of the
signal peptide on the TM proteins. These constructs were then co-expressed with
the full length HeV F protein in Vero cells at a DNA transfection ratio of 2:1 (F:TM).
Cells were radiolabeled for 30 minutes and chased for 1.5 hrs, then a pull down
with an anti-HA antibody was used to examine if the full length HeV F protein would
co-immunoprecipitate with the HA-tagged TM proteins. As a control, a plasmid
encoding an HA tagged HeV F was co-transfected with the mock control and then
FHA was immunoprecipitated with the anti-HA antibody (Fig 3.1C). When the TM
constructs were co-transfected with wt F, the uncleaved form, F0, was pulled down
with the SL and LL TM constructs. Interestingly, the HRB TM construct did not
appear to pull down F. These results demonstrated that the TM proteins colocalize and that the SL and LL constructs interact with the full-length F protein.
Exogenous TM proteins affect HeV F expression and protein stability
To facilitate fusion the HeV F protein must be at the surface and in its
cleaved, F1+F2, form. Previous work has shown that disruption of the HeV TM
interactions significantly lowered the amount of F protein expressed at the cell
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surface [161]. To determine whether the F protein was trafficked to the cell surface
in the presence of the exogenous TM proteins, proteins were analyzed with a
radiolabel surface biotinylation assay. When HeV F was co-expressed with an
empty vector and cells were radiolabeled for 3 hours, the F protein was observed
as two bands, F0 (uncleaved) and F1 (cleaved) in both total expression and the
surface population. Upon co-expression of each of the TM constructs, total and
surface expression of HeV F was reduced to 20-30% when compared to the HeV
F expressed with empty vector (Fig 3.2A, B). Additional transfection ratios were
tested using a radiolabel IP, but the 2:1 of HeV F:TM construct ratio resulted in the
greatest change in F protein expression levels and was the transfection ratio used
for the rest of the experiments, unless otherwise noted (Fig 3.2D). Though the
presence of the exogenous TM constructs dramatically reduced the levels of HeV
F detected in cells, a small population of cleaved, potentially fusogenically active
F was detected at the surface. A pulse-chase experiment was performed to
determine whether the TM proteins affected initial F protein synthesis or stability
over time (Fig 3.2C). When co-expressed with mock vector at the early time points,
F was detected in its uncleaved form, F0. By 8 h, the majority of F was present in
the cleaved form ( F1+F2, only F1 visible on the gel), consistent with the previously
reported time necessary for cathepsin L cleavage [150]. Co-expression of HeV F
with the SL TM protein resulted in a dramatic decrease in expression starting at
early time points. However, the overall expression of F was not affected at the
earlier time points for LL or HRB TM protein co-expression, indicating that the
presence of these proteins does not affect initial protein synthesis. The coexpression of the LL TM protein instead affected the overall stability of HeV F over
time, as shown by the reduced amount of either form of F detected at the 6h and
8h time points. The HRB TM protein appeared to have a less dramatic effect, but
still showed a reduced amount of either form of F at 8h, indicating that some protein
destabilization may be occurring. In the presence of each of the TM proteins at
the earlier time points (0-2h), a band appeared between the F0 and F1 bands, which
may be a degradation product or the result of a change in glycosylation. Coexpression with any of the three TM proteins still allowed for some level of cleavage
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(F1+F2, only F1 visible on the gel) by the 2hr time point, which is when the most
cleaved product is detected for the mock co-expression. Differences in protein
expression between Fig 2 panels A and C can be accounted for by differences in
metabolic labeling and chase time; A represents a 3-hour label and no chase, while
C represents a 30 min label and chase times are indicated. These findings suggest
that the presence of the exogenous TM proteins, especially the LL and SL,
destabilized the full-length F protein, but did not affect the ability of synthesized
protein to be cleaved to its fusogenically active form.
Since HeV F associates as a homo-trimer, an assay to detect higher
molecular weight complexes was performed to determine if destabilization of the
protein in the presence of exogenous TM proteins was due to a destabilization of
F trimerization. Cells transfected with F alone or F plus the TM constructs were
radiolabeled for 45 minutes, and chase media was added for 30 minutes. Cell
lysates were then immunopreciptated with anti-HeV F antibody to the c-tail, heated
at various temperatures to destabilize oligomeric interactions, as indicated, and
separated on a gel under non-reducing conditions (Fig 3.2E). When HeV F protein
was expressed alone, a majority of the protein migrated as a monomer, however
heat stable trimers and dimers are also detectable. These results are consistent
with previous reports on other paramyxoviruses that have shown that uncleaved
forms of the fusion protein can migrate as stable trimers even up to 100C [250].
However, when any of the TM proteins are present, a large amount of the protein
migrated in the monomeric form. These results suggest that the presence of the
TM proteins may destabilize HeV F protein trimeric associations at early time
points in protein synthesis.

Interestingly, this destabilization of protein

oligomerization appears to occur even before protein expression levels are
affected in the presence of the LL and HRB constructs (compare LL and HRB in
3.2E to 1-2-hour time point in 3.2C).
Exogenous TM proteins reduce HeV F fusion activity
A syncytia fusion assay was used to determine whether the TM proteins
affected F protein function. The F protein and its homotypic attachment protein, G,
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were co-expressed in Vero cells with each of the TM constructs at a transfection
ratio of 3:1:1 for G:F:TM. After 24hr, the cells were imaged to visualize syncytia
formation. HeV F and G co-expressed with empty vector resulted in syncytia
formation, as indicated by the white arrows. When the TM constructs were coexpressed with HeV and G, syncytia formation was ablated (Fig 3.3A). The
reduced overall expression levels of HeV F might explain a reduction in syncytia
formation. However, a small population of fusogenically active HeV F was still
detected in the surface population in the presence of the TM proteins (Fig 3.2A),
so reduced levels of fusion activity, rather than a complete loss, would be
expected. Previous work demonstrated that reduction of HeV F expression to 2030% of wild-type resulted in fusion levels at 30-40% of wild-type [251].
Interestingly, co-expression of the TM constructs reduced HeV F expression to
these levels, but fusion activity was completely ablated. The lack of fusion seen
may be the result of pre-mature triggering or misfolding of the fusion protein
present at the plasma membrane. Alternatively, the presence of the TM proteins
could prevent the fusion protein from being able to fully trigger or affect further
conformational changes needed to drive fusion.
To further investigate the fusion activity of F in the presence of the TM
constructs, a luciferase reporter gene assay was performed. HeV F, G, a luciferase
plasmid under the control of a T7 promoter (labeled as T7-Luciferase in Fig 3.3B),
and each of the TM constructs were co-expressed in Vero cells. At 18-24 hours
post transfection, BSR cells that constitutively express the T7 polymerase were
overlaid onto the Vero cells at a ratio of 1:1 and allowed to incubate for 3 hours
(Fig 3.3B, Experimental Condition #1). After 3 hours, cells were lysed, incubated
with luciferin, and then the luminescence was measured as an output of the fusion.
Relative luminescence compared to HeV F and G without the TM constructs
indicated that fusion was significantly reduced with each construct (Fig 3.3C). The
presence of the SL and LL constructs reduced the fusion to background levels,
suggesting again that the SL and LL constructs interfere with the fusion activity of
HeV F beyond just reducing the protein surface expression.

Fusion in the

presence of the HRB construct, however, reduced fusion to levels consistent with
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that expected with the cleaved population of F present at cell surface (Fig 3.1B).
However, when considering these results with the lack of syncytia formation (Fig
3.3A) and the destabilization of protein oligomerization (Fig 3.2E) seen in the
presence of the HRB construct, it may suggest that this construct is having an
effect on F protein fusion pore expansion or other cellular rearrangements needed
for syncytia formation.
Upon triggering, HeV F extends into a hairpin structure that inserts the
fusion peptide into the target membrane. Since interactions between viral fusion
protein TMs and the fusion peptide have previously been shown [252], a luciferase
gene reporter assay was again employed to investigate the effect the exogenous
TM peptides had when located in the target cell membrane (Fig 3.3B, Experimental
Condition #2). Relative luminescence compared to WT HeV demonstrated that
when the SL and HRB TM proteins were present in the target cell membrane there
was a 20-30% reduction in fusion (Fig 3.3D). The LL TM protein did not produce
a significant decrease in fusion. This reduction may be due to a disruption of proper
refolding of HeV F or a destabilization of the fusion peptides caused by the
exogenous TM proteins associating with the fusion peptide. Though an effect was
seen under these conditions, it is apparent that the TM peptide effects are most
significant when the peptides are co-expressed with HeV F.
The effects of the exogenous TM proteins are sequence specific
The previous results demonstrated that HeV F protein levels were reduced
upon co-expression of homologous TM constructs. To determine whether the HeV
F TM proteins were specifically targeting the HeV F protein, analogous
experiments were performed with another class I fusion protein of the
paramyxovirus family, parainfluenza virus 5 (PIV5) F. The predicted TM domain
sequences of HeV F and PIV5 F exhibit approximately 40% homology, as
calculated with the ExPASy SIM alignment tool (Fig 3.4A). Co-expression of the
exogenous HeV F TM constructs with PIV5 F in Vero cells demonstrated no
significant change in PIV5 F protein expression levels. The TM proteins also did
not coIP the PIV5 F protein in its F0 or F1 form (Fig 3.4B, C). Immunofluorescence
67

of PIV5 F with the HeV F TM constructs was also performed. While, the HRB TM
protein did not appear to co-localize with PIV5 F in immunofluorescence staining,
the SL and LL TM proteins expressed in similar cellular compartments as PIV5 F
(Fig 3.4E), and the PIV5 F protein was able to drive membrane fusion and promote
syncytia formation in the presence of all three exogenous TM constructs, as
indicated by white arrows (Fig 3.4D). Together, these data indicate that the TM
constructs designed to target the HeV F TM domain do not produce the same
effects on PIV5 F expression or fusion activity, suggesting that the effect is
sequence specific.
TM peptides reduced viral infection
The results presented thus far utilized transient transfection experiments to
test whether the TM domain can be targeted to affect fusion protein expression
and function. To determine if the F protein TM domain could be targeted in the
context of a viral particle, an infection assay was performed. As Hendra virus is a
BSL-4 pathogen, TM peptide effects were examined in two other closely related
enveloped viruses, PIV5 and human metapneumovirus (HMPV), which both utilize
class I fusion proteins to mediate membrane fusion. The predicted TM domains for
these two viruses, however, only exhibit approximately 26% sequence homology.
Recombinant viruses contained a GFP gene for either virus to allow for
visualization of infection. A peptide was designed based on the sequence of the
PIV5 F TM domain, not including the C-tail or HRB domain, and the highly
hydrophobic peptide was resuspended in DMSO.

HMPV or PIV5 virus was

incubated with varying concentrations of peptide for 30 min and then added to Vero
cells to allow for infection (MOI=1 pfu/cell). After 24 hr, the cells were imaged and
prepared for flow cytometry to count GFP expressing cells (Fig 3.5A). When the
viruses were mock treated with DMSO (0 μM peptide), the infection for both was
widespread. Treatment with TM peptide reduced the number of GFP expressing
cells for PIV5 (Fig 3.5B). Addition of 10μM of peptide resulted in approximately
75% reduction in PIV5 infection, as determined by flow cytometry (p<0.0001
Student’s t-test). The HMPV samples treated with peptide did not exhibit a
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significant reduction in GFP expressing cells, suggesting that the effect of the TM
peptide utilized was specific to PIV5 F. Together, these results demonstrate that
the TM domain can be targeted to disrupt F protein function and viral infection in a
sequence specific manner.
Discussion
Viral fusion proteins drive the fusion of viral and cellular membranes, a key
early step in the entry of enveloped viruses. We have previously shown that the
TM domains of several paramyxovirus fusion proteins associate in isolation and
that disruption of TM-TM association by mutagenesis of a key L/I zipper motif
resulted in a HeV F protein that triggered prematurely [160, 161]. Based on these
previous studies, we examined the ability of paramyxovirus TM-TM interactions to
be targeted with exogenous proteins containing the TM domain to cause a
disruption in overall protein structure and function (Fig 3.6). With the creation of
three constructs containing the HeV F TM domain, we confirmed that coexpression of the native HeV F protein with any of the three constructs resulted in
a reduction of HeV F protein expression (Fig 3.2A), protein stability (Fig 3.2C), and
a disruption of the trimeric interactions of HeV F (Fig 3.2E). Interestingly, the
successful cleavage and presence of HeV F on the cell surface (Fig 3.2A), as well
as the cleavage patterns seen in the pulse chase experiment (Fig 3.2C) suggests
that the exogenous TM containing proteins were not altering proper trafficking of
the F protein that successfully exited the ER. Additionally, examination of protein
stability and oligomerization suggests that either the destabilization of trimeric
interactions and/or premature triggering could cause early protein degradation, as
it has been previously shown that prematurely triggered protein is quickly degraded
[253].
The fusion process by which paramyxoviruses enter cells involves a series
of steps including: attachment protein mediated receptor binding, a triggering event
of the fusion protein facilitated by the attachment protein, a dramatic, irreversible
conformational change to merge the cellular and viral membranes to form a fusion
69

pore, and fusion pore expansion [10]. Not only were protein expression, stability,
and stable oligomerization of native HeV F disrupted in the presence of the TM
constructs, the co-expression of the TM constructs also dramatically reduced the
fusion activity of HeV F (Fig 3.3). The presence of the SL and LL constructs
reduced fusion to background levels in both syncytia (Fig 3.3A) and reporter gene
fusion assays (Fig 3.3C), suggesting the presence of these constructs may disrupt
key steps in the membrane fusion process such as protein triggering or protein
conformational changes.

Interestingly, the presence of the HRB construct

appeared to completely abolish syncytia formation (Fig 3.3A) similar to the other
constructs, however in reporter gene fusion experiments HeV F was still able to
facilitate about 20-30% of fusion compared to WT levels (Fig 3.3C). It has been
previously shown that there is a correlation between cell surface expression and
fusogenic activity [251], while the reporter gene results in the presence of HRB
construct would fit with that correlation, the lack of syncytia formation would not.
This discrepancy may be due to the presence of HRB constructs disrupting late
stages of fusion, such as the fusion pore expansion or further cellular
rearrangements, as reporter gene fusion assays only require fusion pore opening
and expansion, while syncytia formation requires additional dramatic cellular
rearrangements. A previous study has shown that several enveloped viruses
demonstrated luciferase fusion activity, while not showing syncytia formation [254],
suggesting that downstream cellular rearrangements may be blocked even when
fusion pore formation and expansion has occurred. Additionally, the reporter gene
assay results with the exogenous TM constructs inserted into the target membrane
(Fig 3.3, Experimental Condition #2), provided evidence that the nature of TM
construct disruption was not simply due to global membrane alterations.
Interestingly, there was a small, but significant decrease seen with the addition of
the SL and HRB constructs in the target membrane (Fig 3.3D). Since it has been
previously shown that the TM domain and fusion peptide of HeV F interact [252],
the presence of these constructs may be interfering with the ability of the fusion
peptide to induce membrane disorder needed for cell-cell fusion. Alternatively, the
HRB construct may be interfering with the formation of the six helix bundle
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formation, a critical step in paramyxovirus membrane fusion [7], as it has been
shown for the viral family that peptides mimicking the HRB region can interact with
the HRA in the hairpin intermediate to block viral fusion [255].
While the presented experiments in this paper support a model where
disruptions to TM domain interactions cause lower proteins expression and
function, the created constructs do contain other portions of the F protein (various
lengths of the HRB, c-tail, signal peptides, and an HA tag). Based on the cellular
experiments completed (Fig 3.2 and 3.3), more dramatic reductions in protein
expression and fusion activity correlated with presence of shorter lengths of the
HRB region (SL construct elicited the largest effect, then the LL construct). This
suggests that these effects are not due to the HRB region. While the cellular
experiments cannot rule out the possibility that the HA tag, c-tail, or signal peptides
present are not causing the examined effects, the peptides tested in the PIV5
infection system (Fig 3.5) contained only the TM domain and still promoted a
reduction in viral infection. This demonstrates that the exogenous TM domain
alone can create effects similar to those seen in the cellular experiments. In
addition to recent work completed in suppression of hyperactive immune cells
[225], inhibition or suppression of tumor growth in several cancers [226, 229, 230],
and inhibition of oncogenic activation induced by Epstein Barr Virus [231], these
experiments further support that effects seen are specific to destabilizing TM
interactions.
The effects on protein stabilization and fusion activity in the presence of the
HRB construct were less dramatic than when the SL or LL construct was present.
We have previously shown that including the full length HRB destabilizes HeV F
TM-TM interactions [165], supporting the idea that the lower effectiveness of these
constructs could be due to the full length HRB creating weakened TM interactions
between the exogenous construct and the TM of the native F protein. This may
impair the ability of the HRB construct to interact with the native F protein, as
shown by the failure to coIP (Fig 3.1C). Alternatively, the full length HRB on the
exogenous TM construct could interact with HRA of the native protein [255],
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reducing the ability to associate with the native F protein TM, or the HRB on the
exogenous TM construct could be self-trimerizing, causing the exogenous TM
proteins to traffic as a trimeric unit. In the infection assay which served as a proof
of concept tool, a peptide containing only the TM domain could specifically affect
viral infection. Our cellular experiments presented here demonstrate that small
portions of the protein ectodomain (HRB region) can be added without significantly
effecting the reduction of viral protein mediated fusion. The inclusion of these small
portions of this region may help with the peptide solubility of the highly hydrophobic
TM peptides.
F proteins of paramyxoviruses, and other enveloped viruses have specific
sequence requirements for their TM domain, and simply substituting the TM
domain of one paramyxovirus F protein into another related F protein can abolish
membrane fusion of that F protein without effecting overall cell surface expression
[162]. The specificity of the effect of exogenous TM protein was determined by coexpressing PIV5 F with the HeV F TM containing proteins in cellular experiments,
and co-expressing hMPV F with PIV5 F TM peptides in the infection system.
Neither PIV5 F (Fig 3.4), nor hMPV F (Fig 3.5) demonstrated a significant effect
on expression or function in the presence of a non-homologous exogenous TM
construct or peptide. Interestingly, these PIV5 F and hMPV F proteins are
predicted to have a heptad repeat leucine/isoleucine zipper motif in the TM domain
similar to HeV F [161], so while this is an important oligomerization motif in TM-TM
interactions for these proteins, there appears to be sequence specific requirements
for these interactions happening beyond this motif. These findings support the
premise that the TM-TM interactions are sequence specific interactions and not
simply the result of proximity to certain interaction motifs or hydrophobicity.
The results from the PIV5 infection system, taken with the results from the
HeV F cellular experiments highlight the critical nature of fusion protein TM-TM
interactions for maintenance of viral infectivity, and demonstrate a potential for
small molecule inhibitors that disrupt TM-TM interactions or modulators of lipid
environment to serve as antiviral candidates. A study with paramyxoviruses found
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that a broad-spectrum small molecule drug (JL103) could prevent membrane
fusion by altering lipid architecture [256]. Changes in lipid environment caused by
small molecule inhibitors may be able to alter fusion protein TM-TM interactions
and, therefore, disrupt fusion protein function. A recent study with Epstein-Barr
virus showed that a small molecule targeting the TM domain could disrupt homotrimerization of the latent membrane protein-1, a step that is critical for oncogenic
activation of the virus [231]. Other studies have shown that targeting antiviral
peptides to the cell membrane with cholesterol enhanced efficacy [227]. The
inclusion of some portion of the TM domain may be able to further enhance
specificity in addition to physically anchoring the peptide. Beyond viral proteins,
the concept of disrupting TM-TM interactions may prove to be a viable therapeutic
option. The tyrosine kinase receptor, ErbB2, was found to be overexpressed in
high-grade inflammatory breast cancer. ErbB2 requires dimerization in order to
trigger downstream signaling cascades that include the MAPK pathway. TM
peptides that disrupt ErbB2 TM dimerization were found to reduce tumor cell
growth and metastasis [224]. Other studies have demonstrated the potential use
of small molecules that disrupt TM domain oligomerization to suppress tumor
growth in glioma and metastasis by targeting the TM of Plexin-A1 [229], and inhibit
tumor growth in melanoma by TM interactions in p75NTR [230]. The results
presented may further help in development or improvement of antivirals and other
TM targeting therapeutics. More importantly, our results show the important role
of TM-TM interactions in the stability of the viral fusion protein on a global level.
Utilizing TM-TM interactions to disrupt fusion protein function may also extend
beyond paramyxoviruses, as we have recently shown that TM-TM interactions
occur for fusion proteins of the corona-, rhabdo-, orthomyxo-, and filoviridae
families [184]. These studies further broaden our understanding of the hydrophobic
TM domain, and demonstrate their functional role beyond serving as a hydrophobic
membrane anchor.
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Figure 3-1 HeV F TM constructs co-localize and interact with WT HeV F.
A) The domain structure of the HeV F protein containing a fusion peptide (FP), two
heptad repeat regions (HRA and HRB), a transmembrane domain (TM), and a Ctail (CT). General schematic of TM protein design is shown with amino acid sites
indicated. Each construct includes a signal peptide, the full TM and CT, an HA
tag, and a linker region that has varying lengths of the HRB domain.

B)

Immunofluorescence of co-expression of HeV F (green) and each of the TM
constructs (red).

The inset shows a 4x zoom of the white box. C) Co74

immunoprecipitation of HeV F with the TM constructs. Cells were starved for 45
min, radiolabeled for 30 min, and chased for 1.5 hr prior to lysis and pulldown with
an anti-HA antibody.
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Figure 3-2 Co-expression of HeV F with the TM proteins reduces expression,
protein stability, and stable oligomerization
A) Surface biotinylation was used to analyze the total and surface populations of
HeV F when co-transfected with mock empty vector or each of the TM constructs.
Proteins were radiolabeled for 3 hrs. B) Relative HeV F protein expression was
quantified using band densitometry (ImageQuant); experiments were performed in
triplicate with the standard deviation shown.

C) Pulse-chase radiolabel IP was

used to determine the effect the TM constructs had on WT HeV F over time.
Proteins were radiolabeled for 30 min with indicated chase times noted above each
panel in hours. D) Various transfection ratios of the HeV F:TM constructs were
tested in a radiolabel IP using the SL construct. E) The effect of exogenous TM
constructs co-expression on HeV F protein oligomerization was analyzed by nonreducing SDS PAGE.
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Figure 3-3 Co-expression of HeV F with the TM proteins reduces fusion
activity.
A) To determine the fusion activity of HeV F in the presence of the TM constructs,
cells were imaged for the presence of syncytia (indicated by the white arrows) at
24 hr after transfection of HeV F with each of the TM constructs. B) Schematic of
the reporter gene fusion assay experimental set up, showing experimental
condition #1 with the TM constructs in the same cells as HeV F and G and
experimental condition #2, in which the TM constructs are in the target (BSR/T7)
cells. Results from the luciferase reporter gene assay for condition #1 (C) and
condition #2 (D). Results are representative of three independent experiments,
with each performed in duplicate. Significance was determined by a student t-test,
compared to WT, *p <0.05, **p<0.001.
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Figure 3-4 PIV5 F expression and fusion activity is not affected by HeV F TM
proteins
A) TM sequences of HeV and PIV5 F, predicted with TMHMM Server v2.0. B)
PIV5 F expression was determined when co-expressed with each of the HeV TM
proteins by radiolabeled immunoprecipitation with pull down by anti-PIV5 F or antiHA. Protein expression levels were determined by band density (C) Experiments
were performed in triplicate. D) Syncytium formation assay revealed that coexpression TM constructs did not inhibit PIV5 F fusion activity. Syncytia indicated
by white arrows. E) Immunofluorescence analysis of the co-expression of PIV5 F
(green) with HeV TM constructs (red).
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Figure 3-5 PIV5 F TM peptide inhibits PIV5 infection selectively.
A. GFP expressing PIV5 or HMPV was incubated with TM peptide designed to
target the PIV5 F TM domain, then cells were infected with treated virus. GFP cells
were imaged 24hr later and counted for quantification via flow cytometry (B).
Experiments were performed in triplicate. A student’s t-test was used to determine
significance; * p<0.0001.
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Figure 3-6 Model for TM peptide interaction with fusion protein.
The introduction of homologous TM protein may cause the fusion protein to misfold
or prematurely trigger, as a result of the exogenous TM protein interacting with the
native fusion protein TM domain.
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CHAPTER 4. THE N-TERMINAL
TRANSMEMBRANE DOMAIN

RESIDUES

OF

THE

HENDRA

F

*This work completed was completed in collaboration with Hadley Neal, Dr. Juana
Reyes-Zamora, and Kearstin Edmonds.

Hadley, Juana, Kearstin, and I all

completed independent replicates of syncytia assays and reporter gene assays
(Fig. 4.4a and 4.4b). Hadley, Kearstin, and I completed independent replicates of
the surface biotinylation assay and pulse chase experiments (Fig. 4.1b/c/d and Fig.
4.3b/c/d). Fluorescent images were taken by me and processed by Dr. Carole
Moncman (Fig. 4.2). All other experiments, as well as figure generation was
completed by me.
Introduction:
Hendra virus (HeV) is a zoonotic, enveloped virus within the viral family
Paramyxoviridae. HeV, similar to all enveloped viruses, uses surface glycoproteins
to promote binding to a host cell and fusion with host cell membranes to facilitate
viral entry [11, 50, 54, 257, 258]. In HeV, these proteins are termed the attachment
protein (G), responsible for binding the host cell, and the fusion protein (F),
responsible for merging the viral and host cell membranes. F is a trimeric
transmembrane protein [259]. Following proteolytic cleavage, receptor binding,
and receipt of a triggering signal, HeV F undergoes a large, dynamic
conformational change enabling the viral and host cell membranes to merge [11,
50, 258, 259]. In order to be cleaved by cellular cathepsins, HeV, and the closely
related Nipah virus, F proteins undergo a unique trafficking pattern. They are
initially synthesized, trafficked through the secretory pathway to the cellular
surface, then are endocytosed to be cleaved by cathepsin L in recycling
endosomes before being trafficked back to the cell surface [150, 151, 172, 173,
260]. Throughout this trafficking, the F protein remains associated as a trimer [50,
54, 69, 160]. Interactions within the transmembrane (TM) regions of F trimers have
been implicated in protein stability and fusion function [160, 164, 165, 173, 261].
Additionally, residues S490 and Y498, have been demonstrated to be involved in
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the endocytosis of F [173]. Previously alanine scanning mutagenesis of the Cterminal end of the HeV F TM region has been performed [165], however this has
not been completed for the N-terminal end of the TM region.
Here we performed double-alanine scanning mutagenesis of the first 20
amino acids of the TM region of HeV F and assessed the effect on protein stability,
expression, proteolytic processing, and fusion. Mutants altering residues S490
and Y498 show defects in protein cleavage, surface expression and fusion,
consistent with previous work showing these residues are important in protein
endocytosis [173]. Additionally, a mutant altering S493 had lower protein surface
expression, slightly lower cleavage, and significantly reduced fusion, again
consistent with previous work [160].

Interestingly, we found that the alanine

mutation of residues M491 and L492 significantly reduced fusion without altering
protein expression, newly implicating these residues in the fusion process.
Additionally, we demonstrate that alanine mutation of the remaining residues does
not have an effect on protein expression, stability or fusion function. The work
presented here, when considered with previously published work [160, 165, 172,
173, 261], provides a comprehensive analysis of the entire HeV F TM region and
identifies the critical residues within it.
Results
To assess the potential role of residues at the N-terminus of the HeV F
protein TM region, double alanine scanning mutants were created (Fig. 4.1a).
Surface biotinylation was then performed to determine the surface and total protein
population of transiently transfected wild-type (WT) HeV F or mutant F (Fig. 4.1b).
WT HeV F and most TM mutants were detected after immunoprecipitation as two
bands, corresponding to F0 (un-cleaved F) and F1 (cleaved F) (Fig. 4.1b). Using
band densitometry, percent expression (Fig. 4.1d) and percent cleavage (Fig. 4.1c)
were calculated for both surface and total protein populations and normalized to
WT HeV F. Mutants IS, SM, and LY all showed reduced surface expression
compared to WT F.

SM also demonstrated lower total protein expression.
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Additionally, mutants IS, SM, and LY all had a significant reduction in protein
cleavage in both surface and protein populations. Interestingly, the ML mutant had
a slight, but significant reduction in cleavage in the surface protein population,
while showing no cleavage differences in the total protein or overall protein
expression. This suggests, consistent with previous studies, that mutant IS, SM,
and LY have defects in the endocytosis process needed for proteolytic processing.
When

WT

or

mutant

F

protein

expression

was

assessed

using

immunofluorescence, mutants IS, SM, LY, SI, and VL appear to have more
staining near the nucleus, though at least some staining is observed throughout
the cell in all samples (Fig. 4.2).
Pulse-chase analysis was utilized to examine WT F or mutant protein
cleavage kinetics and protein stability (Fig. 4.3a). Most TM mutants displayed no
change in protein cleavage compared to WT F, however two showed lower
cleavage at later chase time points (Fig. 4.3b). At four and eight hours of chase,
the SM mutant demonstrated a significant reduction in cleavage compared to WT
F (p<0.01 at four hours and p<0.0001 at eight hours). Additionally, the LY mutant
exhibited a reduction in cleavage at eight hours of chase (p<0.01). Despite these
two differences in cleavage, all TM mutants had similar protein turnover kinetics
compared to WT F, with protein remaining stably expressed through 2 hours of
chase. After four and eight hours of chase, only about 40-50% of protein remains,
and only about 10-15% remains after twenty-four hours (Fig. 4.3b). This suggests
that even mutations that alter F protein cleavage do not disrupt protein stability.
HeV F associates as a trimer shortly after synthesis and remains in a
trimeric association throughout protein trafficking and fusion. To assess the effect
the TM mutations had on trimer stability WT HeV F or each mutant was transiently
expressed

and

metabolically

labeled.

Following

cell

lysis,

and

immunoprecipitation, samples were treated at 60°C or 100°C prior to separation
on non-reducing SDS-PAGE. After either treatment temperature, WT HeV F
migrated primarily as a monomer, although some dimer and trimer species were
observed (Fig. 4.3d). Similar migration patterns were observed for each of the TM
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mutants, suggesting that the introduced mutations were still able to form oligomeric
species of the protein.
To understand how the mutations created effected the overall fusion
function of HeV F syncytia formation analysis and a luciferase reporter gene fusion
assay were performed. For the syncytia assay, WT HeV F or the TM mutants were
transiently co-expressed with HeV G and imaged at 48 hours (Fig. 4.4a). The
formation of large syncytia was observed in WT samples, as well as mutants SL,
II, VL, SI, and LC. Very few syncytia were observed in samples IS and ML, and
no syncytia were found in samples with mutant SM or LY (Fig. 4.4a). To quantitate
fusion, a luciferase reporter gene assay was employed by transiently coexpressing WT HeV F or each TM mutant with HeV G in Vero cells, and overlaying
them with BSR/T7 cells. All samples were normalized to samples expressing WT
HeV F and G. Similar to the syncytia results, samples SL, II, VL, SI, and LC
demonstrated fusion levels similar to WT (Fig. 4.4b). Samples SM and LY did not
exhibit any fusion about background levels (p<0.0001), and mutants IS and ML
exhibited significantly reduced fusion levels (20% [p<0.01] and 50% [p<0.05],
respectively) compared to WT. The reduction in cleavage observed for mutants
IS, SM, and LY is consistent with the significantly reduced protein expression and
cleavage observed for these mutations (Fig. 4.1c and 4.1d). However, the slight
reduction in cleavage observed for the surface population of ML is not enough to
account for the 50% reduction in fusion since previous work has shown that the
amount of cleaved protein at the cell surface directly correlates to the amount of
fusion [251].
Discussion
The role of several residues within the N-terminus of the TM of HeV F have
previously been explored. Residues L488 (mutant SL), I495 (mutant II), and I502
(mutant SI) were determined to be part of a Leucine-Isoleucine zipper (LI Zipper)
motif that ran through the TM region [261]. Single mutations of each of these
residues resulted in only minor protein expression, cleavage, and fusion activity
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change [261] consistent with our study. However, mutation of the entire LI zipper
resulted in a significantly destabilized the pre-fusion conformation protein, thus
abolishing the fusion activity of the protein [261].

Interestingly, including the

neighboring residues (S, I, S) with mutations to the LI Zipper had no appreciable
effect on protein expression, stability, or fusion function suggesting that these
serine residues and isoleucine residue are dispensable for HeV F function (Fig.
4.1, 4.3, 4.4).

Residues S490 (mutant IS) and Y498 (mutant LY) were

demonstrated to play a role in protein endocytosis and subsequent recycling, with
the hydroxyl group and aromatic nature being critical in each residue, respectively
[173]. Efficient endocytosis and recycling of the HeV F protein was also shown to
be critical for proper virus-like particle assembly, as endosomes are the likely
location of HeV F association with HeV matrix protein during particle assembly
[172]. Remarkably, inclusion of the neighboring residues methionine and leucine
seemed to allow for slightly more protein cleavage and slightly enhanced stability
compared to previous work on the single point mutations [173]. This suggest that
mutation of the two neighboring residues may have compensatory effect,
potentially restoring some of the protein endocytic recycling.

Residue S493

(mutant SM) has been demonstrated to have slightly reduced cell surface
expression and fusion levels reduced by about 80% in a previous study [160].
Interestingly, when we included the neighboring methionine residue in the
mutation, cell surface expression was further reduced and fusion activity was
abolished, indicating a compounding effect when both the S and M are mutated.
This may indicate both of these residues play critical roles in fusion, protein
conformation, and stability.
Residues M492 and L493 (mutant ML) had not previously been explored in
the context of HeV F. Residue M492 is predicted to lie on the contact interface
between the protomers in the trimeric protein [173], suggesting it may have a role
in TM-TM associations of this protein. While this mutant is still able to form protein
oligomers (Fig. 4.3d), it does exhibit a significant reduction in protein fusion (Fig.
4.4b). The mutation of the large methionine and β-branched leucine residues to
alanines may cause the protein trimer to pack together too tightly disrupting the
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TM-TM dissociation needed to carry out fusion [164]. Alternatively, this mutation
could increase the flexibility of the protein in this region, loosening TM-TM
associations, causing the TM regions to dissociate too much during the fusion
process, thus destabilizing protomer association during intermediate steps of
fusion or these mutations disrupt interactions with the fusion peptides that are
needed for fusion pore expansion.
In addition to mutation of residues M492 and L493, this work also
represents the first-time residues V499/L500 and L505/C506 were investigated.
When the C-terminal end of the HeV F TM region was studied, mutations of βbranched residues appeared to play a critical role. Interestingly, both mutant VL
and LC, which lie in the middle of the predicted HeV F TM and contain β-branched
residues, demonstrate no change to protein expression or fusion activity indicating
these residues are not critical. This suggests that these residues play a larger role
in the C-terminus of the HeV F TM, potentially contributing to an increase in
flexibility needed by that end [165]. This work, when partnered with previous
studies [160, 165, 172, 173, 261], completes characterization of the entire HeV F
TM region. While this work has investigated HeV F protein stability, expression,
and cell-cell fusion function, understanding the interactions of HeV F TM residues
with viral proteins other than HeV G, or host proteins and membrane lipids remains
to be explored.
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Figure 4-1 Several HeV F TM mutants have impaired protein expression and
protein cleavage
(a) Alanine scanning mutations at the N-terminus of the HeV F TM were generated
to assess the importance of these residues.

(b) Surface biotinylation was

performed to analyze the surface and total population of HeV F for WT and each
of the mutants created.

Cells were radiolabeled for 3 hours. Using band

densitometry, percent expression (c) and percent cleavage (d) was measured for
the total and surface protein. All measurements represent the average of three
independent experiments ± SD, and all samples for protein expression were
normalized to WT. Significance was determined by two-way ANOVA * = p < 0.05,
** = p < 0.01, *** = p < 0.005, **** = p < 0.001.
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Figure 4-2 HeV F TM mutants have a similar distribution to WT F in
immunofluorescence.
Immunofluorescence of WT HeV F or each of the mutants created (Green is F,
Blue is DAPI) transiently expressed in Vero cells. Insets represent enlargements
of the boxed area
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Figure 4-3 HeV F TM mutations at residues SM and LY decrease protein
cleavage levels.
(a) Vero cells were transfected with WT HeV F or the TMD mutant DNA,
metabolically labeled for one hour, and chased for times indicated (hours). Using
band densitometry (b) percent cleavage and (c) percent stability were calculated.
Graphs are shown as the average of three independent experiments ± SEM. d)
Vero cells transiently expressing WT F or each TM mutant were metabolically
labeled for 6 hours. Samples were treated at the indicated temperatures before
separation on a non-reducing SDS-PAGE. Oligomers are labeled on the right
based on size (n=3).
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Figure 4-4 Mutations at residues IS, ML, SM, and LY in the HeV F TM reduce
fusion.
(a) Vero cells were transfected with the HeV attachment protein (G), and WT HeV
F or one of the TMD mutants. Syncytia formation was analyzed at 48 hpt. Black
arrows indicate syncytia formation. Images are representative of 4 independent
experiments. (b) A luciferase reporter gene assay was performed using BSR/T7
cells overlaid onto Vero cells transfected with HeV G and WT HeV F or each of the
TMD mutants at 24 hpt. Results are normalized to samples with WT HeV F and G
and representative of 3 independent experiments ± SD, performed in duplicate.
Significance was determined by one-way ANOVA. * = p < 0.05, ** = p < 0.01, ***
= p < 0.005.
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CHAPTER 5. EFFECT OF MUTATIONS IN THE SARS-COV-2 SPIKE PROTEIN
ON PROTEIN STABILITY, CLEAVAGE, AND CELL-CELL FUSION
FUNCTION
*This chapter is from the submitted manuscript: Barrett CT, Neal HE, Edmonds
K, Moncman CL, Thompson R, Branttie JM, Boggs KB, Wu CY, Leung DW, Dutch
RE. 2021. Effect of mutations in the SARS-CoV-2 spike protein on protein stability,
cleavage, and cell-cell fusion function. Submitted to J. Biol. Chem January 2021.

*This work was completed with the help of several individuals. Hadley Neal,
Rachel Thompson, and Dr. Cheng-Yu Wu generated all of the SARS-CoV-2
mutants used. Kearstin Edmonds, Hadley Neal, and I all performed the pulse
chase and surface biotinylation experiments (Fig. 5.1, Fig. 5.3b-g, Fig 5.4b-e, Fig
5.6). Kearstin Edmonds and I completed all of the reporter gene assays (Fig. 5.2ce, Fig. 5.3h/i, Fig. 5.4f, Fig. 5.8b). Hadley Neal and I performed all of the syncytia
assays (Fig. 5.2 a/b, Fig. 5.9). All fluorescent images were taken and processed
by Dr. Carole Moncman. Jean Branttie and I performed the western blotting (Fig.
5.8c). All other experiments, figure generation, and writing were completed by me.
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
causative viral agent of the ongoing coronavirus disease of 2019 (COVID-19)
global pandemic. Thus far, COVID-19 has impacted over 86 million people
globally, resulting in the death of more than one and a half million individuals [262].
Due to the widespread global impact of this pandemic, a concerted effort has been
made to rapidly develop a vaccine or antiviral treatment.
The SARS-CoV-2 spike (S) protein is the major transmembrane
glycoprotein studding the surface of the viral particle, and is exclusively
responsible for viral attachment and cell entry, thus making it the major target of
current vaccine strategies and antiviral therapeutics [263]. The S protein consists
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of two distinct subunits: the S1 subunit, which binds to the known host receptor,
angiotensin converting enzyme 2 (ACE2) [181, 264-271], and the S2 subunit that
promotes the viral-to-host cell membrane fusion event needed for viral infection
[50, 263, 269, 272-277]. Most known coronavirus (CoV) S proteins undergo two
post-translational proteolytic cleavage events, one at the border of the S1 and S2
subunits, and one downstream within the S2 subunit (termed S2’) [50, 263, 273,
275-280].
Similar to several other CoVs, SARS-CoV-2 likely utilizes bats as a reservoir
species, specifically Rhinolophus affinis or horseshoe bats [37, 271, 281-283].
SARS-CoV-2 has 96% sequence identity to a CoV found in this bat population,
RaTG13, with limited differences between them [283]. One difference is the
polybasic, PRRA, insertion at the S1/S2 border which gives this site the canonical
sequence requirements for cleavage by the cellular proprotein convertase furin
[178, 284-286]. This change may be a key factor in the zoonotic transmission of
SARS-CoV-2. The presence of a furin consensus sequence at the cleavage site
has been observed in other human infecting CoVs [178, 287-289], including highly
pathogenic forms of influenza [290, 291] and previous studies have demonstrated
its functional significance. For SARS-CoV-2, the insertion is suggested to allow for
expanded cellular tropism and infectivity [178, 179, 273, 292]. For most CoVs,
cleavage at a downstream S2’ site may be carried out by a number of cellular
proteases, including serine proteases like transmembrane serine protease 2
(TMPRSS2), or endopeptidases, including members of the cathepsin family [273,
274, 278-280].
Following receptor binding by the S1 subunit and priming by proteolytic
cleavage, the S2 subunit of S promotes the critical membrane fusion step of viral
entry by undergoing dynamic conformational changes to promote merging of the
viral and host cell membranes [179, 181, 182].

For entry of SARS-CoV-2,

cleavage at the S1/S2 border (by furin or a similar protease), is critical for
TMPRSS2 cleavage and entry at the plasma membrane. However, when S1/S2
border cleavage is blocked, viral entry can be mediated through endosomal
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compartments with proteolytic cleavage carried out by a member of the cathepsin
family, similar to the entry pathway of SARS-CoV [179, 181, 182, 293, 294]. In
addition to promoting virus-cell fusion during viral particle entry, S can also
promote cell-cell fusion, a pathogenic effect observed in the lungs of COVID-19
patients where neighboring cells fuse together to form large multi-nucleated cells,
termed syncytia [234-237, 295, 296]. While the role of cellular proteases and S
cleavage in viral entry is being extensively investigated, insight into the cleavage
requirements for cell-cell fusion in SARS-CoV-2 remains more limited. Recent
studies have suggested that S cleavage at the S1/S2 border is critical for cell-cell
fusion, and TMPRSS2, while not required, appears to enhance this cell-cell fusion
[182, 234, 297, 298]. However, relatively little is known about the timing and
efficiency of these cleavage events, and how mutations in S may affect the
process.
Though CoVs mutate at a slower rate than most RNA viruses due to the
presence of viral proofreading machinery, a meta-analysis of genomes of SARSCoV-2 strains found several mutations within S circulating in significant
percentages of the analyzed populations [299, 300]. The most common mutation,
now found in most of the global population, is an aspartate to glycine mutation at
residue 614 (D614G) in the S1 subunit. Additional mutations throughout the S1
and S2 subunits of S have been found in a smaller percentage of the viral
population. Since S2 contains the fusion machinery, mutations in this region may
have an impact on overall protein stability and fusion. Understanding the effects of
mutations in this region will allow for a more comprehensive understanding of the
overall S function.
We tested wild-type (wt) SARS-CoV-2 S and variants in different host cell
strains to analyze the effects on stability, proteolytic processing, and cell-cell
fusion. Here we demonstrate that furin cleavage of S at the S1/S2 border is
required for efficient cell-cell fusion, and that the presence of TMPRSS2 in target
cells enhances S mediated cell-cell fusion, consistent with previous studies [182,
297]. We also show that mutations of the cleavage sites at the S1/S2 border, S2’
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site, or a cathepsin L (cath L) cleavage site, conserved from SARS-CoV S, all
reduce initial cleavage at the S1/S2 border during viral protein synthesis,
suggesting that mutations downstream of the S1/S2 border likely alter the overall
conformation of the protein. Additionally, we identify two S2 subunit residues, one
in the internal fusion peptide and another in the cytoplasmic tail, that alter protein
fusion function when mutated without changing overall protein expression and
cleavage, providing more insight into regions of the protein important for the
regulation of the fusion process. Finally, we demonstrate protein turnover and
cleavage kinetics in a range of host cells, as well as in the presence of several
exogenous proteases, providing a more comprehensive picture of the S protein.
Results
Stability and proteolytic cleavage of SARS-CoV-2 Spike in Various Cell Lines
To examine the stability and cleavage patterns of SARS-CoV-2 S in a range
of mammalian cell lines, the following cells were transiently transfected with
pCAGGS-S: Vero, A549, MEFs, Cath L- MEFS, and LoVo cells (a human colon
carcinoma line that does not express functional furin). Stability of S and the timing
of proteolytic processing were determined by pulse-chase labeling and
immunoprecipitation. S protein detected from immunoprecipitation was observed
as two bands, a band around 150 kDa corresponding to an un-cleaved full-length
species of the protein, labeled S, and a band around 97 kDa corresponding to a
species of S cleaved at the border of the S1 and S2 subunits, labeled S2 (Fig.
5.1a). After a one-hour chase, a band corresponding to S2 was observed in Vero,
A549, and both MEF cell lines (Fig. 5.1a). In LoVo cells, a band corresponding to
the S2 subunit did not appear until four hours of chase, verifying that lack of furin
impedes efficient processing at S1/S2, and that the S1/S2 border can be cleaved
by cellular protease other than furin (Fig. 5.1a) in a slower and less efficient
process. Veros, A549s, MEFs, and Cath L- MEFs displayed similar cleavage
patterns over time, while LoVo cells displayed significantly less cleavage at two
and four hours. LoVo cells had only 2% cleavage at two hours and 18% cleavage
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at four hours, compared to about 20-40% at two hours and 30-60% at four hours
for all other cell types (p<0.05). However, LoVo cells reached cleavage levels
similar to the other cell lines at later chase time points (Fig. 5.1b). Bands smaller
than 90 kDa that would correspond to cleavage at the S2’ site were not observed
in any cell line. In the examined cell lines, expressed S remained stable through
the first four hours (Fig. 5.1c). By 24 hours post label, only 20-30% of the original
labeled protein remained for all cell lines.
Several studies have examined the cellular proteases involved in the
cleavage of S. Furin and TMPRSS2 appear to play key roles in cleavage at the
S1/S2 border and S2’ site, respectively [178-180, 301, 302]. Additionally,
lysosomal proteases such as cath L/B can be utilized for viral entry in TMPRSS2
deficient cells [181, 293, 297]. To examine how higher expression levels of these
proteases affect S stability and cleavage, Vero and A549 cells were transiently
transfected with S alone or S with TMPRSS2, furin, or cath L. Pulse-chase
analysis demonstrated that the transient expression of TMPRSS2 or cath L did not
affect the cleavage pattern of S (Fig. 5.1d and 5.1e, 5.7b), and a band
corresponding to S2’ cleavage was not observed in either Veros or A549s.
However, transient over-expression of furin increased the cleavage observed at
the S1/S2 border in Veros at four and eight hours of chase (p<0.05) and at all times
after zero for A549s (p<0.01 for one- and eight-hour chase, p<0.0001 for two- and
four-hour chase times) (Fig. 5.1e and 5.1f). This suggests that the normal levels of
cellular furin can eventually promote maximal levels of S1/S2 cleavage in both
Veros and A549s, but over-expression of furin facilitates more rapid cleavage of
the S1/S2 border. Interestingly, in both experiments (Fig. 5.1a and 1d) some uncleaved S remains even after 24 hours, indicating that a small portion of the S
population is not cleaved by furin or other endogenous proteases in these cell
lines. Finally, overall protein stability was not affected by co-expression of any
tested proteases (Fig. 5.7b).
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Spike Mediated Cell-Cell Fusion
The S2 subunit of S mediates both viral-cell fusion and cell-cell fusion [234,
235, 237], with cell-cell fusion readily observed both in a laboratory setting and in
the lungs of SARS-CoV-2 infected patients [234-237, 295, 296]. To better
understand the requirements and contribution of cellular proteases to S2 mediated
cell-cell fusion, we performed syncytia and reporter gene assays. For syncytia
analysis, a small number of syncytia, were observed at 24 hpt in all samples (Fig.
5.2a). At 48 hpt, similar numbers of large syncytia were observed with S alone or
S co-expressed with TMPRSS2 or cath L (Fig. 5.2b). However, co-expression of
S with furin resulted in increased syncytia formation. The cells exhibited nearly
complete fusion, suggesting that the presence of exogenous furin further increases
S mediated cell-cell fusion (Fig. 5.2b, panel 3).
To quantitate S mediated cell-cell fusion, luciferase reporter gene fusion
assays were performed (Fig. 5.8a), using a nine hour overlay that was determined
to be optimal (Fig. 5.8b). To characterize the role of cellular proteases in the
hACE2 expressing target cells, S-expressing effector cells were overlaid with
target cells containing hACE2 alone or hACE2 with TMPRSS2, furin, or cath L.
The amount of plasmid transfected was kept constant by supplementing with a
plasmid encoding an empty expression vector (EV). When Vero cells were used
as the S-expressing effector cell and TMPRSS2 was present in the target cells, a
significant increase in fusion was observed. This is consistent with the concept that
TMPRSS2 plays a role in fusion after or during the hACE2 (receptor) binding step
in the fusion cascade (Fig. 5.2c) [181, 182, 272, 289, 297], although the presence
of TMPRSS2 in these target cells also appeared to process hACE2 (Fig. 5.8c, also
observed in[234]). In samples with cath L or furin in the target cells, fusion levels
were similar to hACE2+EV (Fig. 5.2c). When A549 cells were used as the Sexpressing effector cell, none of the conditions produced statistically significant
differences from background levels (Fig. 5.2c), so Vero cells were used as the
effector cells for the remainder of the experiments performed.
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Having analyzed the function of proteases in the target cells, we were also
interested in the role of proteases present in the S-expressing effector cells. To
test this, EV, TMPRSS2, cath L, or furin were co-expressed with S and samples
were overlaid with target cells expressing hACE2. Similar to what we observed in
syncytia assays, only co-expression of S and furin produced a statistically
significant increase in fusion. This increase is likely due to the increase in the
amount of cleaved protein present when S is co-expressed with furin (Fig. 5.1e).
Neuropilin-1 has been suggested as a co-receptor for SARS-CoV-2 S and
may be important for the viral infection infiltrating the neuronal network [303-305].
To assess the contribution of neuropilin in cell-cell fusion, effector cells were
transfected with S and either EV, furin, neuropilin, or furin and neuropilin (F+N).
Target cells were transfected with EV, hACE2, neuropilin, or hACE2 and
neuropilin. However, no significant increase in fusion was observed when
neuropilin was present in either the target or effector cells (Fig. 5.2e), suggesting
that neuropilin does not appear to play a significant role in cell-cell mediated fusion.
Interestingly, when neuropilin is co-expressed in S containing effector cells, there
is no difference observed in fusion compared to samples with S+EV, suggesting
that neuropilin also does not have an inhibitory effect (Fig. 5.2e). Additionally,
when neuropilin alone is expressed in the target cells, fusion levels above
background levels are not observed. This indicates that in cell-cell fusion, S
binding hACE2 appears to be the major interaction during the receptor attachment
function.
Importance of CoV-2 cleavage sites
Early protein sequence analysis of CoV-2 S protein demonstrated the
presence of three potential cleavage sites [178]: a putative furin cleavage site at
the S1/S2 border; a conserved site 10 residues downstream from the S1/S2
border, shown to be cleaved by cath L in SARS-CoV; and the S2’ site which is
potentially cleaved by TMPRSS2 [178]. To functionally understand the role of each
cleavage site in S cell-cell fusion, a series of mutants were made.

Alanine

mutations of all the residues within each potential cleavage site (S1/S2 AAAAA,
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Cath L AAAA, S2’ AA), and single alanine mutations at the terminal arginine of the
S1/S2 border and S2’ site (S1/S2 PRRAA, S2’ KA) were created. Finally, a mutant
with residues (PRRA) upstream of the S1/S2 border deleted (del. PRRA), leaving
a single R residue at this site, was made, creating an S1/S2 border similar to
SARS-CoV S (Fig. 5.3A). Pulse-chase analysis (Fig. 5.3b) showed that all mutants
had similar protein turnover compared to wt S in Veros. However, in A549s several
mutants demonstrated more rapid protein turnover than wt S at later chase time
points. Surprisingly, mutations at all three sites led to either a complete loss or
significant delay in the proteolytic processing of the S protein at the S1/S2 border,
indicated by the lack of a band corresponding to the S2 subunit. This suggests
that mutations at distal sites can strongly influence cleavage at S1/S2. After an
eight-hour chase, no cleavage at the S1/S2 border was observed for the mutants
del. PRRA and S1/S2 AAAAA, confirming that deletion or mutation of the furin
consensus prevents cleavage at this site. For all other mutants, cleavage at the
S1/S2 border reached 30-50% of wt levels in both Vero and A549 cells the eighthour time point (Fig. 5.3c and 5.3d). Accurate analysis of protein cleavage was not
possible by the 24-hour time point, since only 20-30% of protein remained (Fig.
5.7b).

Finally, surface biotinylation showed that both total and cell surface

expression of all mutants were similar to wt S levels (Fig. 5.3e, f, and g).
To assess the effects of the mutations on cell-cell fusion, syncytia formation
assays in Vero cells were performed. While syncytia were readily observed in all
samples containing wt S, none of the mutants exhibited syncytia formation at 24
or 48 hpt when expressed alone (Fig. 5.9, panel 2). Addition of TMPRSS2 did not
recover syncytia formation in any mutant (Fig. 5.9, panel 3), and the addition of
furin only recovered syncytia formation in the S1/S2 PRRAA mutant (Fig. 5.9,
panel 4, syncytia denoted with black arrows). To analyze this result, cells were
lysed following the 48-hour imaging and protein levels examined by western blot.
Results showed that co-expression of furin with the S1/S2 PRRAA mutant restored
cleavage at the S1/S2 border, while all other mutants did not show cleavage at this
site (data not shown). This suggests that cleavage at the S1/S2 border is critical
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for cell-cell fusion, and that the double R motif in the PRRAA mutant can be
cleaved by over-expressed furin.
Luciferase reporter gene analysis of fusion in Veros transfected with wt S
or each mutant showed similar results to the syncytia assays, with none of the
mutants showing fusion levels above background (Fig. 5.3h). Interestingly, the S2’
AA mutant displayed high background levels, suggesting this mutant may have a
conformational change, or characteristics that increase receptor binding or alter
S2 trimeric association, leading to higher background signals. Reporter gene
assays were also carried out with addition of transiently expressed furin in the Sexpressing effector cells, but no significant increases in fusion were observed.
Since all cleavage mutants created reduced cleavage at the S1/S2 subunit border,
the reductions in cell-cell fusion may be attributable to loss of cleavage at this site.
Effect of Circulating S Mutations on Protein Stability, Cleavage, and Fusion
An early examination revealed several mutations in the S protein gene in
circulating viral strains [299, 300], including the D614G substitution now found in
most of the global SARS-CoV-2 strains [299, 306-312]. The D614G mutation lies
in the S1 subunit of the protein, just downstream of the receptor binding domain,
and is proposed to play a critical role in receptor binding by alteration of the
positioning of the receptor binding domain. Other mutations in circulating strains
were found throughout the S2 subunit [300]. To assess the effect(s) of these
mutations, we created the mutants D614G, A831V, D839Y/N/E, S943P, and
P1263L (Fig. 5.4a). Pulse-chase analysis in Vero and A549 cells (Fig. 5.4b, c)
demonstrated that all circulating mutants tested exhibited protein turnover at
similar rates as wt S in both cell lines (Fig. 5.7d). Surface biotinylation confirmed
that all tested mutants displayed total protein and surface protein levels
comparable to wt S, suggesting that none of the mutants caused major defects or
enhancement of protein trafficking to the cell surface (Fig. 5.4d, e). Syncytia
formation and evaluation of protein location by immunofluorescence were similar
between all mutants and wt S (Fig. 5.10).

Interestingly, cellular extensions

containing the S protein were observed for the wt and each of the mutants (Fig.
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5.10, white arrows) [313]. Finally, luciferase reporter gene assays were performed.
While most of the mutants displayed fusion levels similar to wt S, three mutants
exhibited significant changes (Fig. 5.4f). D839Y and D839N displayed significantly
reduced levels of fusion compared to wt (p<0.01 and p<0.05, respectively), and
P1263L showed a significant increase in fusion compared to wt (p<0.05). These
changes in fusion cannot be attributed to differences in cell surface protein
expression or cleavage levels, suggesting that residues near the internal fusion
peptide, where D839 is located, and residues in the cytoplasmic tail, where P1263
is located, may play an important role in controlling the fusion cascade.
Trypsin accessibility and protein-protein association in select spike mutants
Since all the S cleavage site mutants exhibited defects in cleavage at the
S1/S2 border, we evaluated the accessibility of this site using a trypsin treatment
assay to determine if the lack of cleavage was due to misfolding in the S1/S2
border region. Vero or A549 cells were transfected with wt S or each cleavage
mutant and metabolically labeled. Cell surface proteins were biotinylated and then
cells were either left untreated or treated with 0.3 µg/μl of TPCK-Trypsin prior to
lysis. When treated with exogenous TPCK-Trypsin, both the del. PRRA and S1/S2
PRRAA mutants were efficiently cleaved at the S1/S2 border, shown by the
appearance of a band corresponding to S2 in the lanes treated with trypsin (Fig.
5.5a, quantified in Fig. 5.5b). This suggests that the observed defects in cleavage
at the S1/S2 border are not due to inaccessibility at the site, but rather to the
removal of the furin consensus sequence.

Interestingly, mutations at the

downstream cath L or S2’ potential cleavage sites also render defects in protein
cleavage at the S1/S2 border site. However, treatment with exogenous trypsin did
not significantly affect the amount of cleavage observed, a result consistent with a
change in conformation that renders the S1/S2 border cleavage site inaccessible.
CoV S proteins associate as homo-trimers shortly after synthesis and
remain in this trimeric form throughout the fusion cascade [50, 272]. To determine
if proteolytic processing affects the stability of S trimer association, Vero or A549
cells transfected with wt S or mutants D614G, S1/S2 AAAAA, S2’AA, or wt S plus
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additional furin, were metabolically labeled. After lysis and immunoprecipitation,
samples were then treated at 50°C or 100°C prior to separation on non-reducing
SDS-PAGE. When wt S was incubated at 50°C prior to separation, species that
correspond to a full-length S monomer, dimer, and trimer were observed (Fig.
5.5c).

Interestingly, species that fall in between sizes corresponding to a

monomer, dimer, and trimer (Fig. 5.5c, red and purple *) were also observed.
These intermediate species may be the result of dimers or trimers made up of a
mixture of full-length S protomers and cleaved S protomers. When wt S was
incubated at 100°C prior to separation, bands corresponding only to full length S
monomer, dimer, trimers, and cleaved S2 monomers were apparent. Similar
results were also observed in D614G samples, suggesting that species containing
cleaved protomers may be less stable. Consistent with this data, the S1/S2
AAAAA mutant, which cannot undergo cleavage at the S1/S2 border site, migrated
primarily as a trimeric species after 50°C incubation, with little monomer or dimer
observed. Additionally, when wt S was co-expressed with furin (shown to increase
S cleavage in Fig. 5.1e and 5.1f), the predominant observed species was
monomeric, after both 50°C and 100°C incubation. Overall, these results suggest
that cleavage at the S1/S2 border alters the stability of S trimeric association.
Furin or furin-like proteases in bat cells can cleave the S1/S2 border of SARSCoV-2 spike
Rhinolophus affinis horseshoe bats have been identified as the likely
reservoir species for the novel SARS-CoV-2 [283]. To understand the proteolytic
processing, expression, and stability of CoV-2 S in a cell line closely related to its
reservoir host, we utilized Pteropus alecto fetus (pt. fetus) or lung (pt. lung) cells
[240] that have a furin enzyme with ~90% sequence homology to bats in the
Rhinolopus family. Our previous studies on paramyxovirus virus fusion protein
cleavage have shown that efficient furin and cathepsin cleavage occurs in these
cells, although the furin cleavage occurs with delayed kinetics compared to Vero
cells or A549s [314].
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Surface biotinylation demonstrated that wt S and the del. PRRA mutant
were readily expressed at the surface at similar levels in both cell lines, with
cleavage at the S1/S2 border only observed for wt S and not for the del. PRRA
mutant (Fig. 5.6a and 5.6b). Pulse-chase analysis showed that S expressed in
both pt. lung and pt. fetus cells was cleaved at the S1/S2 border by one hour, with
cleavage extent reaching approximately 40% at eight-hours, and 60% at 24 hours
(Fig. 5.6c and 5.6d). Thus, furin or other proteases in P.alecto cells are able to
process S, although this processing occurred more slowly than in other
mammalian cell lines (compare to Fig. 5.1b). Interestingly, some cleavage was
also observed in both pt. lung and pt. fetus cells for the del. PRRA mutation (Fig.
5.6c and 5.6d). Additionally, the wt S and del. PRRA mutant were slightly less
stable in the P. alecto cells, demonstrating about 30-50% protein remaining at eight
hours, and about 20% at 24 hours (Fig. 5.6e). In contrast, previously used
mammalian cells lines showed 60-90% of wt S remained at eight hours, with 3050% at 24 hours of chase (Fig. 5.1c).
Discussion
In this study, we present a detailed characterization of the cleavage
patterns, protein stability, and cell-cell fusion function of the SARS-CoV-2 S
protein, as well as analysis of mutations within the S2 subunit that may affect these
important protein properties. Consistent with recently published work [178-180,
298, 301, 315], our analysis confirms that S is readily cleaved at the S1/S2 border
in a variety of mammalian cell lines. Additionally, we show for the first time, that
cleavage occurs in a bat cell line similar to the SARS-CoV-2 reservoir species.
While cleavage appears to be primarily carried about by the cellular protease furin,
the sequence at this border does have the ability to be cleaved by other members
of the pro-protein convertase family when furin is not present [298], and this likely
accounts for the small amount of cleavage we observed in furin-negative LoVo
cells.
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Additionally, we carefully assessed the role different proteases play in cellcell fusion, finding that furin increases cell-cell fusion when present in the same
cell as S, and TMPRSS2 increases cell-cell fusion when present in a target cell,
consistent with previous studies [182, 297]. Interestingly, when cell-cell fusion
assays were performed using A549 cells as the effector cell (Fig. 5.2c), high
background fusion levels were observed. This could be due to high endogenous
levels of TMPRSS2 in this cell line compared to Vero cells that were ultimately
used for this experiment (Fig. 5.8c). High TMPRSS2 expression or exogenous
treatment with trypsin has been shown to restore cell-cell fusion in low ACE2
receptor expression environments for SARS-CoV S [316, 317]. It is also worth
noting that the presence of TMPRSS2 in the target (BSR/T7) cells also appears to
process hACE2 (Fig. 5.8c, [234]). Therefore, we cannot exclude the possibility that
the increase in fusion observed when TMPRSS2 is present in these cells is due to
an effect on hACE2. In addition to the effect of proteases on cell-cell fusion, we
also assessed the effect of Neuropilin-1, which has been suggested to be a coreceptor for SARS-CoV-2 viral entry and may be key for SARS-CoV-2 infiltration
of the neuronal network [303-305]. We show that the presence of Neuropilin-1 with
hACE2 in target cells does not impact S mediated cell-cell fusion (Fig. 5.2e).
Additionally, co-expressing Neuropilin-1 with S in effector cells did not have an
inhibitory effect on cell-cell fusion. While reports suggest Neuropilin-1 plays a role
in viral entry of SARS-CoV-2, this indicates it does not play a significant role in S
cell-cell fusion in our assay, although this was not investigated in neuronal cells.
The viral entry and cell-cell fusion pathways of SARS-CoV, MERS-CoV, and
SARS-CoV-2 have several noteworthy commonalities, but do have marked
differences. They all share the ability to facilitate entry through endosomal
pathways, with S proteolytic activation mediated by endosomal/lysosomal
proteases [179, 181, 182, 278, 293, 294, 318-321]. Additionally, they all can utilize
cell surface (such as TMPRSS2) or extracellular proteases (trypsin) for S activation
and subsequent viral entry [181, 182, 293, 298, 316, 321-327]. SARS-CoV-2 and
MERS-CoV S differ from SARS-CoV S in that their S1/S2 border harbors a
canonical furin cleavage motif [178, 284, 289], resulting in S pre-activation by furin
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during synthesis and cellular trafficking, prior to reaching the cell surface or being
incorporated into viral particles [179, 182, 278, 294, 324]. This pre-activation by
furin likely enhances the ability of SARS-CoV-2 and MERS-CoV S to participate in
cell-cell mediated fusion without over-expression of cell surface or extracellular
proteases [182, 297]. Addition of this cleavage sequence in SARS-CoV S allows
SARS-S to facilitate cell-cell fusion without exogenous proteases [182, 328]. We
show an increase in both syncytia formation and luciferase reporter gene assay
fusion when cleavage at the S1/S2 border is enhanced by overexpression of furin
(Fig. 5.2b and 5.2c), confirming that furin cleavage of SARS-CoV-2 S plays a
critical role in cell-cell fusion. Interestingly, furin cleavage is not required for SARSCoV-2 infection [179, 181, 182, 298], although removal of the site or inhibition of
furin does appear to attenuate the virus [179, 294, 298] and reduce cellular tropism
[297].
The presence of a furin consensus sequence is not only a marked
difference between SARS-CoV and SARS-CoV-2, but it is also one of the
differences between SARS-CoV-2 and a similar CoV circulating in a bat population
[283]. Analysis of SARS-CoV-2 wt S in P. alecto cells demonstrates that this motif
can be recognized and cleaved by furin in these cells (Fig. 5.6c and 5.6d), although
the kinetics of this cleavage are noticeably slower than in other mammalian cell
lines (compare to Fig. 5.1b). Previous work has shown that the fusion proteins of
Hendra virus, processed by cathepsins, and parainfluenza virus 5, processed by
furin, are also cleaved in P. alecto cells [314]. Pulse-chase analysis in this prior
study demonstrated an increase in processing kinetics, although this kinetic
difference can be accounted for by differences in protease expression levels
between different bat cell lines (pt. kidney cells in [314], and pt. lung and pt. fetus
cells in our work), suggesting there may be cellular differences in protein trafficking
or furin activity. Intriguingly, a CoV-2 S mutant with a deletion of the inserted PRRA
residues still demonstrated some cleavage in both utilized bat cell lines (Fig. 5.6c
and 5.6d), while not showing any in Veros or A549s (Fig. 5.3c and 5.3d). Earlier
work on MERS-CoV S showed that furin or other proprotein convertases in bat
cells can process MERS S S1/S2 border without the presence of a canonical
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recognition motif [329]. Taken together, these results suggest that mutations in
circulating bat CoVs that allow for human protease recognition at critical cleavage
sites may be an important factor for zoonotic transmission of several CoVs.
Two other potential cleavage sites have been identified in work with other
CoVs. The S2’ site is essential for both SARS and MERS infection [272, 289, 330332] while a cath L activated site play a critical role for SARS-CoV S [273, 279,
333, 334].

Interestingly, mutations made at the S2’ site of SARS-CoV-2 S

significantly reduce S1/S2 border cleavage, both in our study and others (Fig. 5.3bd, [297, 335]), even though the sites are distal from each other. A similar reduction
in cleavage is observed when the conserved cathepsin site is mutated (Fig. 5.3bd). Our analysis of the published structures [264, 265, 336, 337] indicates that a
full alanine mutation of this site may simply collapse the exposed S1/S2 loop. Our
finding that exogenous trypsin treatment of cells expressing the S2’ or cathepsin
site mutants does not restore cleavage at the S1/S2 border (Fig. 5.5a and 5.5b)
suggests that these mutations result in proteins with altered furin loop structure
[336], rendering it inaccessible. However, these mutants are still synthesized and
trafficked to the surface despite not being cleaved (Fig. 5.3e-g), thus this change
in conformation is unlikely to have drastically misfolded the protein. These results
suggest that there may be a dynamic interaction between the S1/S2 border and
S2’ cleavage sites in SARS-CoV-2 S needed to facilitate viral entry and cell-cell
fusion. This dynamic control could also be regulated by S receptor binding
exposing cryptic protease sites, although studies analyzing this in SARS and
MERS S conflict on this topic [278, 319, 326, 338, 339].
We also assessed the effect on protein stability, cleavage, and cell-cell
fusion function of a series of mutations in other regions of S. The D614G mutation
emerged during 2020, and is now found in most circulating strains globally [299].
D614G has been shown to increase S incorporation into viral particles [340],
increase receptor binding [341, 342], and reduce S1 subunit shedding and particle
infectivity [343]. Importantly, the D614G mutant shifts S to favor a “heads up”
conformation of the receptor binding domain [342, 344, 345]. In our study, the
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D614G mutation did not impact the cell-cell fusion function (Fig. 5.4f), expression,
or stability of the protein (Fig. 5.4d/e, and Fig. 5.7), consistent with one previous
study [335]. Our fusion results however conflict with two previous studies that
demonstrated D614G increases cell-cell fusion, measured by cell depletion in flow
cytometry [341], and syncytia formation in 293T and Hela cells stably expressing
hACE2 [346]. These discrepancies may be due to differences in experimental
conditions or cell types utilized. We are, however, the first to date to utilize a
luciferase reporter gene assay to quantitate cell-cell fusion of a D614G S mutant.
Using this assay, we also show that mutations found at two other residues
(discovered in small, non-dominant population subsets [300]) alter the cell-cell
fusion activity of S (Fig. 5.4f) without changing the overall protein expression or
stability levels (Fig. 5.4d-e, Fig. 5.7d). Mutations at D839, a residue within the
internal fusion peptide, to the polar amino acids, tyrosine or asparagine,
significantly reduce fusion. Interestingly, a mutation at this residue that conserves
the negative charge, D839E, has no effect on fusion activity. The negative charge
at this residue may play a role in the regulation of S mediated fusion due to its
location in the internal fusion peptide. Alternatively, this residue is in close
proximity to C840, which may participate in a disulfide bond, so mutations at D839
may disrupt this disulfide bond, destabilizing the protein and changing fusion
activity. Additionally, mutation of residue P1263 to a leucine significantly increases
S mediated cell-cell fusion, suggesting that residues in the cytoplasmic tail may
play a role in the S-promoted cell-cell fusion process.

Notably, a study that

removed the entire S cytoplasmic tail still observed syncytia formation at levels
similar to wt S [335], indicating that regulation by the cytoplasmic tail may be
complex or that the role of the cytoplasmic tail in fusion is not regulation, but
interaction with cellular host factors [347].
In this work, we also provide critical insight into the kinetics of protein
cleavage and overall stability of CoV-2 S. S protein processing at the S1/S2 border
occurs within two hours of synthesis (Fig. 5.1a and 5.1b; one hour of label, one
hour of chase) in several mammalian cell lines (Vero, MEF, A549), and continues
to increase over time, reaching 60-80% protein cleavage by eight hours of chase
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time, depending on the cell type. Overexpression of furin increased the efficiency
of S1/S2 border cleavage (Fig. 5.1d-f), and this increase in cleavage may account
for the increase in cell-cell fusion observed when furin is co-expressed with S (Fig.
5.2a-c, [182, 297]). Additionally, we show that transiently transfected S is stable
in several mammalian cells for 4-5 hours post-protein synthesis with demonstrable
turnover after this point, (Fig. 5.1c, Fig. 5.7). This protein turnover is similar to
turnover rates seen in PIV5 fusion protein, also activated by cellular furin [348],
and slightly slower turnover than Hendra fusion protein, activated by cellular
cathepsins [164, 261]. Over-expression of cellular proteases that may process S
did not affect these protein turnover rates. Interestingly, analysis of S in nonreducing conditions found that cleavage of the S1/S2 border appears to destabilize
trimeric interactions (Fig. 5.5b). In these non-reducing conditions, no differences
were observed in oligomeric stability between wt S and the D614G S mutations,
despite the D614G favoring a ‘heads up’ conformation [342, 344, 345] and Vero
cells having sufficient levels of endogenous ACE2 to facilitate syncytia formation
(Fig. 5.8c), suggesting that changes in receptor binding do not alter overall protein
trimeric association.

Notably, in these non-reducing conditions after a 50°C

treatment for wt S, the D614G mutant, and wt S+furin, bands between monomer,
dimer, and trimer species are observed (Fig. 5.5b, indicated with *). These
intermediate species are not observed after treatment at 100°C. These may
represent protein oligomers that are not identically cleaved and are therefore
partially destabilized, a phenomenon proposed for MERS-CoV S [289], and murine
hepatitis virus CoV S, [189]. Protein oligomers with differential proteolytic
processing may also account for the small population of un-cleaved protein we
observed at the cell surface in our experiments (Fig. 5.3e, Fig. 5.4d, Fig. 5.5a, and
Fig. 5.6a).
Through biochemical and cell biological analysis of the SARS-CoV-2 S
protein, we have provided important observations about the stability, proteolytic
processing, and requirements for cell-cell fusion of this highly sought-after
therapeutic target. This information may be helpful in directing treatments that
inhibit S protein fusion, or for discerning methods to stabilize CoV-2 S in
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therapeutic development.

Additional studies are needed to understand the

potential interplay between S cleavage sites and how that may contribute to S
protein function, as well as to further investigate spike S2 subunit regions that are
critical for protein function.
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Figure 5-1 SARS-CoV-2 Spike is cleaved at the S1/S2 subunit border in a
variety of cell lines.
a) The indicated cell types transiently expressing S were metabolically
labeled for one hour, and chased for times indicated (hours). Band densitometry
was used to quantify bands representing full length S or S cleaved at the S1/S2
border (S2) (b) Percent cleavage [S2 divided by S plus S2] and (b) Overall protein
stability [Total S, S plus S2, for each time point, normalized to time point 0] were
calculated for spike in each cell line (n=3). d) S alone, or S with proteases
transiently expressed in Vero and A549 cells, cells were metabolically labeled, and
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chased for the times indicated (hours). Percent cleavage was measured using
band densitometry in both (e) Vero and (f) A549 cells (b, c, e, f are represented as
the average ± SD for 3 independent experiments).
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Figure 5-2 CoV-2 spike alone mediates cell-cell fusion.
Veros expressing S and TMPRRS2, furin, or cathepsin L were imaged at 24 (a)
and 48 (b) hpt for syncytia formation (black arrows). Magnification bar is 100μM.
c) A luciferase reporter gene assay was performed with target cells (BSR/T7s
expressing hACE2 and additional proteases) overlaid onto effector cells (Vero or
A549s expressing S) for 9 hours. d) Luciferase reporter gene experiment was
performed with additional proteases co-expressed with S in Veros and overlain
with target cells expressing hACE2. e) The effect of Neuropilin in both target and
effector (Vero) cells was examined with a luciferase reporter gene assay. Effector
cells expression is listed along the x-axis. Target cell expression is listed in the
graph legend. Results expressed as the percent fusion normalized to samples
with S in the effector cells, and hACE2 only in the target cells (c-e are average ±
SD for 3 independent experiments, performed in duplicate). Significance was
determined by two-way ANOVA. *: p < 0.05, ****: p<0.0001
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Figure 5-3 Mutations at all three potential spike cleavage sites reduce
cleavage at the S1/S2 subunit border.
a) Full or partial alanine substitution mutations were made at each of the three
potential cleavage sites. b) Plasmids expressing wt S or mutants were transfected
into Veros and A549s, cells were metabolically labeled for one hour, and chased
for the times indicated. Percent cleavage was determined in (c) Veros and (d)
A549s (average ± SD for 3 independent experiments) e) Surface biotinylation was
performed on cells expressing wt S and each mutant. Cells were radiolabeled for
6 hours. Protein expression in (f) Vero and (g) A549 cells, results are normalized
to wt S, and error bars represent the standard deviation (average ± SD for 3
independent experiments). h) A luciferase reporter gene assay was performed
using target cells expressing hACE2 and EV or TMPRRSS2, and effector (Vero)
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cells with wt S or each mutant. i) Luciferase reporter gene analysis with cells
expressing hACE2 and effector (Vero) cells transfected with S or S mutants and
EV or furin expressing plasmids. Results of both reporter gene assays are shown
normalized to samples with wt S in the effector with hACE2 in target cells (average
± SD for 3 independent experiments, performed in duplicate).
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Figure 5-4 Spike S2 subunit mutations found in circulating strains variably
affect spike mediated cell-cell fusion.
a) Mutations in the S2 subunit of S identified in circulating SARS-CoV-2 strains, b)
Wt S or the mutants were transfected into Veros and A549s, metabolically labeled
for one hour, and chased for the times indicated.

Percent cleavage was

determined in (c) Veros and A549s (average ± SD for 3 independent experiments).
d) Surface biotinylation on cells expressing wt S or each mutant. e) Total and
surface protein expression normalized to wt S (average ± SD for 3 independent
experiments). f) A luciferase reporter gene assay was performed using target cells
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expressing EV or hACE2, overlaid onto effector cells transfected with wt S or each
mutant. Results are normalized to samples with wt S in the effector cells and
hACE2 in target cells (average ± SD for 3 independent experiments, performed in
duplicate).

Significance was determined by two-way ANOVA, *: p<0.05, **:

p<0.01.
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Figure 5-5 Mutations at downstream potential cleavage sites render the
S1/S2 border cleavage site less accessible to proteases.
a) Veros or A549s expressing wt S or S cleavage mutants were metabolically
labeled for 6 hours. Surface proteins were biotinylated, and samples were either
treated for 10 minutes with TPCK-Trypsin or left as untreated controls (as
indicated). b) Veros or A549s expressing indicated proteins were metabolically
labeled for 6 hours. Samples were treated at the indicated temperatures before
separation on a nonreducing SDS-PAGE. Oligomers are labeled on the right based
on size, and colored * represents potential intermediate species (n=3). Using band
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densitometry to quantify the bands in (a), percent cleavage was measured in (c)
Vero and (d) A549 cells for both the surface (top graphs) and total (bottom graphs)
populations (average ± SD for 3 independent experiments). Significance was
determined by two-way ANOVA, *: p<0.05, **: p<0.01, ***: p<0.0005, ****:
p<0.0001.
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Figure 5-6 Furin or furin-like proteases in pteropus bat cells can cleave the
S1/S2 border site of SARS-CoV-2 Spike.
a) Surface biotinylation was performed on pteropus lung and pteropus fetus cells
transfected with wt S or the del. PRRA mutant.

b) Surface or total protein

expression levels were quantified using band densitometry and normalized to wt
S levels. c) pt. lung and pt. fetus cells were transfected with wt S or del. PRRA
mutant, metabolically labeled for one hour, and chased for the times indicated.
Again, using band densitometry to quantify bands results were expressed as (d)
protein cleavage and (e) protein stability over time. (b,d,e average ± SD for 3
independent experiments)
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Figure 5-7 SARS-CoV-2 protein stability comparisons.
A) Wt S was transfected into Vero or A549 cells, metabolically labeled for one hour,
and chased for times indicated. Blots (shown in Fig 1a) were quantified using band
densitometry. Both percent cleavage and percent stability are shown. B) Overall
protein stability at each time point from blots in Fig. 1D were quantified. C) Overall
protein stability at each time point from blots in Fig. 3B were quantified. D) Overall
protein stability at each time point from blots in Fig. 4B were quantified.
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Figure 5-8 SARS-CoV-2 Spike luciferase reporter gene assay controls
A) The experimental schematic for the luciferase reporter gene fusion assay used
throughout the manuscript is shown here. In all experiments, the target cells used
are BSR/T7 cells that constitutively express a T7 polymerase. Effector cells used
are Vero cells in most experiments and A549 cells in Figure 2c. B) Various overlay
times were tested in a luciferase reporter gene assay, effector cells (Vero) were
transfected with wt S, and target cells were transfected with empty vector (EV) or
hACE2. Results represent three independent experiments, each performed in
duplicate. Significance was determined by two-way ANOVA, ****; p<0.001. C)
Endogenous or transfection levels of TMPRSS2 and hACE2 were assessed in
Vero, A549, and BSR/T7 cells by western blot
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Figure 5-9 Mutations made at any of the three potential cleavage sites
abolish syncytia formation.
Vero cells were transfected with wt S or each of the cleavage mutants. The first
panel shows immunofluorescence of wt S or S cleavage mutants (green,
magnification bar is 20μm). The remaining panels show syncytia formation at 24
hours post transfection with S or mutants co-expressed with EV, TMPRSS2, or
furin. Syncytia are indicated by the black arrows, magnification bar is 100μM.
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Figure 5-10 All circulating mutants form large syncytia, similar to wt spike.
Immunofluorescence of wt S or the circulating mutants (S stained in green)
transiently expressed in Vero cells. White arrows indicated S positive cellular
extensions. The magnification bar is 20μM.

124

CHAPTER 6. RSV FUSION PROTEIN CHARACTERIZATION
Introduction
Respiratory syncytial virus (RSV), a member of the Pneumoviridae family,
was first isolated in 1956, and is one of the leading causes of respiratory tract
infections in young children [30, 349-352]. Initial RSV infections occur in most
people before the age of 5, with RSV continuing to cause reinfections throughout
their lives. For young children, it is estimated that RSV causes 34 million infections
and results in 3.4 million hospitalizations, making it one of the leading causes of
hospitalizations for this population [350, 351, 353]. RSV also poses an increased
risk

for

severe

infections

in

premature

infants,

the

elderly,

and

immunocompromised individuals [349-351, 354]. Despite this high risk and wide
prevalence, there are no vaccines and only one approved treatment for RSV, a
prophylactically given monoclonal antibody, Palivizumab (brand name: Synagis)
[355, 356]. This treatment is extremely costly and comes in a 5-dose regimen.
Due to these factors, this treatment is often reserved for high-risk infants and given
monthly during RSV season[355].
RSV strains are grouped into two subtypes, A and B, differing mainly in the
sequences found in the attachment protein (G) [351, 357]. RSV A2 and A Long
strains are the prototypic A subtype strains utilized for a majority of the RSV
research [30, 358]. These strains were isolated in 1961 and 1956, respectively,
and have been passaged in cell culture since that time [30]. CH-18537 isolated in
1962 and B9320 isolated in 1977, serve as the prototypic laboratory strains from
an RSV B lineage [357]. Despite the widespread use of these prototypic strains in
RSV research, several studies have suggested they vary significantly from current
circulating strains of RSV [358-363].

Even outside of traditional cell culture

experiments, work in pediatric bronchial epithelial cells demonstrated differences
in cytopathology and viral titers produce between lab grown and recent clinically
isolated strains [362].
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For a strain of RSV to facilitate viral entry, the RSV fusion (F) protein
undergoes a large dynamic conformational change, in a similar mechanism as
described for Hendra. Like all class I fusion proteins, RSV F must be proteolytically
processed prior to facilitating membrane fusion. Interestingly, RSV F possesses
two cleavage sites 27 amino acids apart [154, 156]. The small peptide is not
covalently linked to the protein when both sites are cleaved and is termed pep27.
Each cleavage site contains an R-X-X-R motif, making them both canonical
recognition sequences for the cellular proprotein convertase furin [152-154, 156].
Initial investigation of the cleavage sites demonstrated that proteolytic processing
at one site appeared to occur independently of cleavage at the other, but that
cleavage at both sites was required for fusion to occur [154, 156]. This work was
completed in RSV F from strain A Long, but both cleavage motifs are present and
completely conserved in F proteins from both A and B subtypes. To date, no
studies have been done to investigate the coordination between the two cleavage
sites in any RSV F from a subtype B lineage. Additionally, the role of this first
cleavage site remains unclear in the case of either subtype, since it does not
expose a fusion peptide and resides within the F2 region which is thought to have
a limited role in fusion function. Furthermore, the function of the released pep27
remains uncharacterized. Our work on F isolated from both prototypic laboratory
RSV strains, as well as F from recent clinical isolates sought to characterize
differences that may be present in the RSV F protein from different strains.
Ultimately, the goal was to better understand the fusion process that is facilitated
by each RSV F, however our initial analysis discovered that robust laboratory RSV
fusion assays did not exist, apart from simple syncytia analysis. Because of this,
our project also focused on developing a reproducible luciferase reporter fusion
assay to better analyze fusion mechanisms of F from each RSV subtype, as well
as to understand how antiviral treatments may affect the fusion process.
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Results and Discussion
Comparing the RSV F isolates
To understand differences between the cleavage patterns and fusion
function the following RSV F plasmids were utilized: pVAX-RSV F A2, pVAX-RSV
F B9320, pCAGGs-RSV F A clinical, pCAGGs-RSV F B clinical, and pVAX-RSV F
A2 P101Q. RSV F A and B clinical were cloned from clinical samples taken by
AstraZeneca. RSV F A2 P101Q is a single point mutant of RSV F A2,
demonstrated to have an increase in fusion [364]. RSV F between subtypes A and
B shares an approximately 90% sequence homology, while RSV F from clinical
isolates have greater than a 97% sequence homology with their respective lab
adapted isolate (Fig 6.1b). Interestingly, variation in the RSV F protein between
lab grown and current clinical isolates disproportionately falls in the F2 and pep27
regions of the protein. This region possesses four of the eight differences between
RSV F B Clinical and B9320 and ten of the fifteen differences between RSV F A2
and A clinical, despite only accounting for about 20% of the total protein. It has
been shown that F2 is a critical determinant of host cell specificity, so this high
variation is likely due to long time passage in cell culture compared to growth in a
human host [365].
To first assess expression differences between each of the isolates tested,
Vero or HEp-2 cells were transfected with plasmids encoding for each of the
proteins listed. When separated by reducing SDS-PAGE, the RSV F protein was
visualized as multiple bands: a band at 67-69 kDa corresponding to the uncleaved
form (F0), one at approximately 57 kDa corresponding to a protein with cleavage
at site 1 only (F1+), and a band at 49kDa corresponding to protein with cleavage at
site 2 (F1). Occasionally bands corresponding to the F2 subunit, with or without
pep27 attached were visualized around 30 kDa and 23kDa, respectively. RSV F
A2, B9320, and A2 P101Q demonstrated similar expression and cleavage patterns
in both Vero and HEp-2 cells, however RSV F from both clinical isolates displayed
significantly lower protein expression (Fig. 6.1c). Since RSV F expression of the
clinical isolates was so low in a transfection system, we tested the F protein
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expression during a viral infection. RSV A2, A Clinical or B Clinical strains were
used to infect HEp-2 or BSR cells at an MOI of 0.2 or 1 (as indicated).RSV B9320
virus was not available, so this was not included. Twenty-four hours post infection
(hpi) cells were metabolically labeled for three hours. RSV F expression in cells
infected with A2 and A clinical strains was similar in both cell lines (Fig. 6.1d). RSV
F expression in cells infected with RSV B Clinical demonstrated lower protein
expression levels, however still much higher than in transfected cell experiments
(Fig 6.1d).
RSV F mediated cell-cell fusion
To assess the RSV F fusion function, we performed both syncytia and
luciferase reporter gene assays. Since RSV F from A and B clinical isolates
demonstrated low expression in cellular transfection experiments (Fig. 6.1c), they
were excluded from fusion studies. Vero cells transfected with plasmids encoding
for RSV F A2, B9320, and A2 P101Q were imaged at 24 and 48 hours post
transfection (hpt) (Fig. 6.2a). At 24 hpt syncytia were observed in cells expressing
RSV F A2 or A2 P101Q (Fig. 6.2a), with larger and more numerous syncytia
observed at 48 hpt. In cells transiently expressing RSV F B9320, no syncytia were
apparent at 24 hpt, but some small syncytia were present at 48 hpt (Fig. 6.2a). To
better quantitate the fusion of each of these RSV F isolates, two luciferase reporter
gene assays were performed. In the first, BSR cells, which constitutively express
a T7 polymerase, were overlaid onto Vero cells transfected with DNA for each RSV
F isolate and a T7-promoted luciferase plasmid. BSRs were overlaid for 9, 12, or
24 hours (Fig. 6.2b). High levels of fusion were observed in RSV F A2 P101Q at
9 and 12 overlay times, however RSV F A2 and B9320 did not display fusion levels
above the mock transfected background samples (EV) at either the 9 or 12 hour
overlay (Fig. 6.2b). After 24 hours of overlay, the background levels (EV) were
very high in this experiment, so fusion levels of all isolates tested were not different
from background levels at this overlay time (Fig. 6.2b). Based on the few RSV F
reporter gene fusion studies that have been previously published, we changed the
conditions of the luciferase reporter gene experiment. For this second experiment,
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Vero cells were transfected with a T7-promoted luciferase plasmid and RSV F was
transfected into the BSR cells that express the T7 polymerase. 24 hpt the Vero
cells were lifted and overlaid on the BSR cells, again for 9, 12, or 24 hours (Fig.
6.2c). In this experimental set-up, there was a good signal to background ratio for
each sample, at each overlay time measured (Fig. 6.2c). RSV F A2 and A2 P101Q
demonstrated fusion levels significantly higher than RSV F B9320 at each overlay
time, consistent with the syncytia results (Fig. 6.2c). While Fig. 6.2c represents
four independent experiments, several other experiments using the exact same
experimental conditions over the past 3 year have yield incredibly inconsistent
results.
In the decades of research analyzing RSV, there have only been two
published studies which utilized F only reporter fusion studies [352, 366, 367].
Both assays appear to require precise timing, and potentially longer cellular
overlays than other closely related paramyxo- and pneumoviruses when a
hyperfusogenic F variant is not utilized. HMPV F, the most closely related virus
that has more quantitative fusion study published, must be treated with exogenous
trypsin to cleave F and subjected to a low pH pulse before fusion is observed [368].
Manipulation of these factors (pH and exogenous trypsin) for RSV F did not result
in any consistent fusion difference (data not shown) compared to untreated wells.
Additionally, we readily observed syncytia in Vero and BSR cells for RSV F only,
however when we attempted to perform a luciferase reporter assay with BSR cells
overlaid onto Vero cells transfected with DNA for RSV F, we receive very low signal
above background for anything other than an hyperfusogenic F (Fig. 6.2).
However, when the cell types are reversed fusion appears more consistent. Once
primed and at the cell surface, class I proteins must receive a triggering signal to
begin the fusion process, but what triggers RSV F is unknown [358, 369]. This
triggering may be carried out by F binding to a receptor or this may be carried out
by another viral or host protein entirely. If the trigger is F receptor binding, the
inconsistent fusion studies may suggest that receptor used by RSV F, which has
been proposed to be ICAM-1 [370], nucleolin [371], or TLR-4 [372], may have
lower expression on BSR cells. Since any (or all three) of these receptors may
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function as the RSV F receptor, additional fusion studies to investigate their
contribution may be worthwhile. If the triggering signal is carried out by another
protein entirely, that protein may not be expressed as sufficient levels in our
attempted fusion assays. Alternatively, RSV F protein may have an increased
dependence on the attachment protein (G) or small hydrophobic (SH) protein for
function, depending on cell type [360, 373-376]. Previous studies have
demonstrated that RSV that lacks the G protein is still infectious, suggesting that
G may be dispensable for viral entry [377], but this work was completed in a lab
passaged RSV A strains, and may not be reflective of the biology of current clinical
RSV infections. However, our initial work co-expressing RSV F and G from the
same subtype did not influence cell-cell fusion in either a syncytia or luciferase
reporter gene assay (data not shown), supporting the same conclusion that G is
dispensable for fusion. Investigation of different stoichiometric ratios of these are
needed and the ratios needed could vary between subtypes and/or lab grown vs
clinically isolated fusion proteins.
RSV F undergoes rapid post-translational cleavage
To observe the timing and pattern of RSV F cleavage, pulse chase analysis
was performed, again using RSV F A2 and B9320. Initial pulse-chase experiments
performed as described for HeV F experiments (Chapter 4, 45-minute label)
demonstrated that RSV F showed some proteolytic processing at the 0-time point
(data not shown). To better analyze processing of the RSV F protein, pulse-chase
utilizing a 15-minute label period was performed, with chase times of 15 min, 30
min, 1 hour, 2 hours, and 4 hours (Fig. 6.3a).

Interestingly, a faint band

corresponding to cleaved protein (F1) was present after 15 min of chase, growing
more apparent after 30 min of chase. This was seen in both RSV F A2 and B9320.
This suggests that RSV F is cleaved at both sites within 30 minutes of synthesis
(15 min label, 15 min chase) and that most of the protein is processed by 1 hour
post synthesis. This timing for proteolytic cleavage is much quicker than that
observed for PIV5 F, which is also processed by furin.

PIV5 F does not

demonstrate a majority cleavage of the protein population until the 2-hour chase
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time. This suggests that RSV F may more rapidly traffic to the compartment that
contains furin than does PIV5 F. To understand how the cleavage changes in the
presence of a chemical proprotein convertase inhibitor, a pulse chase experiment
was performed in cells transfected with expression plasmids for the RSV F isolates
and then treated with dec-RVKR-CMK during the experiment, with PIV5 F was
again used as a control. PIV5 F, RSV F A2 and B9320 all demonstrated a
reduction in cleavage following treatment with dec-KVRK-CMK, however the PIV5
F reduction was larger (Fig. 6.3b). Interestingly, the presence of dec-KVRK-CMK
appeared to alter the presence of the band corresponding to F1+ more than the
band corresponding to F1 (Fig. 6.3a). This may suggest that cleavage at the first
site may be more readily carried out by furin or a member of the furin family, while
the second site may be able to be processed by a larger number of cellular
proteases. To further assess the contribution of furin to protein cleavage, LoVo
cells transiently expressing the RSV F isolates were examined. In LoVo cells, a
reduction in cleavage was again seen, however a band corresponding to F1 was
still observed, further confirming that other cellular proteases can process RSV F
(Fig. 6.3c). There was also a faint band corresponding to cleaved protein for PIV5
F as well. Additionally, bands corresponding to F1+ were not observed in RSV F
A2 or F B9320 samples.
RSV F from both A2 and B9320 has several predicted N-linked glycans
(Table 6.1) [153]. Since RSV F is observed as several bands on a gel, potentially
due to heterogenous glycosylation, we used PNGase F treatment to remove these
glycans and more accurately observe the size of the RSV F protein products. Vero
cells transiently expressing RSV F A2 or B9320 were metabolically labeled in a
pulse chase experiment. At each chase time, the cell lysates were either treated
with PNGase F or were not (as indicated. Fig 6.4a). Starting at the 1-hour chase
time, untreated samples were primarily observed as two bands (indicated by red
[F0] and blue [F1+] *, Fig. 6.4a). When treated with PNGase F, RSV F was observed
as three distinct bands, likely corresponding to F0, F1+, and F1 cleavage products
from largest to smallest respectively (Fig. 6.4a). This pattern was consistent at
each time point and for both RSV F A2 and F B9320. Because our pulse chase
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experiments suggested that RSV F was trafficking through the secretory pathway
more rapidly than expected, we performed an Endoglycosidase H (Endo H). Endo
H resistance is not conferred until processing in the cis to medial Golgi apparatus.
Pulse-chase analysis was performed on Vero cells transiently expressing RSV F
A2 or F B9320, and then cell lysates were treated with Endo H or left untreated as
a control. When only a band corresponding to F0 was present (indicated by orange
*), the protein appeared to be Endo H sensitive (Fig 6.4b). However, once RSV F
was processed (indicated by yellow *), the cleaved protein appeared to be Endo H
resistant (Fig 6.4b). This observation was the same for RSV F A2 and RSV F
B9320. This indicates that the trafficking of the RSV F protein into the cis/medial
Golgi occurs rapidly, consistent with the rapid cleavage that is observed, since furin

is thought to be active in the trans-Golgi network.
Cleavage at both RSV F sites appears to be required for cell-cell fusion
The relationship of the two cleavage sites or even the function of the first
cleavage site remains unknown. To better understand the role of each cleavage
site we created single or quadruple alanine mutations at each cleavage site in RSV
F A2 or F B9320 (Fig. 6.5a). Both mutations at the first cleavage site did not alter
protein expression in Vero or HEp-2 cells for RSV F A2 or B9320 (Fig. 6.5b and c,
quantified in 6.5d and e). A single alanine mutation at the second cleavage site
slightly reduced protein expression in RSV F B9320 and has less of an effect on
protein expression in RSV F A2 (Fig. 6.5b and c, quantified in 6.5d and e). The
quadruple alanine mutation at site 2 was not observed (data not shown), though it
is worth noting that the antibody used to immunoprecipitated these samples
(Palivizumab) recognizes a conformational antigenic site that lies close to the
fusion loop and pep27 of the neighboring protomer, so loss or reduction in
observed protein expression could be due to lower antibody recognition of these
mutants compared to the wild type (WT) protein [378-380].

Analysis with

antibodies that recognize other sites or antibodies with non-conformational
epitopes should be completed in future studies. A loss of a band corresponding to
F1+ was observed in mutations at the first cleavage for both RSV F A2 and F B9320
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(Fig. 6.5b and c, quantified in 6.5f and g). While a single alanine mutation at site
two did not abolish cleavage at that site (there is a band corresponding to F1), it
did increase the amount of protein observed with only the first site cleaved
(increase in F1+) (Fig. 6.5b and c, quantified in 6.5f and g). These observations
were consistent in both Vero and HEp-2 cells. To assess the fusion function of
these cleavage mutants a syncytia assay was performed.

No syncytia were

observed for any cleavage mutant (Fig. 6.2a). This is particularly interestingly,
since mutations that alter cleavage at just the first site still have protein that is
cleaved in a way that the hydrophobic fusion peptide (FP) is accessible.
Additionally, the single alanine mutation still demonstrated some protein that
appeared to be cleaved at both cleavage sites but showed no syncytia formation.
These results are consistent with two previous studies that analyzed the
role of the cleavage sites in RSV F A2, showing that mutation of the first site
rendered the protein non-functional [154, 156]. This suggests that either
coordination between the two cleavage sites or the release of pep27 may be
essential for protein fusion, though this remains unexplored. Previous work has
suggested that key residues in the apical loop of F2 influence fusion function
potentially by helping propagate the triggering signal through the F protein trimer
[352]. If this is the case, the loss of cleavage at the first site, may enhance the
rigidity or space constraints in this area, not allowing for subtle conformation
changes to occur that would allow for signal transduction to the rest of the protein,
resulting in loss of fusion mechanism. There has also been evidence that the RSV
F trimer may associate and dissociate somewhat at the cell surface in almost a
‘breathing’ mechanism that allows it to sample its environment like Influenza HA
[71, 381]. The presence of pep27 on the F2 subunit that occurs with loss of
cleavage at the first site may inhibit this breathing action, effectively clamping the
protein, not allowing the RSV F protein to properly test its environment, therefore
losing the ability to facilitate fusion at the correct time. Loss of cleavage at the
S1/S2 border of SARS-CoV-2 causes the protomers within a trimeric unit to more
tightly associate (Chapter 5, Fig. 5.5), perhaps indicating the loss of cleavage at
the first site may have a similar effect in RSV F, thus creating too high of an energy
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barrier for this protein to overcome to facilitate membrane fusion.

Further

experimentation is needed to properly understand the mechanism that F2 and
pep27 play is overall protein conformation and fusion function. Because of the
higher variability in this area of the F protein, it would be valuable to analyze the
function of these regions in F proteins from multiple isolates of both clinical and lab
grown lineage. Information presented here in this chapter, as well as in future
planned studies will help yield better insight into the fusion mechanisms of the RSV
F protein. Since there is no vaccine for this virus, and limited available treatments,
deeper understanding of this protein that is critical for viral fusion may provide
necessary details for future therapeutic development.
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Table 6 1 Size predictions of RSV F isolates and their cleavage products

RSV F A2

Predicted
base size
F0
F1+
F1
F2+
F2
Pep27

63.3
51.4
48.1
15.3
12
3.3

# of Nglycans
4
2
0
4
2
2

Size with Nglycans
73.3
56.4
48.1
25.3
17
8.3

RSV F B9320

F0
F1+
F1
F2+
F2
Pep27

Predicted
base size
63.6
51.5
48.2
15.4
12.2
3.3

F0
F1+
F1
F2+
F2
Pep27

Predicted
base size
63.3
51.4
48.1
15.2
11.9
3.3

# of Nglycans
5
3
0
5
2
3

F0
F1+
F1
F2+
F2
Pep27

Predicted
base size
63.7
51.5
48.3
15.4
12.2
3.3

# of Nglycans
3
1

Size w/o signal
peptide
70.8
22.8
14.5

# of Nglycans
5
3
0
5
2
3

Size with Nglycans
76.1
59
48.2
27.9
17.2
10.8

Size w/o signal
peptide
73.4

Size with Nglycans
76.3
58.9
48.1
27.7
16.9
10.8

Size w/o signal
peptide
73.7

RSV F A Clinical

RSV F B Clinical

25.2
14.5

25.1
14.3

Size with N- Size w/o signal
glycans
peptide
70.7
67.9
54
48.3
3
22.9
20.1
2
17.2
14.4
1
5.8
Size predictions from ExPASy
N-glycan predictions from NetNGlyc 1.0 Server
O-glycan predictions from NetNGlyc 4.0 Server
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Table 6 2 Predicted N-linked glycans of RSV F isolates

Residues of predicted N-linked glycans*
RSV F A2

27
70
116
126
500

RSV F
B9320
27
70
116
120
126
500

RSV F A
RSV F B
Clinical
Clinical
27
27
70
70
116
120
120
126
126
500
500
Red indicates a non-jury agreement
*N-glycan predictions from NetNGlyc 1.0 Server

Table 6 3 Predicted O-linked glycans of RSV F isolates

Residues of predicted O-linked glycans**
RSV F A2
99
103
118
244

B9320

RSV
100

F

RSV F A
RSV F B
Clinical
Clinical
None
None

**O-glycan predictions from NetNGlyc 4.0 Server
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Figure 6-1 RSV F is over 88% conserved in different subtypes
a) RSV F is synthesized as a monomeric unit containing a fusion peptide (FP), two
heptad repeat regions (HRA and HRB), a transmembrane domain (TMD), and a
cytoplasmic tail (CT). RSV F also contains two cleavage sites that possess the
recognition motif for cleavage by furin. If both sites are cleaved, a 27 amino acid
peptide (pep27) is released. b) The F protein from different RSV subtypes share
about an 89% sequence homology. Additionally, RSV F isolated from strains that
have been grown in the lab long term (lab adapted) share a 97% and 99%
sequence homology with their respective A and B subtype clinical isolates. c) Vero
or HEp-2 cells were transfected with plasmids encoded for each of the RSV F
subtypes. Cells were metabolically labeled for 3 hours. d) HEp-2 or BSR cells
were infected with RSV A2, A Clinical, or B Clinical strains. 24 hpi cells were
metabolically labeled for 3 hours.
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Figure 6-2 RSV F readily forms syncytia in transfected cells.
a) Vero cells were transfected with RSV F from lab adapted isolates or cleavage
site mutants. Cells were imaged at 24 and 48 hpt. Black arrows indicate syncytia
formation. b) A luciferase reporter gene assay was performed using Vero cells
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(with a T7 promoted-luciferase plasmid) overlaid onto BSR cells (transfected with
plasmids encoding for RSV F) at 24 h pt. c) Another reporter gene assay was
performed this time using BSR cells overlaid onto Vero cells (transfected with
plasmids for RSV F and T7-luciferase. Results of b and c are normalized to WT
A2 from the 9 hr overlay and are representative of 4 independent experiments.
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Figure 6-3 Inhibition of cellular furin reduces RSV F cleavage.
a) Vero cells transiently expressing RSV F were metabolically labeled for 15
minutes, then chased for the times indicated (hours). This was also performed in
the presence of 50µM dec-RVKR-cmk. b) Using band densitometry, reduction in
protein cleavage was quantified in the presence of increasing levels of dec-RVKRcmk. c) LoVo cells transiently expressing RSV F were metabolically labeled for 3
hours.
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Figure 6-4 Treatment with PNGase F and Endoglycosidase H reveal the RSV
size and rapid trafficking rate.
a) Vero cells transiently expressing RSV F were metabolically labeled for 15
minutes and chased for times indicated (hours). Cell lysates were treated with
PNGase F to determine the size of the protein after removal of the N-linked
glycans. b) Vero cells transiently expressing RSV F were metabolically labeled for
15 minutes and chased for times indicated (minutes). Cell lysates were treatment
with Endoglycosidase H (Endo H).
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Figure 6-5 Mutations at the RSV F cleavage sites variably effect protein
expression and reduce protein cleavage.
a) Single or quadruple alanine mutants were created at the two protein cleavage
sites in RSV F A2 and B9320. Vero cells (b) or HEp-2 (c) transiently expressing
RSV F or each of the cleavage mutants were metabolically labeled for 3 hours.
Using band densitometry, protein expression (d/e) or protein cleavage (f and g)
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was measured for each of the mutants.
independent experiments.
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Results are representative of 3

CHAPTER 7. DISCUSSION AND FUTURE DIRECTIONS
The work presented in this dissertation yields key molecular insights into
the class I fusion proteins of important enveloped RNA viruses. Using the HeV
fusion protein, we demonstrated that the transmembrane domain (TMD) of this
protein could be targeted to destabilize the protein and prevent fusion function,
presenting it as a novel therapeutic target (Chapter 3). Additionally, through
mutagenesis we discovered residues M491/L492 within the TMD appear to play a
role in the overall fusion mechanism of the HeV F protein (Chapter 4), further
presenting this region as more than simply a membrane anchor. As the global
pandemic shifted our focus to SARS-CoV-2 S, we discovered regions of the protein
that may play a role in the fusion mechanism, as well as that proteolytic processing
of the protein at the S1/S2 border appears to regulate trimer stability (Chapter 5).
Lastly, we explored the mechanisms and cleavage patterns of RSV fusion proteins
from different lineages, providing better understanding of how the fusion processes
may differ between the RSV subtypes (Chapter 6). Collectively, this provides
critical information on these class I fusion proteins, however several important
research questions surrounding these important therapeutic targets remain
unanswered.
Current vaccine and anti-viral landscape for enveloped RNA viruses
Measles virus, influenza virus, RSV, and the recently emerged SARS-CoV2 are just a few of the important human pathogens that are enveloped RNA viruses.
Among these viruses, current therapeutic success is widely variable. Measles was
also among the first vaccines to be widely utilized, with a live attenuated vaccine
being used since the early 1960s [382]. Most of these vaccines are thought to
confer immunity for several years, if not a person’s entire life. We also have
seasonal influenza vaccines that help protect against three or four influenza
strains, though only short term, seasonal, protection is provided by each vaccine
[383]. Most recently, SARS-CoV-2 has two vaccines that were granted
“Emergency Use Authorization” by the FDA in late 2020 [41, 384]. Both of those
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vaccines use messenger RNA encoding for a stabilized full-length S protein, using
lipid nanoparticles to help deliver the RNA to host cells [385]. This is the first
approved use of this vaccine technology; therefore, the length of protection provide
is still unknown. Despite large efforts, no current human vaccines exist for many
other enveloped RNA viruses, like RSV, HMPV, Henipaviruses, and other human
coronaviruses.
Once a person becomes infected with one of these viruses, treatment
options are limited. Most treatments for viral infections involve simply treating the
systemic symptoms caused by the virus, however there are a few anti-viral
therapeutic options depending on the virus. Several approved therapeutics target
influenza virus, which target the viral neuraminidase to limit the spread or release
of nascent viral particles from infected cells, but these need to be given shortly
after viral infection to be effective [386].

For RSV, the only FDA approved

treatment is a monoclonal antibody against the F protein [355].

Monoclonal

antibody treatment or treatment with convalescent sera from previously infected
patients, have also shown to be effective other respiratory viruses such as SARSCoV and SARS-CoV-2 [387-394], but these are costly to make or harvest, thus
making them a first-world solution.
Fusion protein regions as novel therapeutic targets
In this dissertation, we present the TM region of the viral fusion proteins as
a novel target (Chapter 3).

Our work demonstrates that viral treatment with

peptides that mimic the TM region of F reduces viral infection by disrupting the viral
fusion process. Another study has also shown that targeting the TM region with
peptides blocks function of the HIV envelope protein, again by interacting with the
full-length proteins, disrupting TM-TM interactions, and thus interfering with the
fusion mechanism [125]. Successfully targeting and disrupting TM-TM interactions
has also been shown to work in non-viral systems such as disrupting the
dimerization of neuropilin-1 to suppress tumor formation among others discussed
further in the introduction to this dissertation [227-231]. While these studies provide
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the proof of concept for targeting the TM domain, targeting the TM in practice
presents some challenges. Because of the hydrophobic nature, TM peptides can
be difficult to synthesize and solubilize in aqueous solutions [395], so inclusion of
portion of regions external to the membrane spanning region (as we did in Chapter
3) may help with this. Additionally an over-abundance of membrane proteins can
lead to a disruption of the physical membrane barrier, causes toxicity to the cell
[395]. To help mitigate these challenges, further research is needed to flush out
delivery of these peptides or use of small molecules instead.
Apart from the TM region, peptides or small molecules targeting other
regions of viral fusion proteins are under investigation as anti-viral therapeutics.
Several peptides that target regions of the influenza HA are being developed to
help prevent conformational changes needed for influenza HA fusion [396, 397].
For RSV treatment, there are several small molecule fusion inhibitors currently
being investigated in clinical trials. Many of these small molecules function by
binding to the same antigenic sites found in the pre-fusion RSV F conformation,
thus locking the pre-fusion F in place [386, 396, 398-400]. These molecules
interact with both the fusion peptide and the HRB region of RSV F to create
stabilized pre-fusion F that is unable to undergo the conformational changes
necessary to facilitate fusion. Some of the RSV F anti-viral therapeutics in
development also target the HRB region, and work by interfering with the formation
of the six-helix bundle needed to bring the viral and host cell membrane together
[396, 398, 401]. There is also some evidence that the HRB peptides may also be
able to serve as pan-viral inhibitors, since inhibitors created to the HRB of the
paramyxovirus, PIV3 F protein also demonstrated an inhibitory effect against
Hendra and Nipah [402]. Interestingly, inclusion of cholesterol on these peptides
appeared to increase binding affinity indicating that inclusion of portion of the TM
may also help.
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Targeting the viral fusion protein proteolytic processing
Class I viral fusion proteins must undergo a proteolytic cleavage event
before being able to facilitate viral entry through the membrane fusion process [46].
This cleavage event activates the protein, creating a metastable pre-fusion protein
that can facilitate membrane fusion following the receipt of a triggering signal. A
host cell protease completes this cleavage. Therefore, inhibition of these host
proteases presents another set of antiviral targets that may be applicable for
treatment of a larger number of viral infections. Despite the more than 500 human
proteases that have been discovered [403], several viruses have evolved to use
similar host cell proteases for this viral protein cleavage. SARS-CoV S, Hendra F,
and Nipah F have all been shown to use the endosomal protease Cathepsin L
[150, 175, 318, 319]. HMPV, SARS-CoV-2, SARS-CoV, MERS-CoV, and
Influenza have all been shown to use the transmembrane serine protease 2
(TMPRSS2) [148, 181, 316, 326, 404-407]. RSV, Measles, highly pathogenic
forms of Influenza, and several humans CoVs possess the multi-basic cleavage
recognition site motif for the proprotein convertase, furin or a member the furin
family [152, 154, 156, 180, 404]. In fact, the presence of a recognition site for the
non-tissue specific protease furin has been implicated for expanding cellular
tropism in virus infection [285, 408]. These proteases have been investigated as
druggable targets for other human disease such as heart disease, stroke
treatment, and cancer treatment, but research investigating them as anti-virals
remains limited. Camostat is a broad-spectrum serine protease inhibitor approved
for use in Japan for treatment of chronic pancreatitis and postoperative esophagus
inflammation [409, 410]. Due to the rapid emergence of SARS-CoV-2 in early
2020, there was a substantial amount of investigation into repurposing already
existing drugs for as anti-viral treatments. In vitro studies demonstrated that
camostat reduced SARS-CoV-2 infection [181], and there are currently several
phase 1-2 clinical trials that are on-going to better understand its effectiveness in
humans [411]. Interestingly, cell culture experiments suggest that SARS-CoV-2
can utilize the cell surface or endosomal compartments for viral entry depending
on the host proteases available [181].
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Similarly, our work has suggested that both RSV F (Chapter 6) and SARSCoV-2 S (Chapter 5) demonstrate a reduction, but not a complete loss, of protein
cleavage when active furin is not present. This may suggest that combination
therapy, inhibiting of multiple cellular proteases [412], may be needed to fully inhibit
viral entry, though more investigation into the safety and efficacy of these
treatments is needed. Additionally, developing inhibitors for the member of the furin
family or cathepsin family may also prove to be effect and broadly applicable antiviral treatments. To better understand this, a through investigation of what host
proteases can process each fusion protein needs to be completed. This could be
done by creating a series of knockout cell lines similar to the Cathepsin L MEFs
used in Chapter 5, or purifying the fusion proteins and performing exogenous
protease treatment experiments. Results from the latter experiment would need to
be confirmed in a cell culture system since TM proteins usually need to be
manipulated or truncated before being purified.

Additionally, transfection

experiments over expressing various host proteases could be completed in the
LoVo cell line where a reduction in cleavage is observed (RSV F; Chapter 6 and
SARS-CoV-2, Chapter 5). Alternative to developing protease inhibitors, in line with
our work to target the HeV F TM region (Chapter 4), research could be done to
develop small peptides or small molecules that interact with the cleavage sites of
the fusion proteins to block protein cleavage. Since furin cleavage occurs in the
trans-Golgi network, these molecules would need to interact with the fusion
proteins shortly after synthesis to prevent the proteolytic processing.
RSV- A unique challenge
Since its discovery in the 1950s, there have been significant efforts to
develop an effective RSV vaccine. Currently, there nearly 20 candidates in Phase
1-3 clinical trials in the United States, attempting to use technologies such as live
attenuated viruses, particle-based vaccines, subunit vaccines, and recombinant
vectors [54, 55]. In 2019, a vector-based vaccine, using an adenovirus vector
expressing a prefusion RSV F, was granted “breakthrough therapy” designation by
the FDA for use in adults above 60 [56]. There are also a few trials investigating
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new options for more effective monoclonal antibody treatments, including one by
AstraZeneca that was granted “breakthrough therapy” approval by the FDA in 2019
[57-59]. Absent from current clinical trials is the use of inactivated virus, due to a
tragically failed clinical trial using formalin inactivated RSV particle in children [55,
60]. Vaccination with this virus resulted in more severe respiratory illness in several
of the children who were vaccinated.
The challenge to finding an effective RSV vaccine for all ages could
be due to several reasons. In recent years there is increasing evidence that the
prototypic RSV A and B strains used in laboratory research are not as clinically
relevant as they once were [61-64]. Long term passage in cell culture has placed
selective pressure on these viruses to better replicate in a cell culture dish than in
the complex environment of the human airway. This may suggest that subtle
differences exist between the fusion process or fusion requirements of the clinical
strains compared to the prototypic RSV strains.

This could mean there are

different cellular receptors or fusion triggers utilized, as these are not well
characterized for RSV. To help better understand these, creating and employing
systems to readily study currently circulating RSV strains is needed for future
research, both to investigate differences in the viral entry and the entire viral
lifecycle. This could mean creating a recombinant viral system based on current
clinical strains for RSV A and B that could be readily used in a laboratory setting.
Though since previous work has demonstrated that clinical isolates replicate much
less efficiently in cell culture, presenting additional challenges to studying them
[63-65], it may mean using 3-D model systems like human airway epithelial tissues
may need to be utilized more in preliminary studies to recapitulate the natural
infection environment. Since it appears there are going to continue to be RSV
strain population changes, such as the attachment protein duplication that has
arisen in clinical strains of the virus [66-68]. Future laboratory work can focus on
understanding differences in the F protein mechanisms between different RSV
subtypes. Dye transfer assays in the presence of RSV F antibodies to different
antigenic sites can be utilized to help probe difference in fusion and hemi fusion
states of RSV F in transfected cells. Additionally, peptide binding assays using
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peptides that mimic RSV F HRA and HRB for each subtype can be completed to
biochemically understand the protein movement and triggering process in different
cellular conditions (pH changes, membrane composition, etc) of F from each RSV
subtype.
RSV F peptide 27 and other fusion protein peptides
Another area of RSV that warrants further investigation is the role of pep27,
not covalently linked to the protein following cleavage at both F protein sites during
cellular infection. Studies have demonstrated when this region is deleted, the
protein remains fusogenically functional, though to a qualitatively less extent than
wild-type F [69]. However, other work, including our study (Chapter 6), shows that
keeping pep27 linked to the F2 subunit renders the protein fusion inactive [46, 47].
This may indicate that the release of pep27 provides conformational flexibility
necessary to allow for the subunit association/dissociation needed or for triggering
signal transduction through the protein. The small nature of pep27 and the data
showing that it prevents membrane fusion when attached to F2 (Chapter 6,[46,
47]) suggest this may have therapeutic implications. If a small molecule could be
created to replace the pocket left by pep27 in the pre-fusion structure, the protein
may be locked in the pre-fusion conformation and unable to be triggered. The RSV
F prefusion structures published lack both binding sites and the entire pep27 [70,
71], so elucidating the structure of the pocket left by the release of pep27 could be
challenging. However, finding a way to stabilize that region may help gain key
information about the shape of that pocket may provide a new antigenic site to
target on RSV F. Additionally, further studies that seek to understand the role of
the first cleavage site and track the subcellular localization of pep27 throughout
the RSV viral infection would provide interesting insights into this small peptide,
thus providing a more comprehensive vaccine target.
Interestingly, SARS-CoV-2 and other human infecting coronaviruses also
possess two cleavage sites [72], though they are about 100 amino acids apart
compared to the 27 amino acids of pep27. Our work (Chapter 5) suggests that
cleavage at the first site (S1/S2 border) is required for cell-cell fusion, but the
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function of the second site (S2’) remains evasive. Other studies suggest that
cleavage is required at both sites for SARS-CoV-2 and MERS-CoV to infect cells,
and that this cleavage occurs following receptor binding [39]. This fits with our data,
since the presence of TMPRSS2 in the same cells as hACE2 enhances cell-cell
fusion in our experiments (Chapter 5).

Despite this enhancement and the

numerous conditions tested, we did not readily observe the presence of a band
that would correspond to S cleaved at S2’ (around 65 kDa), suggesting this
cleavage may not be needed for SARS-CoV-2 cell-cell fusion, or that the overall S
protein is unstable and degrades very quickly following cleavage at the S2’ site.
Alternatively, the antibody used (S S2 subunit specific) could bind an epitope that
is blocked in the post-fusion protein conformation. Pulse chase experiments using
a series of different antibodies or with additional later timepoints may yield better
insight in the timing of the S2’ cleavage. To better understand the role of the dual
cleavage sites in general, antibodies could be created to the peptide region
between these two cleavage sites to understand the localization during the fusion
process and protein trafficking in both transfection experiments and infection
experiments.
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APPENDIX
Abbreviations
hACE2

Human angiotensin converting
enzyme 2
Broadly neutralizing antibodies
Cathepsin L
Coronavirus
Coronavirus disease of 2019
Cryo-electron microscopy
Cytoplasmic tail domain
Ebola virus
Envelope protein
Endoplasmic reticulum
Fusion protein
Fusion peptide
Forester resonance energy
transfer
Attachment protein
Glycoprotein
Hemagglutinin
Hydrogen-deuterium exchange
mass spectrometry
Hendra Virus
Human immunodeficiency virus
type 1
Human metapneumovirus
Hours post transfection
Heptad repeat
Herpes simplex virus 1
Influenza
Leucine-Isoleucine zipper
Mouse embryonic fibroblasts
Middle eastern respiratory
syndrome coronavirus
Measles virus
Membrane proximal external
region
Newcastle disease virus
Nuclear magnetic resonance
Phosphatidyl choline
Phosphatidyl ethanolamine
Parainfluenza virus 5
Respiratory Syncytial Virus
Spike protein

bNAbs
Cath L
CoV
COVID-19
Cryo-EM
CTD
EBOV
Env
ER
F
FP
FRET
G
GP
HA
HDX-MS
HeV
HIV-1
HMPV
Hpt
HR
HSV-1
IAV
L-I Zipper
MEFs
MERS-CoV
MeV
MPER
NDV
NMR
PC
PE
PIV5
RSV
S
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SARS-CoV-2

Severe acute respiratory
syndrome coronavirus 2
Severe acute respiratory
syndrome coronavirus
Sedimentation equilibrium
analytical ultracentrifugation
Stable signal peptide
T cell receptor
Toll-like receptor
Transmembrane
Transmembrane domain
Transmembrane serine
protease 2
Venezuelan equine encephalitis
virus
Virus like particles
Vesicular stomatitis virus
Wild-type

SARS-CoV
SE-AUC
SSP
TCR
TLR
TM
TMD
TMPRSS2
VEEV
VLPs
VSV
WT
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